0001564590-21-028008.txt : 20210514 0001564590-21-028008.hdr.sgml : 20210514 20210514160550 ACCESSION NUMBER: 0001564590-21-028008 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210514 DATE AS OF CHANGE: 20210514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbCellera Biologics Inc. CENTRAL INDEX KEY: 0001703057 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39781 FILM NUMBER: 21924546 BUSINESS ADDRESS: STREET 1: 2215 YUKON STREET CITY: VANCOUVER STATE: A1 ZIP: V5Y 0A1 BUSINESS PHONE: (604) 559-9005 MAIL ADDRESS: STREET 1: 2215 YUKON STREET CITY: VANCOUVER STATE: A1 ZIP: V5Y 0A1 10-Q 1 abcl-10q_20210331.htm 10-Q abcl-10q_20210331.htm
false Q1 --12-31 0001703057 00-0000000 Unlimited Unlimited 0001703057 2021-01-01 2021-03-31 xbrli:shares 0001703057 2021-05-10 iso4217:USD 0001703057 2020-12-31 0001703057 2021-03-31 iso4217:USD xbrli:shares 0001703057 2020-01-01 2020-12-31 0001703057 abcl:ResearchFeesMember 2020-01-01 2020-03-31 0001703057 abcl:ResearchFeesMember 2021-01-01 2021-03-31 0001703057 us-gaap:LicenseMember 2021-01-01 2021-03-31 0001703057 abcl:MilestonePaymentsMember 2021-01-01 2021-03-31 0001703057 us-gaap:RoyaltyMember 2021-01-01 2021-03-31 0001703057 2020-01-01 2020-03-31 0001703057 us-gaap:CommonStockMember 2020-12-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001703057 us-gaap:RetainedEarningsMember 2020-12-31 0001703057 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001703057 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001703057 us-gaap:CommonStockMember 2021-03-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001703057 us-gaap:RetainedEarningsMember 2021-03-31 0001703057 abcl:SeriesA1PreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001703057 us-gaap:CommonStockMember 2019-12-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001703057 us-gaap:RetainedEarningsMember 2019-12-31 0001703057 2019-12-31 0001703057 abcl:SeriesA2PreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0001703057 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001703057 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001703057 abcl:SeriesA1PreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0001703057 abcl:SeriesA2PreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0001703057 us-gaap:CommonStockMember 2020-03-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001703057 us-gaap:RetainedEarningsMember 2020-03-31 0001703057 2020-03-31 0001703057 abcl:PreInitialPublicOfferingPlanMember 2021-01-01 2021-03-31 0001703057 abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember 2021-01-01 2021-03-31 0001703057 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001703057 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001703057 us-gaap:ComputerEquipmentMember 2020-12-31 0001703057 us-gaap:ComputerEquipmentMember 2021-03-31 0001703057 abcl:LaboratoryEquipmentMember 2020-12-31 0001703057 abcl:LaboratoryEquipmentMember 2021-03-31 0001703057 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001703057 us-gaap:FurnitureAndFixturesMember 2021-03-31 0001703057 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001703057 us-gaap:LeaseholdImprovementsMember 2021-03-31 0001703057 abcl:OperatingLeaseRightOfUseAssetsMember 2020-12-31 0001703057 abcl:OperatingLeaseRightOfUseAssetsMember 2021-03-31 0001703057 abcl:LicenseBasedIntangibleAssetsMember 2021-03-31 0001703057 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-03-31 0001703057 us-gaap:InProcessResearchAndDevelopmentMember 2021-03-31 abcl:JointVenture 0001703057 abcl:DayhuJointVentureMember 2020-01-01 2020-12-31 0001703057 abcl:BeedieJointVentureMember 2021-01-01 2021-03-31 iso4217:CAD 0001703057 abcl:DayhuJointVentureMember srt:MaximumMember 2021-01-01 2021-03-31 xbrli:pure 0001703057 abcl:DayhuJointVentureMember us-gaap:PrimeRateMember 2021-01-01 2021-03-31 0001703057 abcl:DayhuJointVentureMember 2021-01-01 2021-03-31 0001703057 abcl:DayhuJointVentureMember 2021-03-31 0001703057 2021-03-01 2021-03-31 0001703057 abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember 2021-03-31 0001703057 abcl:TwoThousandTwentyEmployeeSharePurchasePlanMember 2020-12-31 0001703057 abcl:PreInitialPublicOfferingPlanMember 2020-12-31 0001703057 abcl:PreInitialPublicOfferingPlanMember 2021-03-31 0001703057 abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember 2020-12-31 0001703057 abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001703057 abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2021-03-31 0001703057 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001703057 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001703057 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001703057 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001703057 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-03-31 0001703057 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-03-31 0001703057 abcl:ResearchCollaborationAndLicenseAgreementMember abcl:EliLillyMember srt:MaximumMember 2020-03-31 0001703057 abcl:ResearchCollaborationAndLicenseAgreementMember abcl:EliLillyMember srt:MinimumMember 2020-03-31 0001703057 abcl:ResearchCollaborationAndLicenseAgreementMember abcl:EliLillyMember 2020-01-01 2020-12-31 0001703057 abcl:ResearchCollaborationAndLicenseAgreementMember abcl:EliLillyMember 2021-01-01 2021-03-31 0001703057 abcl:ResearchCollaborationAndLicenseAgreementMember abcl:EliLillyMember 2020-01-01 2021-03-31 0001703057 abcl:ResearchCollaborationAndLicenseAgreementMember abcl:EliLillyMember 2020-12-31 0001703057 abcl:ResearchCollaborationAndLicenseAgreementMember abcl:EliLillyMember 2021-04-01 2021-03-31 0001703057 abcl:VariousOtherAgreementsMember 2021-03-31 0001703057 abcl:VariousOtherAgreementsMember 2021-04-01 2021-03-31 0001703057 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001703057 us-gaap:FairValueInputsLevel2Member 2021-03-31 0001703057 us-gaap:FairValueInputsLevel2Member abcl:OtherLongTermLiabilitiesMember 2020-12-31 0001703057 us-gaap:FairValueInputsLevel2Member abcl:OtherLongTermLiabilitiesMember 2021-03-31 0001703057 abcl:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001703057 abcl:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-03-31 0001703057 abcl:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0001703057 abcl:OfficeAndLaboratorySpaceMember country:AU 2021-03-31 0001703057 abcl:OfficeAndLaboratorySpaceMember country:CA 2021-03-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________

Commission File Number: 001-39781

 

AbCellera Biologics Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

British Columbia

Not Applicable

( State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

2215 Yukon Street

Vancouver, BC

V5Y 0A1

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (604) 559-9005

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common shares, no par value per share

 

ABCL

 

The Nasdaq Stock Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  ☒    No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes  ☒    No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

  

Smaller reporting company

 

 

 

 

 

 

 

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes      No  

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.     Yes      No  

As of May 10, 2021, the registrant had  270,925,888 common shares, no par value per share, outstanding.

 

 

 


 

 

Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

 

Item 1.

Financial Statements (Unaudited)

1

 

Condensed Consolidated Balance Sheets

1

 

Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)

2

 

Condensed Consolidated Statements of Stockholders’ Equity

3

 

Condensed Consolidated Statements of Cash Flows

4

 

Notes to Unaudited Condensed Consolidated Financial Statements

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

12

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

23

Item 4.

Controls and Procedures

23

PART II.

OTHER INFORMATION

 

Item 1.

Legal Proceedings

25

Item 1A.

Risk Factors

25

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

26

Item 3.

Defaults Upon Senior Securities

26

Item 4.

Mine Safety Disclosures

26

Item 5.

Other Information

26

Item 6.

Exhibits

27

 

Signatures

28

 

 

 

i


 

 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

AbCellera Biologics Inc.

Condensed Consolidated Balance Sheets

(Expressed in thousands of U.S. dollars except share data)

(Unaudited)

 

 

 

December 31, 2020

 

 

March 31, 2021

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

594,116

 

 

$

685,795

 

Accounts receivable

 

 

903

 

 

 

23,371

 

Accrued accounts receivable

 

 

212,336

 

 

 

193,071

 

Other current assets

 

 

5,970

 

 

 

5,745

 

Total current assets

 

 

813,325

 

 

 

907,982

 

Long term assets:

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

17,923

 

 

 

34,618

 

Intangible assets

 

 

115,153

 

 

 

112,688

 

Goodwill

 

 

31,500

 

 

 

31,500

 

Investments in and loans to equity accounted investees

 

 

19,247

 

 

 

32,187

 

Other long-term assets

 

 

8,388

 

 

 

9,548

 

Total long-term assets

 

 

192,211

 

 

 

220,541

 

Total assets

 

$

1,005,536

 

 

$

1,128,523

 

Liabilities and shareholders' equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable and other liabilities

 

$

20,195

 

 

$

13,287

 

Current portion of contingent consideration payable

 

 

13,411

 

 

 

13,762

 

Income taxes payable

 

 

36,152

 

 

 

30,030

 

Accrued royalties payable

 

 

27,143

 

 

 

20,010

 

Deferred revenue

 

 

6,589

 

 

 

11,306

 

Total current liabilities

 

 

103,490

 

 

 

88,395

 

Long-term liabilities:

 

 

 

 

 

 

 

 

Operating lease liability

 

 

3,715

 

 

 

16,973

 

Deferred revenue and grant funding

 

 

25,894

 

 

 

28,730

 

Contingent consideration payable

 

 

9,148

 

 

 

9,378

 

Deferred tax liability

 

 

26,161

 

 

 

26,992

 

Other long-term liabilities

 

 

6,620

 

 

 

931

 

Total long-term liabilities

 

 

71,538

 

 

 

83,004

 

Total liabilities

 

 

175,028

 

 

 

171,399

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Shareholders' equity:

 

 

 

 

 

 

 

 

Common shares: no par value, unlimited authorized shares at December 31, 2020 and March 31, 2021:  269,497,768 and 270,925,930 shares issued and outstanding at December 31, 2020 and March 31, 2021 respectively

 

 

710,387

 

 

 

711,139

 

Additional paid-in capital

 

 

5,919

 

 

 

14,562

 

Accumulated earnings

 

 

114,202

 

 

 

231,423

 

Total shareholders' equity

 

 

830,508

 

 

 

957,124

 

Total liabilities and shareholders' equity

 

$

1,005,536

 

 

$

1,128,523

 

Subsequent events

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

1


 

AbCellera Biologics Inc.

Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)

(Expressed in thousands of U.S. dollars except share and per share data)

(Unaudited)

 

 

 

Three months ended March 31,

 

 

 

2020

 

 

2021

 

Revenue:

 

 

 

 

 

 

 

 

Research fees

 

$

4,657

 

 

$

3,986

 

Licensing revenue

 

 

-

 

 

 

20,259

 

Milestone payments

 

 

-

 

 

 

7,000

 

Royalty revenue

 

 

-

 

 

 

171,496

 

Total revenue

 

 

4,657

 

 

 

202,741

 

Operating expenses:

 

 

 

 

 

 

 

 

Royalty fees

 

 

-

 

 

 

20,010

 

Research and development(1)

 

 

4,118

 

 

 

12,352

 

Sales and marketing(1)

 

 

437

 

 

 

2,578

 

General and administrative(1)

 

 

1,650

 

 

 

6,422

 

Depreciation and amortization

 

 

574

 

 

 

3,305

 

Total operating expenses

 

 

6,779

 

 

 

44,667

 

Income (loss) from operations

 

 

(2,122

)

 

 

158,074

 

Other (income) expense

 

 

 

 

 

 

 

 

Other (income) expense

 

 

1,001

 

 

 

(265

)

Grants and incentives

 

 

(1,030

)

 

 

(3,148

)

Total other income

 

 

(29

)

 

 

(3,413

)

Net earnings (loss) before income tax

 

 

(2,093

)

 

 

161,487

 

Provision for income tax

 

 

-

 

 

 

44,266

 

Net earnings (loss) and comprehensive income (loss) for the period

 

$

(2,093

)

 

$

117,221

 

Net earnings (loss) per share attributable to common shareholders

 

 

 

 

 

 

 

 

Basic

 

$

(0.01

)

 

$

0.43

 

Diluted

 

$

(0.01

)

 

$

0.37

 

Weighted-average common shares outstanding

 

 

 

 

 

 

 

 

Basic

 

 

151,859,924

 

 

 

269,697,212

 

Diluted

 

 

151,859,924

 

 

 

320,282,747

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

1Exclusive of depreciation and amortization

 

2


 

 

AbCellera Biologics Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(Expressed in thousands of U.S. dollars except share data)

(Unaudited)

 

 

 

Series A1

Preferred Shares

 

 

Series A2

Preferred Shares

 

 

Common Shares

 

 

Additional

Paid-in

 

 

Accumulated

Earnings

 

 

Total

Shareholders'

 

(in thousands, except share data)

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

(Deficit)

 

 

Equity

 

Balances as of December 31, 2020

 

 

-

 

 

$

-

 

 

 

-

 

 

$

-

 

 

 

269,497,768

 

 

$

710,387

 

 

$

5,919

 

 

$

114,202

 

 

$

830,508

 

Shares issued under stock option plan

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,428,162

 

 

 

752

 

 

 

(579

)

 

 

-

 

 

 

173

 

Stock-based compensation expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

4,021

 

 

 

-

 

 

 

4,021

 

Reclassification of liability classified

   options

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

5,201

 

 

 

-

 

 

 

5,201

 

Net earnings

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

117,221

 

 

 

117,221

 

Balances as of March 31, 2021

 

 

-

 

 

$

-

 

 

 

-

 

 

$

-

 

 

 

270,925,930

 

 

$

711,139

 

 

$

14,562

 

 

$

231,423

 

 

$

957,124

 

 

 

 

Series A1

Preferred Shares

 

 

Series A2

Preferred Shares

 

 

Common Shares

 

 

Additional

Paid-in

 

 

Accumulated

Earnings

 

 

Total

Shareholders'

 

(in thousands, except share data)

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

(Deficit)

 

 

Equity

 

Balances as of December 31, 2019

 

 

2,105,264

 

 

$

7,546

 

 

 

-

 

 

$

-

 

 

 

151,681,382

 

 

$

5,122

 

 

$

2,300

 

 

$

(4,716

)

 

$

10,252

 

Issuance of Series A2 preferred shares

 

 

-

 

 

 

-

 

 

 

6,017,784

 

 

 

74,662

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

74,662

 

Shares issued under stock option plan

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

535,000

 

 

 

235

 

 

 

(111

)

 

 

-

 

 

 

124

 

Share-based compensation expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

744

 

 

 

-

 

 

 

744

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,093

)

 

 

(2,093

)

Balances as of March 31, 2020

 

 

2,105,264

 

 

$

7,546

 

 

 

6,017,784

 

 

$

74,662

 

 

 

152,216,382

 

 

$

5,357

 

 

$

2,933

 

 

$

(6,809

)

 

$

83,689

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3


 

 

AbCellera Biologics Inc.

Condensed Consolidated Statements of Cash Flows

(Expressed in thousands of U.S. dollars)

(Unaudited)

 

 

 

Three months ended March 31,

 

 

 

2020

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net income (loss)

 

$

(2,093

)

 

$

117,221

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Depreciation of property and equipment

 

 

415

 

 

 

840

 

Amortization of intangible assets

 

 

158

 

 

 

2,465

 

Amortization of operating lease right-of-use-assets

 

 

73

 

 

 

661

 

Stock-based compensation

 

 

1,237

 

 

 

5,427

 

Deferred tax expense

 

 

-

 

 

 

623

 

Other

 

 

(28

)

 

 

(191

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts and accrued research fees receivable

 

 

(26,611

)

 

 

(30,073

)

Accrued royalties receivable

 

 

-

 

 

 

26,861

 

Income taxes payable

 

 

-

 

 

 

(6,123

)

Accounts payable and accrued liabilities

 

 

(156

)

 

 

(5,194

)

Deferred revenue

 

 

27,676

 

 

 

6,086

 

Accrued royalties payable

 

 

-

 

 

 

(7,134

)

Other assets and liabilities

 

 

(1,435

)

 

 

(1,924

)

Net cash (used in) provided by operating activities

 

 

(764

)

 

 

109,545

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(583

)

 

 

(3,644

)

Purchase of intangible assets

 

 

(5,000

)

 

 

-

 

Investment in equity investees

 

 

-

 

 

 

(12,195

)

Net cash used in investing activities

 

 

(5,583

)

 

 

(15,839

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Repayment of long-term debt

 

 

(2,033

)

 

 

(1,716

)

Proceeds from long-term debt

 

 

16,171

 

 

 

-

 

Payment of deferred financing fees

 

 

(799

)

 

 

-

 

Short-term borrowings

 

 

(387

)

 

 

-

 

Issuance of common shares pursuant to exercise of stock options

 

 

124

 

 

 

173

 

Proceeds from issuance of preferred shares - series A2 financing

 

 

74,662

 

 

 

-

 

Net cash provided by (used in) financing activities

 

 

87,738

 

 

 

(1,543

)

Effect of exchange rate changes on cash and cash equivalents

 

 

 

 

 

 

(484

)

Increase in cash and cash equivalents

 

 

81,391

 

 

 

91,679

 

Cash and cash equivalents, beginning of period

 

 

7,553

 

 

 

594,116

 

Cash and cash equivalents, end of period

 

$

88,944

 

 

$

685,795

 

Supplemental disclosure of non-cash investing and financing activities

 

 

 

 

 

 

 

 

Property plant and equipment in accounts payable

 

 

95

 

 

 

423

 

Right-of-use assets obtained in exchange for operating lease obligation

 

741

 

 

 

14,188

 

Purchase of intangible assets in exchange for in-licensing agreement payable

 

 

9,060

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4


 

 

AbCellera Biologics Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

(Unaudited)

1. Nature of operations

AbCellera Biologics Inc.’s (the “Company”) mission is to improve health with technologies that transform the way that antibody-based therapies are discovered. The Company aims to become the centralized operating system for next generation antibody discovery. The Company’s full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The Company believes its technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable. Rather than advancing its own clinical pipeline of drug candidates, the Company forges partnerships with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies. 

2. Basis of presentation

The accompanying interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2020.

These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended March 31, 2021 and 2020 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2020, except for the new accounting guidance adopted during the period (Note 3).

All amounts expressed in the consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share and per share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” and “CAD” are to Canadian dollars.

3. Significant accounting policies

Use of estimates

The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and determining whether an option for additional goods or services represents a material right, recoverability of investment tax credits receivable, value of contingent consideration payable and the fair value of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.

COVID-19 Pandemic

With the global spread of the ongoing COVID-19 pandemic, the Company has implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on its employees and its business. The Company has taken measures to secure its research and development activities, while work in its laboratories and facilities has been re-organized to reduce risk of COVID-19 transmission. Given the global economic impact, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company’s business, financial condition, and results of operations could be materially adversely affected. The Company continues to closely monitor the COVID-19 pandemic as it evolves its business continuity plans and response strategy. As of the date of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Company’s financial statements.

5


 

Recent accounting pronouncements not yet adopted

The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the consolidated financial statements as a result of future adoption.

4. Net Earnings (Loss) per share

Basic and diluted net earnings (loss) per share attributable to common shareholders was calculated as follows:

 

 

 

Three months ended March 31,

 

 

 

2020

 

 

2021

 

 

 

(in thousands, except share and per share data)

 

Basic earnings (loss) per share

 

 

 

 

 

 

 

 

Net earnings (loss)

 

$

(2,093

)

 

$

117,221

 

Net earnings (loss) attributable to common shareholders - basic

 

$

(2,093

)

 

$

117,221

 

Weighted-average common shares outstanding - basic

 

 

151,859,924

 

 

 

269,697,212

 

Net earnings (loss) per share attributable to common shareholders - basic

 

$

(0.01

)

 

$

0.43

 

 

 

 

 

 

 

 

 

 

Diluted earnings (loss) per share

 

 

 

 

 

 

 

 

Net earnings (loss) attributable to common shareholders - diluted

 

$

(2,093

)

 

$

117,221

 

Weighted-average common shares outstanding - basic

 

 

151,859,924

 

 

 

269,697,212

 

Stock options and RSUs

 

 

-

 

 

 

50,585,535

 

Weighted-average common shares outstanding - diluted

 

 

151,859,924

 

 

 

320,282,747

 

Net earnings (loss) per share attributable to common shareholders - diluted

 

$

(0.01

)

 

$

0.37

 

 

The Company’s potentially dilutive securities, which include convertible preferred shares and stock options have been excluded from the computation of diluted net loss per share for the three months ended March 31, 2020 as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding for the three months ended March 31, 2020 used to calculate both basic and diluted net loss per share attributable to common shareholders is the same.

The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net earnings (loss) per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:

 

 

 

Three months ended March 31,

 

 

 

2020

 

 

2021

 

Options to purchase common shares

 

 

13,310,018

 

 

 

-

 

Convertible preferred shares

 

 

2,640,178

 

 

 

-

 

Total potential common shares excluded

 

 

15,950,196

 

 

 

-

 

 

5. Other current assets

Other current assets consisted of the following:

 

 

 

 

 

December 31,

2020

 

 

March 31,

2021

 

 

 

 

 

(in thousands)

 

Tax and investment tax credit receivable

 

 

 

$

489

 

 

$

249

 

Prepaid expenses

 

 

 

 

4,073

 

 

 

4,287

 

Materials and supplies

 

 

 

 

1,408

 

 

 

1,209

 

Total other current assets

 

 

 

$

5,970

 

 

$

5,745

 

 

6


 

 

6. Property and equipment, net

Property and equipment, net consisted of the following:

 

 

 

 

 

December 31,

2020

 

 

March 31,

2021

 

 

 

 

 

(in thousands)

 

Computers

 

 

 

$

6,324

 

 

$

6,309

 

Laboratory equipment

 

 

 

 

9,423

 

 

 

13,035

 

Furniture and fixtures

 

 

 

 

119

 

 

 

119

 

Leasehold improvements

 

 

 

 

3,708

 

 

 

3,977

 

Operating lease right-of-use assets

 

 

 

 

3,935

 

 

 

17,463

 

Property and equipment

 

 

 

 

23,509

 

 

 

40,903

 

Less accumulated depreciation

 

 

 

 

(5,586

)

 

 

(6,285

)

Property and equipment, net

 

 

 

$

17,923

 

 

$

34,618

 

 

Depreciation expense on property and equipment for the three months ended March 31, 2020 and 2021 was $0.4 million and $0.8 million, respectively.

7. Intangible assets:

 

Intangible assets consisted of the following:

 

 

 

March 31, 2021

 

 

 

Gross

carrying

amount

 

 

Accumulated

amortization

 

 

Net book

value

 

 

 

(in thousands)

 

License

 

$

35,873

 

 

$

4,125

 

 

$

31,748

 

Technology

 

 

41,400

 

 

 

860

 

 

 

40,540

 

IPR&D

 

 

40,400

 

 

 

-

 

 

 

40,400

 

 

 

$

117,673

 

 

$

4,985

 

 

$

112,688

 

 

At March 31, 2021, amortization expense on intangible assets is estimated to be as follows for each of the next five years:

 

 

 

Amortization

Expense

 

 

 

(in thousands)

 

2021

 

$

9,860

 

2022

 

 

9,860

 

2023

 

 

9,834

 

2024

 

 

3,476

 

2025

 

 

3,476

 

 

 

$

36,506

 

 

8. Investments in and loans to equity accounted investees

The Company has entered into two joint ventures as part of the construction of future office and laboratory headquarters. During 2020, the Company entered into a joint venture with Dayhu (Dayhu JV). To date, the equity investment balance of $19.3 million represents the cash contribution made since inception.   In the three months ended March 31, 2021 the Company entered into the Beedie joint venture (Beedie JV). To date we have contributed $11.7 million into the Beedie JV. To date, the Company has not recorded any amount of proportionate income or loss with respect to either venture.

In the three months ended March 31, 2021, the Company made a commitment up to CAD$

7


 

82.7 million ($61.5 million) to the Dayhu JV to fund the construction at a rate referenced to an applicable Canadian bank prime rate plus 0.6%, and repayment on the earlier of thirty months from the date of initial advancement and September 1, 2023, or upon the trigger of certain liquidity events as defined in the agreement. The loan is secured by the underlying land and future assets of the joint venture. At March 31, 2021, the outstanding related party loan balance was $1.2 million to the joint venture.

9. Accounts payable and other liabilities

Accounts payable and other liabilities consisted of the following:

 

 

 

 

 

December 31,

2020

 

 

March 31,

2021

 

 

 

 

 

(in thousands)

 

Accounts payable and accrued liabilities

 

 

 

$

7,130

 

 

$

3,585

 

Liability for in-licensing agreement

 

 

 

 

5,000

 

 

 

4,545

 

Operating lease liability

 

 

 

 

675

 

 

 

1,533

 

Liability classified options

 

 

 

 

4,270

 

 

 

474

 

Government remittances payable

 

 

 

 

1,988

 

 

 

1,207

 

Current portion of deferred grant funding

 

 

 

 

942

 

 

 

1,943

 

Current portion of long-term debt

 

 

 

 

190

 

 

 

-

 

Total accounts payable and other liabilities

 

 

 

$

20,195

 

 

$

13,287

 

 

10. Shareholders’ equity

Sixth Amended and Restated Stock Option Plan:

The Company maintains the AbCellera Biologics Inc. Sixth Amended and Restated Stock Option Plan and our Pre-IPO Plan. Any awards granted under the Pre-IPO Plan will remain subject to the terms of our Pre-IPO Plan and applicable award agreements.

In March 2021, substantially all employee option holders whose awards were liability-classified elected to convert the currency of their option exercise price from Canadian dollars to U.S. dollars for administrative convenience. As a result of the modification, $5.2 million was reclassified from liability to equity.

2020 Share Option and Incentive Plan:

Our 2020 Share Option and Incentive Plan, or 2020 Plan, was approved by our board of directors on November 18, 2020 and approved by our shareholders on December 1, 2020.

As of March 31, 2021, the number of shares available for issuance under the 2020 Plan was 20,075,196, which includes awards granted and outstanding under the Pre-IPO Plan that are forfeited after December 10, 2020.

2020 Employee Share Purchase Plan:

In December 2020, the Company’s Board of Directors approved the 2020 Employee Share Purchase Plan, or the 2020 ESPP. A total of 2,700,000 shares of common stock was initially reserved for issuance under the ESPP. At March 31, 2020 the Company had not yet commenced the ESPP.

The following table summarizes the Company’s stock options granted in Canadian dollars under the Pre-IPO Plan since December 31, 2020:

 

 

 

Number of

Shares

 

 

Weighted-

Average Exercise

Price

 

Outstanding as of December 31, 2020

 

 

53,204,810

 

 

$

0.71

 

Granted

 

 

-

 

 

 

-

 

Exercised

 

 

(1,428,120

)

 

 

0.12

 

Forfeited

 

 

(41,000

)

 

 

10.41

 

Outstanding as of March 31, 2021

 

 

51,735,690

 

 

 

0.72

 

Options exercisable as of March 31, 2021

 

 

25,038,995

 

 

$

0.29

 

 

8


 

 

The following table summarizes the Company’s stock options granted under the 2020 Plan since December 31, 2020:

 

 

 

Number of

Shares

 

 

Weighted-

Average Exercise

Price

 

Outstanding as of December 31, 2020

 

 

1,260,840

 

 

$

20.00

 

Granted

 

 

321,356

 

 

 

52.06

 

Exercised

 

 

-

 

 

 

-

 

Forfeited

 

 

(900

)

 

 

52.30

 

Outstanding as of March 31, 2021

 

 

1,581,296

 

 

$

26.50

 

Options exercisable as of March 31, 2021

 

 

-

 

 

 

-

 

 

As part of the 2020 Plan, restricted share units (RSUs) were available to be granted and offer holders are subject to a one year cliff vesting followed by monthly vesting thereafter. The following table summarizes the Company’s restricted share units granted under the 2020 Plan since December 31, 2020:

 

 

 

Number of

Shares

 

 

Weighted-

Average Grant

Date Fair Value

 

Outstanding as of December 31, 2020

 

 

-

 

 

$

-

 

Granted

 

 

185,108

 

 

 

52.02

 

Exercised

 

 

-

 

 

 

-

 

Forfeited

 

 

(600

)

 

 

52.30

 

Outstanding as of March 31, 2021

 

 

184,508

 

 

$

52.02

 

 

Stock-based compensation:

Stock-based compensation expense was classified in the consolidated statements of income (loss) and comprehensive income (loss) as follows:

 

 

 

Three months ended March 31,

 

 

 

2020

 

 

2021

 

 

 

(in thousands)

 

Research and development

 

$

616

 

 

$

3,158

 

General and administrative

 

 

608

 

 

 

1,316

 

Sales and marketing

 

 

13

 

 

 

953

 

 

 

$

1,237

 

 

$

5,427

 

 

At December 31, 2020, there were 1,012,000 liability classified options outstanding, of which $4.3 million was included in other liabilities. At March 31, 2021 there were 60,000 liability classified options outstanding, of which $0.5 million was included in other liabilities.

11. Revenue

The disaggregated revenue categories are presented on the face of the statement of income (loss) and comprehensive income (loss).

Deferred revenue

Deferred revenue represents payments received for performance obligations not yet satisfied and are presented as current or long-term in the accompanying balance sheets based on the expected timing of satisfaction of the underlying goods and/or services.  

Deferred revenue outstanding in each respective period is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in thousands)

 

December 31, 2019

 

 

March 31, 2020

 

 

December 31, 2020

 

March 31, 2021

 

Deferred revenue

 

$

(5,544

)

 

$

(28,983

)

 

$

(26,230

)

$

(32,375

)

9


 

 

 

During the three months ended March 31, 2020 and 2021, the Company recognized $1.4 million and $1.3 million, respectively, of revenue that had been included in deferred revenue in the previous year.

In March of 2020, the Company entered into a research collaboration and license agreement with Eli Lilly pursuant to which the Company will perform discovery research for several targets for Eli Lilly to develop and commercialize. Under the agreement, the Company is entitled to receive an aggregate of up to $29.0 million of milestone payments as well as royalties in the low single digits based on net sales for non-COVID-19 targets and in the low- to mid-teens for aggregate sales below $125.0 million and mid-teens to mid-twenties on aggregate sales above $125.0 million.

The agreement resulted in initial upfront of $26.7 million, of which $21.9 million was included in deferred revenue at December 31, 2020. In the three months ended March 31, 2021 the Company received an additional $1.1 million in payments, for total payments received in respect of this agreement of $27.8 million. The Company expects to recognize approximately $9.4 million  in revenue in the next 12 months related to these payments under the agreement.

Of the remaining deferred revenue balance of $10.3 million which is related to various other agreements, approximately $1.9 million is expected to be recognized in revenue in the next 12 months.  

License revenue

For the licenses to our intellectual property the Company recognizes revenue from non-refundable, up-front fees when the license is transferred to the customer and the customer is able to use and benefit from the license. For the three months ended March 31, 2021, the Company recognized $20.3 million from license revenue relating to license of the Trianni platform.

 

12. Financial instruments

The Company categorizes its financial assets and liabilities measured at fair value into a three-level hierarchy established by U.S. GAAP that prioritizes those inputs to valuation techniques used to measure fair value based on the degree to which they are observable. The three levels of the fair value hierarchy are as follows: Level 1 inputs are quoted prices in active markets for identical assets and liabilities; Level 2 inputs, other than quoted prices included within Level 1, are observable for the asset or liability either directly or indirectly; and Level 3 inputs are not observable in the market.

The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, loans to related parties, accounts payable and accrued liabilities and royalties payable, operating lease obligations, long-term debt, and contingent consideration payable. The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, and bank indebtedness approximate their fair values due to the immediate and short-term maturity of these financial instruments. The fair value of loans to related party approximate the carrying value as the interest rates approximate the rates applicable for non-related party loans.

At December 31, 2020 and March 31, 2021, the carrying value of long-term debt was $2.2 million and $0.9 million, respectively, and have been included in Other long-term liabilities on the balance sheet. The estimated fair value of long-term debt of $2.3 million and $1.2 million at December 31, 2020 and March 31, 2021, respectively, are classified as Level 2 and have been determined by discounting future principal and interest amounts at estimated interest rates expected to be available to the Company at period end.  

Contingent consideration related to business acquisitions are recorded at fair value on the acquisition date and adjusted on a recurring basis for changes in its fair value. Changes in the fair value of contingent consideration liabilities can result from changes in anticipated payments and changes in assumed discount periods and rates. These inputs are unobservable in the market and therefore categorized as Level 3 inputs.  

The following table presents the changes in fair value of the liability for contingent consideration:

 

(in thousands)

 

Liability at

beginning of

the period

 

 

Increase

(decrease) in fair

value of liability

for contingent

consideration

 

Liability at

end of the

period

 

Three months ended March 31, 2021

 

$

22,559

 

 

581

 

$

23,140

 

 

10


 

 

13. Commitments and contingencies

From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company does not have contingency reserves established for any litigation liabilities and any of the costs related to such legal proceedings are expensed as incurred.

The Company may enter into certain agreements with strategic partners in the ordinary course of operations that may include contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements.

Pursuant to the agreements, the Company may be obligated to make research and development and regulatory milestone payments upon the occurrence of certain events and upon receipt of royalty payments in the low single-digits to mid-twenties based on certain net sales targets. During the three months ended March 31, 2021, the Company has expensed approximately $20.0 million related to such obligations, of which that same amount is included in current liabilities.

During the quarter ended March 31, 2021 the Company entered into a lease for office and laboratory space in Sydney, Australia representing future lease payments of $0.7 million for the current year, approximately $1.5 million for each of the next four years and $9.7 million thereafter. In the three months ended March 31, 2021, the Company recognized a lease liability of $13.9 million , with a corresponding right of use asset , utilizing a ten year term and 3.0% discount rate.  

The Company entered into a lease for office and laboratory space in Vancouver, Canada, in conjunction with our 50% owned joint venture agreement, representing future lease payments of $1.5 million due in four years, $5.9 million due in five years, and approximately $135.0 million thereafter.  The lease liability and corresponding right of use asset will be recognized on lease commencement date after completion of construction of the office and laboratory space.

 

 

11


 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings “Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. Forward-looking statements can often be identified by the use of terminology such as “subject to”, “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. In particular, these forward-looking statements include, but are not limited to:

 

our expectations regarding the rate and degree of market acceptance of our drug-discovery platform;

 

companies and technologies in our industry that we compete with;

 

our ability to manage and grow our business by expanding our sales to existing partners or introducing our drug-discovery platform to new partners;

 

our ability to provide our partners with a full solution from target to IND submission;

 

our expectations regarding the completion of our GMP facility and our manufacturing capabilities;

 

our ability to establish and maintain intellectual property protection for our technologies and workflows, including with      respect to our intellectual property litigation with Berkeley Lights, or avoid or defend against claims of infringement;

 

our ability to attract, hire and retain key personnel and to manage our future growth effectively;

 

our ability to obtain additional financing in future offerings;

 

the volatility of the trading price of our common shares;

 

our ability to attract and retain key scientific and engineering personnel;

 

our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act;

 

business disruptions affecting our operations and the development of our platform due to the global COVID-19 pandemic;

 

our ability to remediate our material weaknesses;

 

our expectations regarding our PFIC status for our taxable year ended December 31, 2020 or any future taxable year;

 

our expectations regarding the Trianni acquisition and our ability to realize the intended benefits of such transaction;

 

our expectations regarding the use of proceeds from our initial public offering;

 

our expectations about market trends; and

 

our ability to predict and manage government regulation.

We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. Moreover, we operate in a competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures, or investments we may make or enter into.

12


 

You should read this Quarterly Report and the documents that we file with the Securities and Exchange Commission, or the SEC, with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Quarterly Report are made as of the date of this Quarterly Report, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

This Quarterly Report includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties as well as our own estimates of potential market opportunities. All of the market data used in this Quarterly Report involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research, and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.

We express all amounts in this Quarterly Report on Form 10-Q in U.S. dollars, except where otherwise indicated. References to “$” and “US$” are to U.S. dollars and references to “C$” and “CAD$” are to Canadian dollars.

Except as otherwise indicated, references in this Quarterly Report on Form 10-Q to “AbCellera,” the “Company,” “we,” “us” and “our” refer to AbCellera Biologics Inc. and its consolidated subsidiaries.

Impact of COVID-19

At the onset of the pandemic in March 2020, the Company took proactive measures to protect the health and safety of our employees, business partners, vendors, and contractors. Some of the actions taken include the following:

 

We implemented a comprehensive COVID-19 policy and communication platform and provided real-time updates company-wide relying on directives from local health authorities. As the situation progressed, we adapted accordingly, including adjusting all administrative staff to work from home.

 

We implemented protocols for employees necessary to carryout Company functions in the office and laboratory facilities including physical distancing, personal and protective equipment, signage, erecting barriers between desks and lab benches, and implementing space restrictions for different areas of the facilities.

 

Consistent with national and local health authorities, we restricted business travel and implemented procedures to control and monitor all office and facility access.

 

We have not been required to stop laboratory and research activities due to the COVID-19 pandemic. We will continue to adapt and apply new measures as required and as directed by local health authorities.

Overview

We believe that the surest path to a better future is through technological advancement and that the new frontier of technology lies at the interface of computation, engineering and biology. Our mission is to improve health with technologies that transform the way that antibody-based therapies are discovered. We aim to become the centralized operating system for next generation antibody discovery.

Our full-stack, artificial intelligence-, or AI, powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. We believe our technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable. Rather than advancing our own clinical pipeline of drug candidates, we forge partnerships with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies. We empower them to move quickly, reduce cost and tackle the toughest problems in drug development As of March 31, 2021, we had 119 discovery programs that are either completed, in progress or under contract

13


 

with 29 partners. As a recent example, in a collaboration with Eli Lilly and Company, or Lilly, we applied our technology stack to co-develop bamlanivimab, a potential antibody therapy to treat and prevent COVID-19. Starting from a single blood sample obtained from a convalescent patient, we and our partners identified a viable antibody drug candidate within three weeks that advanced into clinical testing 90 days after initiation of the program. Lilly progressed into these clinical trials at a greatly accelerated pace as a result of the Coronavirus Treatment Acceleration Program, which is a special emergency program for possible coronavirus therapies created by the FDA in 2020 to expedite the development of potentially safe and effective life-saving treatments to combat the COVID-19 pandemic. With respect to other or future product candidates, there is no assurance that any of our partners or collaborators will be able to advance a product candidate into clinical development on this timeframe again in the future, or at all. We initiated our partnering program in 2015 and have only had this one program result in milestone and royalty payments to us to date and we have not yet had a program receive marketing approval.

We structure our agreements in a way that is designed to align our partners’ economic interests with our own. We forge partnerships with large cap pharmaceutical companies, biotechnology companies of all sizes and non-profit and government organizations. Our partners select a target and define the antibody properties needed for therapeutic development. We provide discovery solutions to partners that have a range of discovery capabilities, from the highly enabled to the less enabled. We enable discovery against targets that have traditionally been intractable, and we accelerate programs against less difficult targets.

Our deals emphasize participation in the success and upside of future antibody therapeutics. Our partnership agreements include near-term payments for technology access, research and intellectual property rights, and downstream payments in the form of clinical and commercial milestones, and royalties on net sales. Longer-term we are eligible to receive additional payments upon satisfaction of clinical and commercial milestones, which we refer to as milestone payments, as well as royalties on sales of products derived from antibodies that we discover for our partners. Our discovery partnerships generally include royalty payments on net sales in the single digit to low-double digit range.

We generated revenue of $4.7 million and $202.7 million for the three months ended March 31, 2020 and 2021, respectively. As of March 31, 2021, we had a total of 29 partners for whom we were conducting drug discovery activities. For the three months ended March 31, 2020, three of our partners accounted for 51%, 12%, and 11% of research fees revenue and five partners accounted for the remaining 26% of research fees revenue. For the three months ended March 31, 2021, three of our partners accounted for 36%, 24% and 20% of research fees revenue, and seven partners accounted for the remaining 20% of research fees revenue. For the three months ended March 31, 2021 we recognized a milestone payment and royalty revenue streams, totaling $178.5 million, exclusively from our partnership with Lilly. Our partnership with Lilly constituted one of the partnerships that generated 10% or more of our consolidated revenues during the one or more periods described above. With respect to the other partners, we do not believe the loss of any one or more of such partners would have a material adverse effect on us and our subsidiaries taken as a whole. We have also grown the number of programs that we have under contract with our partners, as illustrated by the following charts.

 

 

We incurred sales and marketing expenses of $0.5 million and $2.6 million for the three months ended March 31, 2020 and 2021, respectively. We are significantly increasing investment into our business development team and into marketing our solutions to new and existing partners.

14


 

We focus a substantial portion of our resources on research and development efforts towards deepening our technology and expertise along our technology stack, and we expect to continue to make significant investments in this area for the foreseeable future. We incurred research and development expenses of $4.1 million and $12.4 million for the three months ended March 31, 2020 and 2021, respectively. We incurred general and administrative expenses of $1.7 million and $6.4 million for the three months ended March 31, 2020 and 2021, respectively. We expect to continue to incur significant expenses, and we expect such expenses to increase substantially in connection with our ongoing activities, including as we:

 

Invest in research and development activities to improve our technology stack and platform;

 

Market and sell our solutions to existing and new partners;

 

Expand and enhance operations to deliver programs, including investments in manufacturing;

 

Acquire businesses or technologies to support the growth of our business;

 

Attract, hire and retain qualified personnel;

 

Continue to establish, protect and defend our intellectual property and patent portfolio, including our ongoing litigation; and

 

Operate as a public company.

To date, we have financed our operations primarily from revenue from our drug discovery partnerships in the form of research fees, government funding from grants, external borrowings, and from the issuance and sale of convertible preferred shares and notes, and common shares.

Our net loss for the three months ended March 31, 2020 was $2.1 million and our net earnings for the three months ended March 31, 2021 were $117.2 million. As of March 31, 2021, we had accumulated earnings of $231.4 million and we had cash and cash equivalents totaling $685.8 million.

 

Recent Developments

In March 2020, we entered into a discovery partnership agreement with Eli Lilly and Company, or Lilly, pursuant to which we will perform discovery research for a number of targets for Lilly that will result in antibodies for Lilly to develop and potentially commercialize. This partnership includes the licensing of bamlanivimab, a monoclonal antibody designed to block viral attachment of the COVID-19 virus and its entry into human cells as well as other candidate antibodies against COVID-19 discovered by AbCellera. On June 1, 2020, 90 days after program initiation, bamlanivimab moved to first-in-human testing and progressed to Phase 3 clinical trials by July 2020.

In December 2020, we completed AbCellera’s IPO on the Nasdaq. The Company completed the sale of 27,772,500 shares of its common shares in the IPO at a price to the public of $20.00 per share. The Company raised gross proceeds of $555.5 million, or aggregate net proceeds of $522.8 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. Immediately prior to the completion of our IPO, our convertible preferred shares and notes were converted to common shares.

In February 2021, it was announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), administered with a second Lilly antibody, etesevimab (LY-CoV016) 1400 mg, has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization. New protocols enable front-line clinicians to administer bamlanivimab alone, and bamlanivimab and etesevimab together, in as few as 16 minutes and 21 minutes, respectively.

In February 2021, we announced the appointment of Ester Falconer, Ph.D. as our Chief Technology Officer.  As CTO, Dr. Falconer will lead our long-term strategy in the development, aggregation, and integration of technologies that improve the speed and success of therapeutic antibody discovery from target to investigational new drug application submission.

15


 

In March 2021, we entered agreements to expand our collaboration with Gilead Sciences, Inc. including a multi-year, multi-target antibody discovery collaboration and access to our humanized mouse technology, the Trianni Mouse®.  Under the financial terms of the agreements, we will receive an upfront payment and we are eligible for milestone payments and royalties based on the development and commercialization of antibodies generated by the Company under this collaboration.

On March 5, 2021 the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion for bamlanivimab alone and bamlanivimab administered together with etesevimab. The opinion advises bamlanivimab alone and bamlanivimab administered together with etesevimab can be used for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at high risk of progressing.

On March 10, 2021 Lilly reported Phase 3 clinical trials results that showed that bamlanivimab 700 mg and etesevimab 1400 mg together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19.

In April 2021, the Company announced it entered into a joint venture (Beedie JV) whereby we will invest in equal shares of a Vancouver building development to be leased exclusively by AbCellera for additional office and lab facilities for our future office headquarters.

In April 2021, Eli Lilly and Company (Lilly) requested the U.S. FDA revoke the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg alone. Lilly made this request due to the evolving variant landscape in the U.S. and the full availability of bamlanivimab and etesevimab together. The request was not due to any new safety concern. This final step in Lilly's transition to only supply bamlanivimab and etesevimab for administration together in the U.S. for the treatment of COVID-19 – as planned with the FDA – followed the modification of contracts with the U.S. government to ensure adequate supply of etesevimab to be used together with bamlanivimab. The FDA announced that it had revoked the EUA for bamlanivimab 700 mg alone on April 16, 2020.

In April 2021, we entered multi-target collaboration agreement with Empirico Inc. The agreement will leverage the Company's hyper-scale datasets, machine learning, and advanced computation to both identify high-value, genetically-validated drug targets and discover novel therapeutic antibodies while Empirico will use its Precision Insights Platform, a human genetics-focused discovery platform, to select up to five therapeutic targets. Under the terms of the agreement, Empirico will have the rights to develop and commercialize novel antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products from Empirico.

In May 2021, the Company announced that a second antibody from its collaboration with Lilly, LY-CoV1404, entered clinical trials in patients with mild-to-moderate COVID-19. Lilly expanded its ongoing BLAZE-4 trials to evaluate LY-CoV1404 alone and together with other monoclonal antibodies.

 

Key Factors Affecting Our Results of Operations and Future Performance

We believe that our financial performance has been, and in the foreseeable future will continue to be, primarily driven by multiple factors as described below, each of which presents growth opportunities for our business. These factors also pose important challenges that we must successfully address in order to sustain our growth and improve our results of operations. Our ability to successfully address these challenges is subject to various risks and uncertainties, including those described in Part II, Item 1A of this report, captioned “Risk Factors”.

 

Securing additional programs under contract. Our potential to grow revenue, in both the near and long term, is dependent on our ability to secure additional programs under contract from new and existing partners. For existing partners, we seek to expand our relationships with them to cover multi-year, multi-target programs. Since our first commercial partnership in 2015, as of March 31, 2021, we had 119 discovery programs that are either completed, in progress or under contract with 29 partners. We are building our business development team across the major biotechnology geographic hubs in order to bring in new partners and new programs under contract, and we believe that we have a significant opportunity to continue to increase the number of partners who have programs based on our platform. Our ability to continue to grow our number of programs under contract is dependent upon our ability to educate the market and support the business through investment in our sales and marketing efforts and through further research and development to enhance our technological differentiation.

 

Our partners successfully developing and commercializing the antibodies that we discover. Until recently, we had generated nearly all of our revenue from research fees. We estimate that, based on the terms of our existing contracts and estimates of historical rates of success of antibody drug development, the vast majority of the potential value for each

16


 

 

program under contract is represented by potential future milestone payments and royalties rather than research fees. As a result, we believe our business and our future results of operations will be highly reliant on the degree to which our partners successfully develop and commercialize the antibodies that we discover based on contracts with our partners. As our partners continue to advance development of the antibodies that we have discovered, we expect to start receiving additional milestone payments and royalties if any partners commence commercial sales of such antibodies.

 

Rate and timing of selecting and initiating discovery projects by our partners. Once programs are secured under contract, partners must select targets and agree on a detailed statement of work before we commence discovery research on any antibodies. The rate and timing of such selection and initiation differs from partner to partner. Because the vast majority of research fees that we are entitled to recognize under our partnerships depend on our delivery of antibodies for development by our partners, any delays by our partners in selecting targets and agreeing on statements of work will impact revenue recognition.

 

Investing in enhancements to our technology stack. Our ability to maintain and expand our partnerships is dependent on the advantages our technology stack delivers to our partners. We intend to maintain our leading position through research and development investments to refine and add capabilities in areas such as computation, protein engineering, immunization technologies, genetically engineered rodents and cell line selection. We have successfully closed and will continue to look for strategic technology acquisitions to improve, broaden and deepen our capabilities and expertise in antibody drug discovery and development, or those that offer opportunities to expand our partnership business into adjacent therapeutic modalities. We intend to devote substantial resources to continue to improve our technological differentiation which will impact our financial performance.

 

Scaling our operations to execute on discovery programs. As we secure additional programs under contract and as our partners initiate discovery programs, our operational capacity to execute such research activities may become strained. We are making significant investments in capital and time to increase our ability to address future growth, including building new headquarters, building a new small-scale manufacturing plant, investing in research and development and hiring more talented personnel across functions. We have new facilities under development scheduled to take occupancy in late 2021 and 2023 that are intended to materially expand capacity. As we expand our workforce, we expect a significant increase in our operating expenses, including stock-based compensation.

Key Business Metrics

We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops. For example, as our business matures and to the extent programs are discontinued, we anticipate updating these metrics to reflect such changes.

 

Metric

 

March 31,

2020

 

 

March 31,

2021

 

 

Change %

 

Number of discovery partners

 

 

24

 

 

 

29

 

 

 

21

%

Programs under contract, cumulative

 

 

73

 

 

 

119

 

 

 

63

%

Program starts, cumulative

 

 

47

 

 

 

54

 

 

 

15

%

Programs in the clinic

 

 

-

 

 

 

1

 

 

N/M

 

 

Number of discovery partners represents the unique number of partners with whom we have executed partnership contracts. We view this metric as an indication of the competitiveness of our technology stack and our current level of market penetration. The metric also relates to our opportunities to secure programs under contract from existing customers through repeat business opportunities.

Programs under contract represent the number of antibody development programs that are under contract for delivery of discovery research activities. A program under contract is counted when a contract is executed with a partner under which we commit to discover antibodies against one selected target. A target is any relevant antigen for which a partner seeks our support in developing binding antibodies. We view this metric as an indication of commercial success and technological competitiveness. It further relates to revenue from technology access fees. The cumulative number of programs under contract with downstream participation is related to our ability to generate future revenue from milestone payments and royalties.

Program starts represent the number of unique programs under contract for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of our

17


 

operational capacity to execute on programs under contract. It is also an indication of the selection and initiation of discovery projects by our partners and the resulting near-term potential to earn research fees. Cumulatively, program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties in the mid- to long-term.

Programs in the clinic represent the count of unique molecules for which an Investigational New Drug, or IND, New Animal Drug or Pre-Market Approval, or PMA, application, or equivalents under other regulatory regimes, has been filed based on an antibody that was discovered by us. Where the date of such application is not known to us, the date of the first public announcement of clinical trials will be used instead for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.

Components of Results of Operations

Revenue

Our revenue is comprised of partnership research fees, licensing revenue, development milestones, and royalty payments from commercial products. Research fees consist primarily of technology access fees, which are generally generated upon execution of our partnership agreements, and discovery research fees, which are generated through our performance of antibody discovery research for our partners. Licensing revenue is primarily from our licensing of our humanized rodent platform, Trianni™. Our partnership agreements also entitle us to receive payments upon the satisfaction of clinical, approval, and commercial milestones as well as royalties on our partners’ commercial sales of the molecules that we discover.

We expect revenue to increase over time as we secure additional programs under contract and conduct discovery efforts for our partners, and as our partners continue the development of the antibodies that we deliver. We expect that our revenue will fluctuate from period to period due to the timing of securing additional programs under contract, the inherently uncertain nature of the timing of milestone achievement and our dependence on the program decisions of our partners.

Operating Expenses

Royalty Fees. Royalty fees consist of certain contractual royalty payments to our strategic partners upon receipt of royalty revenue based on our customers third-party net sales.  Royalty fees are not included in every program. For royalties received from Lilly for commercial sales of bamlanivimab, royalty fees are due to collaboration partners in AbCellera’s DARPA P3 (Pandemic Preparedness Program) project focused on rapid pandemic response. Royalty fees are recorded when the third-party sale occurs.

Research and Development Expenses. Research and development expenses primarily consist of salaries, benefits, incentive compensation, stock-based compensation, laboratory supplies, materials expenses for employees and contractors engaged in research and product development, and facilities expenses related to direct research and development activities. These expenses are exclusive of depreciation and amortization. Research and development activities consist of discovery research for partners as well as our internal platform development. We derive improvements to our technology stack from both types of activities.

We expect to continue to incur substantial research and development expenses as we conduct discovery research for our partners. In addition, we plan to continue to invest in research and development to enhance our solutions and offerings to our partners, including hiring additional employees and continuing research and development projects obtained through strategic technology acquisitions. As a result, we expect that our research and development expenses will continue to increase in absolute dollars in future periods and vary from period to period as a percentage of revenue.

Sales and Marketing Expenses. Our sales and marketing expenses consist primarily of salaries, benefits, and stock-based compensation costs for employees within our commercial sales functions, as well as marketing, travel expenses and information technology costs that are directly associated with sales and marketing efforts, such as client relationship management tools and other information technology data tools to provide insight into market segments and trends. This activity has been complemented with research and development staff attending a variety of scientific conferences, which has helped increase the business development pipeline. The associated expenses are included in research and development expenses as scientific conference attendance is primarily related to our research and development efforts. We expect our sales and marketing expenses to increase in absolute dollars as we expand our commercial sales, marketing and business development teams; increase our presence globally; and increase marketing activities to drive awareness and adoption of our platform.

General and Administrative Expenses. General and administrative expenses primarily consist of salaries, benefits and stock-based compensation costs for employees in our executive, accounting and finance, project management, corporate development, office administration, legal and human resources functions as well as professional services fees, such as consulting, audit, tax and legal fees, general corporate costs and allocated overhead expenses. We expect that our general and administrative expenses will continue to

18


 

increase in absolute dollars in future periods, primarily due to increased headcount to support anticipated growth in the business and due to incremental costs associated with operating as a public company, including costs to comply with the rules and regulations applicable to companies listed on a securities exchange and costs related to compliance and reporting obligations pursuant to the rules and regulations of the SEC and stock exchange listing standards, public relations, insurance and professional services. We expect these expenses to vary from period to period as a percentage of revenue.

Depreciation and Amortization. Depreciation expense consists of the depreciation of property and equipment used actively in the business, primarily by research and development activities. Amortization expense includes the amortization of intangible assets over their respective useful lives.

Other (Income) Expense. Other (Income) Expense consists of interest income earned on our cash balances, interest expense related to borrowings under any credit agreements, and foreign exchange (gain) loss due to fluctuation in exchange rates between the Canadian dollar and the U.S. dollar.

Grants and Incentives. Grants and incentives include cost recovery on activities that qualified for approved projects supported by grant funding or tax credits. Grants primarily include the benefit from programs administered by the Canadian government’s Ministry of Innovation, Science and Economic Development, such as their Industrial Research Assistance Program, and the Strategic Innovation Fund. To the extent that grant funding covers capital expenditures, a deferred credit is recorded on the balance sheet and recognized rateably over the benefit period of the related expenditure for which the grant was intended to compensate.

Results of operations

Comparison of the three months ended March 31, 2020 and 2021

The following table summarizes our unaudited results of operations data for the three months ended March 31, 2020 and 2021:

 

 

 

Three months ended

March 31,

 

 

 

2020

 

 

2021

 

Revenue:

 

 

 

 

 

 

 

 

Research fees

 

$

4,657

 

 

$

3,986

 

Licensing revenue

 

 

-

 

 

 

20,259

 

Milestone payments

 

 

-

 

 

 

7,000

 

Royalty revenue

 

 

-

 

 

 

171,496

 

Total revenue

 

 

4,657

 

 

 

202,741

 

Operating expenses:

 

 

 

 

 

 

 

 

Royalty fees

 

 

-

 

 

 

20,010

 

Research and development(1)

 

 

4,118

 

 

 

12,352

 

Sales and marketing(1)

 

 

437

 

 

 

2,578

 

General and administrative(1)

 

 

1,650

 

 

 

6,422

 

Depreciation and amortization

 

 

574

 

 

 

3,305

 

Total operating expenses

 

 

6,779

 

 

 

44,667

 

Income (loss) from operations

 

 

(2,122

)

 

 

158,074

 

Other (income) expense:

 

 

 

 

 

 

 

 

Other (income) expense

 

 

1,001

 

 

 

(265

)

Grants and incentives

 

 

(1,030

)

 

 

(3,148

)

Total other income

 

 

(29

)

 

 

(3,413

)

Net earnings (loss) before income tax

 

 

(2,093

)

 

 

161,487

 

Provision for income tax

 

 

-

 

 

 

44,266

 

Net earnings (loss) for the year

 

$

(2,093

)

 

$

117,221

 

Net earnings (loss) per share attributable to common shareholders

 

 

 

 

 

 

 

 

Basic

 

$

(0.01

)

 

$

0.43

 

Diluted

 

$

(0.01

)

 

$

0.37

 

Weighted-average common shares outstanding

 

 

 

 

 

 

 

 

Basic

 

 

151,859,924

 

 

 

269,697,212

 

Diluted

 

 

151,859,924

 

 

 

320,282,747

 

 

(1)

Amounts are exclusive of depreciation and amortization. Amounts include stock-based compensation as follows:

19


 

 

 

 

 

 

Three months ended March 31,

 

 

 

2020

 

 

2021

 

 

 

(in thousands)

 

Research and development

 

$

616

 

 

$

3,158

 

General and administrative

 

 

608

 

 

 

1,316

 

Sales and marketing

 

 

13

 

 

 

953

 

 

 

$

1,237

 

 

$

5,427

 

 

 

Revenue

 

 

 

Three months ended

March 31,

 

 

Change

 

 

 

2020

 

 

2021

 

 

Amount

 

 

%

 

 

 

(in thousands, except percentages)

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research fees

 

$

4,657

 

 

$

3,986

 

 

$

(671

)

 

 

-14

%

Licensing revenue

 

 

-

 

 

 

20,259

 

 

 

20,259

 

 

N/A

 

Milestone payments

 

 

-

 

 

 

7,000

 

 

 

7,000

 

 

N/A

 

Royalty revenue

 

 

-

 

 

 

171,496

 

 

 

171,496

 

 

N/A

 

Total revenue

 

$

4,657

 

 

$

202,741

 

 

$

198,084

 

 

 

4253

%

 

Revenue increased by $198.1 million from the three months ended March 31, 2020 to March 31, 2021. We received a milestone payment upon the first commercial sale in Europe by Lilly relating to molecule bamlanivimab for treatment of COVID-19 in the amount of $7.0 million. Royalty payments of $171.5 million are directly associated with the specified percentage of proceeds that Lilly received from the sales of bamlanivimab. We earned $20.3 million in licensing revenue related to the recently acquired Trianni humanized rodent platform business. Despite a significant increase in cumulative Programs Under Contract compared to the same period in the previous year, revenues associated to research fees decreased by $0.7 million for the three months ended March 31, 2021. The decrease was driven by a reduction in revenue from our DARPA COVID-19 antibody discovery program.

Operating Expenses

Royalty Fees

 

 

 

Three months ended

March 31,

 

 

Change

 

 

2020

 

 

2021

 

 

Amount

 

 

%

 

 

(in thousands, except percentages)

Royalty fees

 

$

 

 

$

20,010

 

 

$

20,010

 

 

N/A

 

Royalty fees for the three months ended March 31, 2021 were $20.0 million. These were directly attributable to the royalty revenues received by the Company from sales of bamlanivimab by Lilly due to AbCellera’s collaborators in pandemic response.

Research and Development

 

 

 

Three months ended

March 31,

 

 

Change

 

 

 

2020

 

 

2021

 

 

Amount

 

 

%

 

 

 

(in thousands, except percentages)

 

Research and development

 

$

4,118

 

 

$

12,352

 

 

$

8,234

 

 

 

200

%

 

Research and development expenses increased by $8.2 million, or 200%, from the three months ended March 31, 2020 to March 31, 2021. $5.9 million of the increase is due to the increase in compensation expense consistent with the increase in headcount. $2.3 million of the increase is attributed to an increase in research materials, facilities, supplies and services consistent with the overall increase in research and development activities.

 

20


 

 

Sales and Marketing

 

 

 

Three months ended

March 31,

 

 

Change

 

 

 

2020

 

 

2021

 

 

Amount

 

 

%

 

 

 

(in thousands, except percentages)

 

Sales and marketing

 

$

437

 

 

$

2,578

 

 

$

2,141

 

 

 

490

%

 

Sales and marketing expenses increased by $2.1 million, or 490%, from the three months ended March 31, 2020 to March 31, 2021. $1.1 million of the increase is due to the increase in compensation expense consistent with increased headcount. $0.8 million of the increase is attributable to a donation made to Surrey Hospital to fund a study related to bamlanivimab in Canada. Sales and marketing expenses related to travel were significantly lower for the three months ended March 31, 2021 due to continued COVID-19 related travel restrictions.

General and Administrative

 

 

 

Three months ended

March 31,

 

 

Change

 

 

 

2020

 

 

2021

 

 

Amount

 

 

%

 

 

 

(in thousands, except percentages)

 

General and administrative

 

$

1,650

 

 

$

6,422

 

 

$

4,772

 

 

 

289

%

 

General and administrative expenses increased by $4.8 million, or 289%, from the three months ended March 31, 2020 to March 31, 2021. $1.4 million of the increase was driven by increased headcount within the general and administrative function and the associated compensation expenses. $2.2 million is attributable to legal and corporate matters as a public company. $1.0 million of the increase in general and administrative expense is due to increased expenditures related to director and office insurance and increased general office expense.

Depreciation and Amortization

 

 

 

Three months ended

March 31,

 

 

Change

 

 

 

2020

 

 

2021

 

 

Amount

 

 

%

 

 

 

(in thousands, except percentages)

 

Depreciation and amortization

 

$

574

 

 

$

3,305

 

 

$

2,731

 

 

 

476

%

 

Depreciation and amortization expenses increased by $2.7 million, or 476%, from the three months ended March 31, 2020 to March 31, 2021. Amortization expense increased by $2.5 million due to the amortization of acquired intangible assets over their respective useful lives. Depreciation expense increased by $0.3 million due to the depreciation of equipment and facilities related to capital equipment purchases.

Other (Income) Expense

 

 

 

Three months ended

March 31,

 

 

Change

 

 

 

2020

 

 

2021

 

 

Amount

 

 

%

 

 

 

(in thousands, except percentages)

 

Other (income) expense

 

$

1,001

 

 

$

(265

)

 

$

(1,266

)

 

 

-126

%

 

Other (income) expense decreased by $1.3 million, or 126%, from the three months ended March 31, 2020 to March 31, 2021. Other (income) expense for 2020 included a foreign exchange loss of $0.9 million along with offsetting interest income and expense amounts. Other (income) expense for the three months ended March 31, 2021 included a foreign exchange loss of $0.5 million and a $1.1 million gain on fair value adjustments.

21


 

Grants and Incentives

 

 

 

Three months ended

March 31,

 

 

Change

 

 

 

2020

 

 

2021

 

 

Amount

 

 

%

 

 

 

(in thousands, except percentages)

 

Grants and incentives

 

$

(1,030

)

 

$

(3,148

)

 

$

(2,118

)

 

 

206

%

 

Grants and incentives increased by $2.1 million, or 206%, from the three months ended March 31, 2020 to March 31, 2021. This increase is attributable to increased research and development expenditures incurred during the quarter that are eligible for the SIF project.

Liquidity and Capital Resources

As of March 31, 2021, we had $685.8 million of cash and cash equivalents. The increase of $91.7 million since December 31, 2020 was driven primarily from cash flow from operations in the first quarter of 2021.

We have generated positive operating cash flow cumulatively since our inception in 2012 and in every year since 2018. We intend to significantly invest in our business, and as a result may incur operating losses in future periods. We will continue to invest in research and development efforts towards expanding our capabilities and expertise along our technology stack, the building of our business development team and marketing our solutions to new and existing partners, and the expansion of our future office headquarters, and related infrastructure, including execution of long-term office-lease arrangements. Based on our current business plan, we believe that our existing cash and cash equivalents and anticipated cash flows from operations, will be sufficient to meet our working capital and capital expenditure needs over at least the next 24 months following the date of this report.

Cash Flows

The following table summarizes our cash flows for the periods presented:

 

 

 

Three months ended

March 31,

 

 

 

2020

 

 

2021

 

 

 

(in thousands)

 

Net cash provided by (used in):

 

 

 

 

 

 

 

 

Operating activities

 

$

(764

)

 

$

109,545

 

Investing activities

 

 

(5,583

)

 

 

(15,839

)

Financing activities

 

 

87,738

 

 

 

(1,543

)

Net increase in cash and cash equivalents

 

$

81,391

 

 

$

92,163

 

 

Operating activities

Net cash (used in) provided by operating activities increased from cash used of $0.8 million in the three months ended March 31, 2020 to cash provided by operating activities of $109.5 million in the three months ended March 31, 2021. The increase resulted primarily from increased revenue from royalty and licensing streams, satisfaction of clinical milestones under our partnership with Lilly, and continued discovery research activities, as well as securing new multi-year, multi-target contracts with partners.

Investing activities

Net cash used in by investing activities increased from $5.6 million in the three months ended March 31, 2020 to $15.8 million in the three months ended March 31, 2021. Investing activities during the three months ended March 31, 2020 were directly attributed to the purchase of intangible assets.  Investing activities during the three months ended March 31, 2021 are attributable to our investment in real estate, facilities and equipment in our Vancouver offices.

Financing activities

Net cash provide by financing activities was $87.7 million for the three months ended March 31, 2020. This was due to proceeds from our Series A2 financing. Net cash used by financing activities was $1.5 million for the three months ended March 31, 2021 due to repayment of long-term debt.

22


 

Critical Accounting Policies and Significant Judgements and Estimates

Detailed information about our critical accounting policies and estimates is set forth in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2020. There have been no significant changes to these policies during the three months ended March 31, 2021 other than for the inclusion of license revenue as disclosed in the condensed consolidated financial statements included elsewhere in this report.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Concentration of Credit Risk

For the three months ended March 31, 2020, three of our partners accounted for 51%, 12%, and 11% of research fees revenue and five partners accounted for the remaining 26% of research fees revenue. For the three months ended March 31, 2021, three of our partners accounted for 36%, 24% and 20% of our research fees revenue and seven partners accounted for the remaining 20% of research fees revenue. For the three months ended March 31, 2021 we recognized a clinical milestone payment and royalty revenues, totaling $173.8 million, exclusively from our partnership with Lilly. Our partnership with Lilly constituted one of the partnerships that generated 10% or more of our consolidated revenues during the one or more periods described above. With respect to the other partners, we do not believe the loss of any one or more of such partners would have a material adverse effect on us and our subsidiaries taken as a whole.

Interest Rate Risk

As of March 31, 2021, we had a cash and cash equivalents balance of $685.8 million, a majority of which was maintained in bank accounts and term deposits. Our primary exposure to market risk is to interest income volatility, which is affected by changes in the general level of interest rates. As such rates are at a near record low, a 10% change in the market interest rates would not have a material effect on our business, financial condition or results of operations.

Foreign Currency Risk

We are exposed to financial risks as a result of exchange rate fluctuations between the U.S. dollar and the Canadian dollar and the volatility of these rates. In the normal course of business, we earn revenue denominated in U.S. dollars and we incur expenses in Canadian denominated, U.S. denominated and Australian denominated dollars. Our reporting currency is the U.S. dollar. We hold a majority of our cash in U.S. dollars. To date, we have not entered into any hedging arrangements with respect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to manage our risk relating to fluctuations in currency exchange rates.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, are designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures are designed to ensure that information required to be disclosed is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, to allow timely decisions regarding required disclosure.

 

Based upon our evaluation of the Company’s disclosure controls and procedures, as of March 31, 2021, the CEO and the CFO concluded that the disclosure controls were not effective, due to the material weakness in internal control over financial reporting disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.  In light of this fact, our management has performed additional analyses, reconciliations, and other post-closing procedures and has concluded that, notwithstanding the material weakness in our internal control over financial reporting, the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with GAAP. 

Changes in Internal Control over Financial Reporting

 

We are taking actions to remediate the material weakness relating to our internal control over financial reporting, as described below. Except as otherwise described herein, there was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

23


 

 

Ongoing Remediation of Material Weakness in Internal Control over Financial Reporting

While management believes that progress has been made in enhancing internal controls as of March 31, 2021, and in the period since, the material weakness described in Part II, Item 9A, “Controls and Procedures” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, has not been fully remediated due to insufficient time to assess the design, fully implement remediation and assess operating effectiveness of the related controls. Management will continue to evaluate and work to improve our disclosure controls and procedures and internal control over financial reporting throughout 2021, and will make any further changes management deems appropriate. We expect that the remediation of the identified material weakness will be completed by the end of the fiscal year.

 

24


 

 

PART II—OTHER INFORMATION

There have been no material changes to legal proceedings as set forth in the Form 10-K filed with the SEC on March 30, 2021.

Item 1A. Risk Factors.

 

There have been no material changes to the risk factors from the information provided in Item 1A. Risk Factors of our 2020 Annual Report on Form 10-K, with the exception of the below.

Our quarterly and annual operating results have fluctuated significantly in the past and may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.

Our quarterly and annual operating results have fluctuated in the past and may fluctuate in the future, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:

 

the level of demand for our antibody discovery platform and solutions, which may vary significantly;

 

the timing and cost of, and level of investment in, research, development and commercialization activities relating to our platform and technology, which may change from time to time;

 

the start and completion of programs in which our platform is utilized;

 

the relative reliability and robustness of our platform, including the data generation and computational tools within our technology stack;

 

the introduction of new technologies, platform features or software, by us or others in our industry;

 

expenditures that we may incur to acquire, develop or commercialize additional technologies;

 

expenditures involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including costs related to our intellectual property litigation with Berkeley Lights, and the outcome of this and any other future patent litigation we may be involved in;

 

the degree of competition in our industry and any change in the competitive landscape of our industry, including consolidation among our competitors or future partners;

 

natural disasters, outbreaks of disease or public health crises, such as the COVID-19 pandemic;

 

the timing and nature of any future acquisitions or strategic partnerships;

 

future accounting pronouncements or changes in our accounting policies; and

 

general social, political and economic conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.

For example, 2020 was the first year in which we received payments from a partner beyond upfront fees. The antibody, bamlanivimab developed by Eli Lilly and Company, or Lilly, has undergone clinical testing and has received Emergency Use Authorization from the FDA, and we have received associated milestone payments and royalties on net sales in 2020 and during the three months ended March 31, 2021. Lilly progressed into these clinical trials at a greatly accelerated pace as a result of the Coronavirus Treatment Acceleration Program, which is a special emergency program for possible coronavirus therapies created by the FDA in 2020 to expedite the development of potentially safe and effective life-saving treatments to combat the COVID-19 pandemic. With respect to other or future product candidates, there is no assurance that any of our partners or collaborators will be able to advance a product candidate through clinical development on this timeframe again in the future, or at all. We initiated our partnering program in 2015 and have only had this one program result in milestone and royalty payments to us to date and we have not yet had a program receive marketing approval. There is no guarantee that we will continue to generate the levels of revenue, particularly milestone and royalty revenues, from our partnerships as we have experienced in recent periods. For example, in April 2021, the FDA revoked the EUA for bamlanivimab as monotherapy, but maintained the EUA for bamlanivimab and etesevimab when administered together. Such decisions or similar decisions by regulatory agencies may adversely impact the payments that we receive from bamlanivimab in future periods. In addition, we have only recently begun to generate licensing revenue from our Trianni humanized

25


 

rodent platform. There can be no assurance that we will continue to generate or expand our licensing revenue from this product offering in future periods.

The effect of one of the factors discussed above, or the cumulative effects of a combination of factors discussed above, could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

Sale of Unregistered Securities

 

There were no unregistered sales of the Company’s equity securities during the three months ended March 31, 2021.

 

Use of Proceeds from our Initial Public Offering

On December 15, 2020, we completed the initial public offering, or IPO, of our common shares pursuant to which we issued and sold 27,772,500 common shares at a price to the public of $20.00 per share, which included the exercise in full of the underwriters’ option to purchase additional common shares. The offer and sale of all of the common shares in our IPO was registered under the Securities Act pursuant to a registration statement on Form S-1, as amended (File No. 333-250838), which was declared effective by the SEC on December 10, 2020.

We received aggregate gross proceeds from our IPO of $555.5 million, or aggregate net proceeds of $522.8 million after deducting underwriting discounts and commissions and other offering costs. None of the underwriting discounts and commissions or offering expenses were incurred or paid, directly or indirectly, to any of our directors or officers or their associates or to persons owning 10% or more of our common shares or to any of our affiliates.

Cash used since the IPO is described elsewhere in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our periodic reports filed with the SEC. There has been no material change in our planned use of the net proceeds from the IPO as described in the final prospectus for our IPO.

Item 3. Defaults Upon Senior Securities.

Not applicable.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

26


 

Item 6. Exhibits.

The following exhibits are filed with this Quarterly Report on Form 10-Q:

 

Exhibit

Number

 

Description

 

 

 

    3.1

 

Articles of the Registrant, as currently in effect.

    4.1

 

Amended and Restated Investors Rights Agreement among the Registrant and certain of its shareholders, dated March 23, 2020 (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-250838) filed on November 20, 2020).

    4.2

 

Form of Specimen Common Share Certificate (incorporated by reference to Exhibit 4.2 of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-250838) filed on December 7, 2020).

    4.3

 

Description of Securities.

  31.1*

 

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

  31.2*

 

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

  32.1**

 

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

  32.2**

 

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS

 

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

*

Filed herewith.

**

The certifications furnished in Exhibit 32.1 and 32.2 hereto are deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates them by reference

27


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

AbCellera Biologics Inc.

 

 

 

 

Date: May 14, 2021

 

By:

/s/ Carl L.G. Hansen

 

 

 

Carl L.G. Hansen, Ph.D.

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

 

Date: May 14, 2021

 

By:

/s/ Andrew Booth

 

 

 

Andrew Booth

Chief Financial Officer

 

 

 

(Principal Financial Officer)

 

28

EX-31.1 2 abcl-ex311_11.htm EX-31.1 abcl-ex311_11.htm

 

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Carl L. G. Hansen certify that:

1.

I have reviewed this quarterly report of AbCellera Biologics Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: May 14, 2021

 

By:

/s/ Carl L. G. Hansen

 

 

 

Carl L. G. Hansen, Ph.D.

 

 

 

Chief Executive Officer and Director

(Principal Executive Officer)

 

 

EX-31.2 3 abcl-ex312_10.htm EX-31.2 abcl-ex312_10.htm

 

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Andrew Booth, certify that:

1.

I have reviewed this quarterly report of AbCellera Biologics Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: May 14, 2021

 

By:

/s/ Andrew Booth

 

 

 

Andrew Booth

 

 

 

Chief Financial Officer

(Principal Financial Officer)

 

 

EX-32.1 4 abcl-ex321_8.htm EX-32.1 abcl-ex321_8.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AbCellera Biologics Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: May 14, 2021

 

By:

/s/ Carl L. G. Hansen

 

 

 

Carl L. G. Hansen

 

 

 

Chief Executive Officer and Director

(Principal Executive Officer)

 

EX-32.2 5 abcl-ex322_9.htm EX-32.2 abcl-ex322_9.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AbCellera Biologics Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: May 14, 2021

 

By:

/s/ Andrew Booth

 

 

 

Andrew Booth

 

 

 

Chief Financial Officer

(Principal Financial Officer)

 

GRAPHIC 6 gv4rnzlkpfex000001.jpg GRAPHIC begin 644 gv4rnzlkpfex000001.jpg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

1?%!GU;QWX> M\/R2,MI*8RP'',DA0GZX7CZUUGBGP;H+^#K^&'2[2!K>V>2&2.(*RLJDCYNI MZGZ_HD;2WMCC=&OWL*VY64=R#GCWK"\0>._%6J>';K3_^ M$4N[)GB*W5P8Y"%3'S8!4;=K:UOR46 M-]N5"A@N?3+-4'PTMH;/XE^)K6W0)!"9HXT!SM43 ?D*E\#>(K30_ .S1K2 M;5]4$WF75E$&61=W&X85LJ %&1^E8WAW4/$>A>+=5UL^#=5F&HO(?)\F1?+W M2;_O;#G'3H*?<.Q[G1116984444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% &5J_AK1M>,;:G817#QG*.,Y1SE67VW#!Q M[5JT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E6'AO1]+U. M?4;&PBM[J=-DC1Y 89S]WH.1V%:M%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !14^)MRY(S4E !12;EW[-PW8SC/.*6@ HHHH **@N M;VWM #/*$ST'4G\*2VO;:\!\B4/CJ.A'X&@"Q14:3Q22R1H^7CQO&.F:DH * M*** "BBHVGB2=(6?$CY*KCKB@"2BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HJ.2>*)XT=L-(<*,=34E !155]1M([CR&F'F9Q@ G%30S1W$2RQ-N1NA MH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3: %HH MJM'J%K+<_9XY0THSP <<>_2@"S1110 4444 %%%% !1110 44C,J*69@JCJ2 M<"EH **** "BBB@ HHHH ***1F"J68@ =230 M% ((R#D&B@ HHHH **** " MBBD+*&52P#-T!/6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH SM<_P"05+]5_F*BL2=/OGT]R?*?YX"?U%6- M8C>739$C1G8E([XR.N?2@#/MKM[72HEB4--+,R(#TS MGK5AKB]L;B$74B30RML)5<%352.UN?[,MIA"WG03&0QD8)&:L3O)JLUO$EO- M'%&XDD:5=O3L* &/'>'7\+/&'\G()3@+NZ5--?337TEO!/%;I$/FD?!)/H : M6Z9[76([HPR/$8?+)C7.#G-5WA2VOYII[)KB"?#JPCW%#Z$=J +%M>W,\=U M#&US%]UU^ZV>AJ_;>=]G3[1CS2I9V&<<< #_/2IHM3DCLKI[D*TMLVP[> WI4ME&Z:EJ#LC!79-I(X/!Z54 M-E+<1:G'L92\NY"PP&QSQ0 ^2?4[>V6\D>)TX9X0N, ^]6(KYCJ#QNP\EH1+ M$<=N]59KFXN['[&MG,L[ *Y9<*/4YHU6RE%O:_9E9GC7R3M'\)&/\_6@!UIJ M[R6%W-* 'BY48['[M2B>87NGQRA"TD;%SMY!QGCTJK=Z=(+ZVCB5C ZJDN!Q MA?7\*NW,;MK-E($8HJON8#@<=Z (?M-]<:A"WU5V78'8!2Z\-GCCUH 9= M2WZV<,TURIAF9=RQ#:0#SP:V]C);^7$?F5-JEN>W&:Y^%([98Y+BQO66,;OF M.57WQ70Q2+-$LB'*N,@T 9T>IM_8SW+X\Y,H1C^+M_2F27MPURMHL\4+H@,L MK@=2.@%0FU8Z^8 ?W#,+AE]Q_P#7I]S;BWU22XEM#<02J/NIN*$>U $UK?SL M]Q;MY<\T2[D:,@!_\*KS7=];P><][;>8.3;X'Y>M.$E4KB*5K?2\1.2DD9<;3\O'?TJ[-86MQ)YDT*NV,9- %6\OI/MJV MD$D<1V[GEDZ >WO4<6H3(]Q;R2QRND1DCE3H<>HIMY:B#4AF)C6TB+&)9GV#C"KR><5/ M812(M_NC9=\SEGI0!8D%T-2M;>[N2Z/D MCR_EY'K[5>L;F2>:[5R,12E5P.U9]O)!93K+/:W:,?E$LQW!:ECEET^]NU:U MFE$S[XS&N0?:@"1+Z=K&_E)7=#(ZIQV'2F17MVEFU_ MM1V\%P-)U!9(G$KNYVXZ\#IZU:EM'N="2W VR>4F >.0!Q0!5:^O(K<7375L M_0M ,9 /H?6IKS4)/M%O#!+'"LJ;_-D'Y"JP9#"L2:/_ *5P#OA&SZYJU>YC M,4<]BL]J$P?*3)0^WH* +%D]V6=;@QR(/N2H1AOPIFI7K6HBCBV"69L*7/"C MN3572X"M_+)!#+#:E,;9,C+>H%3:M;/(UO<)#YPA8[X\9W T ,CO9H+R&*:Y MAN(YCM#( "I_#M1<:E-8W4T4Z[PPW6Y5>I]#20>7-=Q?9M,6-%.7DEBVD?3W MIMS:W&IS2R?/$L'$ (P6;U^E $LMS>(+6U!3[7,"68CA!2K=7=F\RW@\V-(] MZRHN ?8]LU79[EGM-0:VE+Q@QS1[<-]0.]2NUSJBW$:QM%;&/"^8N"S?X4 0 M_;KS[+]K^U6W3=]GXZ?7KFK-YJ,J6MI-;*"9F VGOD=*IH42V6$Z06NU&WF( M%2?4FIM3$D4&GA8T\Q9EPB<+GT% $AN+ZRNH!=/'+%,VS*KC8:ABCO/[WDMGN:Z#M6'%8SR^'5AV,LRL7"L M,'K[T 333ZC8Q)8SKA5QSUJS-"XU:P948QQHX+ <#CC- %RW69(%6>0/)W8# -4)+B M]EU.>T@=$5%5M[+G;Q6I5"WC<:S=R%&",B88C@\4 5H+C4KHRP*\220,5>4K MG<>V!0-5F-@A"*;IY3"!VSZU8T^-TNKXNC*&ERI(QD>U9XM+@6PF2%C)#=-( M$(P67CI^5 %MKB]L;B$74B30RML)5<%339;VXEU&:VCN(K98L8WC)?\ .DG> M359K>)+>:.*-Q)(TJ[>G847C(;F1;W3VE3_EG)$I)(]S0!'J1O7T=VG\M-IP MX7G>,C!'I6K:K,L $\BNW8JN.*QDL[AM&O(UCD5&<-#$_P!X '-:]GHM4MF-U;W8@^T)&"LD>,DCUQWH 2*_EM[Q8;BXBGCD M4D2( "I'/(%,2XU.YMFO(6C6/DI#MR6 ]_6EB1+JXVP:XU&],XBDBC6*0J&*YW>W^?6F7%Q<7FAO+E4*Y65<9W8/;TJWI,;Q17( MD1E)N&(W#&1QS5:&VF;1;J+RV$C.Y52,$T 7M/69;2/SI%?*C;A<8&*BO;J? M[9%96I59'7>SL,[14FG7'G6ZH8I8VC50P=<6D0F>]MI&!&Z 9_#O3([>\.D7J>6RS/,6*XQN'&<>M1W")+IWE6FF2*X MW.T7(QZ'J30!>N+N\;4OLEKL :,,&8?=]Z@O([P:E8J;A"Y#;&V=#M&<_6K, M$<@UGS#&X0VP&XCC.1Q]:74@\=W9W0B>1(BV\(,D9% #)[V=KS[''/%"T: R MRN.I]@:=9WTKRW%O*\:)2 8VVCYA\WTH M44QYHHR!)(B$]-S 9IQ8!=Q M("]='OZ;=PS0!)152]NGMGME55/FRA#GL#5N@ HIGG1%E42)EON MC<.?I0\T4;!7D12>@9@,T /HI&947&UL6N(MCX( RA!H 6BD9E7[S 9.!DTU98VO'2@"6BH;:X2Y@252/F4$C M.<9J4LJD L 3T!/6@!:*8DL/6F)/#(VV.6-F]%8&@"2BF-+&F[=(J M[>N3C%1&67[8B*(S"R9+;OFS]/2@"Q15.QO3* 'T4U'21= MR,K+ZJYH O45#;&5H%,[1%SWBSM_6 MJ4FH3RW[6UJ;<*@&YY">2>PQ0!IT4@922 P)'4 ]*BGN8X())"RG8"2,]2!T MH FHJ""ZBGMDFW*H902"P^7/:IF95&68 =.30 M%-+HIPS*#C/)[4GFQ^7YF M]=G][/'YT /HIJ2)(NZ-U<>JG-*2%!)( '4F@!:*8)8R^P.I;&=H/./6@31& M3RQ*A?\ NAAF@!]%,>6.(#S)%3/3FS?N7;ZYXH =12%E5=S, OJ3Q56 M>[:+4+>WPNR4,68]L#- %NBJMO?17$\T2D QMM'S#YOI4YFB5]C2H'_NEAF@ M!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1W"N\#K M&$+D?+O'&:H6>F/9W".I1E9/WNX<[O45IT4 %85O#=2ZC?\ V:Z$.)/FR@;/ M7UK=JK;6?V:XN9?,W>/Q!&MQ.)G\@D-M"X&3QQ4"6TUUIEU M'#RPNV)7.-PXXK7:SW:DMYYGW8]FS'N><_C5?^R1]FDB\]@S3&9748VG^M % M*(V@O(5FLI;.0_*,?=?/&#ZU8TVU@%_>$1+F*0!./N\=JE&G7$LL37EWYR1- MN5 @7)]Z>+&:*^>>"X"I*P,D93.<>AH JZ=;0WXN;BZ02.TI7YOX0.PJ*!F& MCZC 6+)"SHA/I5UM-FCFE>TNS"LIRR% PSZBI$TY(].DM$+#QIU^H_E6=-$ATMFBTPK M&%R)W+2G8Y+2QDFM27_5/_NFJLEAYD5FAEQ]F96SM^]C^57&&Y&7U&* ,?0[. M);*.[9=TQSM)/W0,C JI9*]S#)-+IYNFE8YD+@8]AGI6Y96WV.SCM]^_9GYL M8SDYJI_9D\+R"SO##%(S-5 _\BFO^_\ ^S5?&E2H9(X[QDMI&+-&%&>>H!IYTK_B4BQ\[H<[ M]OOGIF@""YM+=]=@5H4(=&9ACJ?6F7MK(FHM<-9_:H"@55!^Y^'^>M7KRRDG MGBN()O*FC! )7((-1OI]P)O/@O/+E=0),IE6([X[4 )I#VQCF2W$J8;+12?P M$^GM2:N8";=)5EE8ME(4Z.?>K%E9&V:6624RS2G+N1C]*2]L6N9(IHIC%-$3 MM;&1^5 &:JM%K%FPLA:[]RD*X.X8]!3[&SBN-1O99AOV3':I/ .>O\JLC3)6 MNX;J:[,DD9Z;,#'H/2K-K:?9I;A]^[SI-^,8Q[4 9)+W.K73/9FZ$1"*I8 * M/H?6KFEPW$$UP'@,,#$,B%@=I[]*DGT^3[4US:W'D2.,."NX-4EE9?9?,=Y6 MEFD.7TNS"LIRR% PSZBIH+"*"R>U!)#@[V/4D] M30 W2X8HK"%T159XU+$#J<56U>(3W=A$Q(5G8'!QQQFK5C:W%JOER7 EB480 M;,$4^XM//N;:;?M\EB<8SG- %*2WBL]8LOLZ",2!U<+T.!52+?6UQOQY.[Y<=V:VFN#=6#7*R.6$J') _I5\:=<2RQ-> M7?G)$VY4"! M@!=>_P"04_\ O+_.H;RW2YUZ".3)3R_\ Y9>7LQ[YSFJHTN:)I$MKQHH)#DH$!(^A[4 4(ACPO<#.<.>? M^!"K+HMWJEK;SC'I5A=*":7)9";ASD/MZ% \Z,?7M^>!^%0W,2:-[N[,RQ'*J$"C/J:T2 1@]#0!BV&GV]W MIGG3J'EFW%I#U!R:I1JES!IKRH&=I=C,1RP'3-:?]E3QH\,%ZT=NY/R; 2,] M0#4S::@6T6-]BV[;@,9W4 7$C2.,1HH5 , #I619VEO_ &S>+Y*8BV%!C[IQ MVK9JM#:>5?7%SOSYVWY<=,#% %:P_P"0KJ7^\G\C5/RHY8]7+J&V,S+GL0#5 MZ;3YOMCW%K=&$R "0; V<=Z6UTM;>&XB,K.L_4D<],&@#/N88HO#:.B*K.L9 M8@=35S7#_HTGN?,AVX3"8*X/%1OI,\ZH+B^+^604^3 _'U- M#+ZW6ZUV"*3/EF'+ 'J 3Q4=\O\ Q,[>T2W,L,<>\0A@H)Y]:U&M-VHI=[_N MQE-N.OOFF7EC]IDCFBE,,\?W7 SQZ$4 4[2"XCU194LS;0,I$BAP1GL<"KNI M_P#(,N?^N9IEM8R)<_:;FX,TVW:OR[0H^E6;F'[1;20[MN]2N<9Q0!C&%;'0 M3=1 _:)(US)GG#8J-K.1K%$ATPI* "LPD7.?6MK[(C6"VDGS((PA/3.!UJE_ M9=PT0MY+YFMA_"$ 8CTS0!7N+>X%XMU<6?VI&B4% >4..>/KFHV>V.BWJ6XE M3# M%)_ 21T]JT9-.E2X,UG@"Y8O$]E$T+L\>W M +]>/6K%9XTPQQVL<%R\:0ME@/\ EIR#SS_G-:% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 (0#U -+110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 E44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$! end EX-101.SCH 7 abcl-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Nature of Operations link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Net Earnings (Loss) Per Share link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Other Current Assets link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Property and Equipment, Net link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Investments in and Loans to Equity Accounted Investees link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Accounts Payable and Other Liabilities link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Shareholders’ Equity link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Revenue link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Financial Instruments link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Net Earnings (Loss) Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Other Current Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Property and Equipment, Net (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Accounts Payable and Other Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Shareholders’ Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Revenue (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Net Earnings (Loss) Per Share - Schedule of Basic and Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Net Earnings (Loss) Per Share - Schedule of Potential Common Shares Excluded from Computation of Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Other Current Assets - Schedule of Other Current Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Property and Equipment, Net - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Intangible Assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Investments in and Loans to Equity Accounted Investees - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Accounts Payable and Other Liabilities - Schedule of Accounts Payable and Other Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Shareholders' Equity - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Shareholders' Equity - Summary of Stock Options Granted (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Shareholders' Equity - Summary of Restricted Share Units Granted (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Shareholders' Equity - Summary of Stock-Based Compensation Expense (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Revenue - Summary of Deferred Revenue Outstanding (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Revenue - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Revenue - Additional Information (Details1) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Revenue - Additional Information (Details1) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Financial Instruments - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 abcl-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 abcl-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 abcl-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Document Period End Date Document Period End Date Current Fiscal Year End Date Current Fiscal Year End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Bankruptcy Proceedings Reporting Current Entity Bankruptcy Proceedings Reporting Current Deferred revenue and grant funding noncurrent. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Accounts receivable Accounts Receivable Net Current Accrued accounts receivable Unbilled Receivables Current Other current assets Other Assets Current Total current assets Assets Current Long term assets: Assets Noncurrent [Abstract] Property and equipment, net Property Plant And Equipment Net Intangible assets Intangible Assets Net Excluding Goodwill Goodwill Goodwill Investments in and loans to equity accounted investees Investments In Affiliates Subsidiaries Associates And Joint Ventures Other long-term assets Other Assets Noncurrent Total long-term assets Assets Noncurrent Total assets Assets Liabilities and shareholders' equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable and other liabilities Accounts Payable And Other Accrued Liabilities Current portion of contingent consideration payable Business Combination Contingent Consideration Liability Current Income taxes payable Accrued Income Taxes Current Accrued royalties payable Accrued Royalties Current Deferred revenue Contract With Customer Liability Current Total current liabilities Liabilities Current Long-term liabilities: Liabilities Noncurrent [Abstract] Operating lease liability Operating Lease Liability Noncurrent Deferred revenue and grant funding Deferred Revenue And Grant Funding Noncurrent Contingent consideration payable Business Combination Contingent Consideration Liability Noncurrent Deferred tax liability Deferred Income Tax Liabilities Net Other long-term liabilities Other Liabilities Noncurrent Total long-term liabilities Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments And Contingencies Shareholders' equity: Stockholders Equity [Abstract] Common shares: no par value, unlimited authorized shares at December 31, 2020 and March 31, 2021: 269,497,768 and 270,925,930 shares issued and outstanding at December 31, 2020 and March 31, 2021 respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated earnings Retained Earnings Accumulated Deficit Total shareholders' equity Stockholders Equity Total liabilities and shareholders' equity Liabilities And Stockholders Equity Subsequent events Subsequent Events [Abstract] Common stock, no par value Common Stock No Par Value Common stock, shares authorized Common Stock Shares Authorized Unlimited Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Grants and Incentives. Income Statement [Abstract] Statement [Table] Statement [Table] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Research fees. Research Fees Research Fees [Member] Licensing Revenue License [Member] Milestone payments. Milestone Payments Milestone Payments [Member] Royalty Revenue Royalty [Member] Statement [Line Items] Statement [Line Items] Revenue: Revenues [Abstract] Total revenue Revenue From Contract With Customer Excluding Assessed Tax Operating expenses: Operating Expenses [Abstract] Royalty fees Royalty Expense Research and development Research And Development Expense Sales and marketing Selling And Marketing Expense General and administrative General And Administrative Expense Depreciation and amortization Depreciation And Amortization Total operating expenses Operating Expenses Income (loss) from operations Operating Income Loss Other (income) expense Nonoperating Income Expense [Abstract] Other (income) expense Other Nonoperating Income Expense Grants and incentives Grants And Incentives Total other income Nonoperating Income Expense Net earnings (loss) before income tax Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Provision for income tax Income Tax Expense Benefit Net earnings (loss) and comprehensive income (loss) for the period Net Income Loss Net earnings (loss) per share attributable to common shareholders Earnings Per Share Basic And Diluted [Abstract] Basic Earnings Per Share Basic Diluted Earnings Per Share Diluted Weighted-average common shares outstanding Weighted Average Number Of Shares Outstanding [Abstract] Basic Weighted Average Number Of Shares Outstanding Basic Diluted Weighted Average Number Of Diluted Shares Outstanding Adjustments to additional paid in capital, reclassification of liability classified options. Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Preferred Shares Preferred Stock [Member] Common Shares Common Stock [Member] Additional Paid-in Capital Additional Paid In Capital [Member] Accumulated Earnings (Deficit) Retained Earnings [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Series A1 preferred stock. Series A1 Series A1 Preferred Stock [Member] Series A2 preferred stock. Series A2 Series A2 Preferred Stock [Member] Beginning balances Beginning balances, Shares Shares Outstanding Issuance of Series A2 preferred shares Stock Issued During Period Value New Issues Issuance of Series A2 preferred shares, Shares Stock Issued During Period Shares New Issues Shares issued under stock option plan Stock Issued During Period Value Stock Options Exercised Shares issued under stock option plan, Shares Stock Issued During Period Shares Stock Options Exercised Stock-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Reclassification of liability classified options Adjustments To Additional Paid In Capital Reclassification Of Liability Classified Options Net earnings (loss) Ending balances Ending balances, Shares Increase (decrease) in accrued royalties receivable. Increase (decrease) in accounts payable and accrued liabilities excluding royalties payable. Noncash or Part Noncash Acquisition Right-of-use assets obtained in exchange for operating lease obligation. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Net income (loss) Profit Loss Cash flows from operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation of property and equipment Depreciation Amortization of intangible assets Amortization Of Intangible Assets Amortization of operating lease right-of-use-assets Operating Lease Right Of Use Asset Amortization Expense Stock-based compensation Share Based Compensation Deferred tax expense Deferred Income Tax Expense Benefit Other Other Noncash Income Expense Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Accounts and accrued research fees receivable Increase Decrease In Receivables Accrued royalties receivable Increase Decrease In Accrued Royalties Receivable Income taxes payable Increase Decrease In Accrued Income Taxes Payable Accounts payable and accrued liabilities Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable Deferred revenue Increase Decrease In Deferred Revenue Accrued royalties payable Increase Decrease In Royalties Payable Other assets and liabilities Increase Decrease In Other Operating Capital Net Net cash (used in) provided by operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of property and equipment Payments To Acquire Property Plant And Equipment Purchase of intangible assets Payments To Acquire Intangible Assets Investment in equity investees Payments To Acquire Equity Method Investments Net cash used in investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Repayment of long-term debt Repayments Of Long Term Debt Proceeds from long-term debt Proceeds From Issuance Of Long Term Debt Payment of deferred financing fees Payments Of Financing Costs Short-term borrowings Repayments Of Short Term Debt Issuance of common shares pursuant to exercise of stock options Proceeds From Stock Options Exercised Proceeds from issuance of preferred shares - series A2 financing Proceeds From Issuance Of Preferred Stock And Preference Stock Net cash provided by (used in) financing activities Net Cash Provided By Used In Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Increase in cash and cash equivalents Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash and cash equivalents, beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash and cash equivalents, end of period Supplemental disclosure of non-cash investing and financing activities Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Property plant and equipment in accounts payable Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 Right-of-use assets obtained in exchange for operating lease obligation Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation Purchase of intangible assets in exchange for in-licensing agreement payable Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 Organization Consolidation And Presentation Of Financial Statements [Abstract] Nature of Operations Nature Of Operations Basis of presentation Business Description And Basis Of Presentation [Text Block] Accounting Policies [Abstract] Significant accounting policies Significant Accounting Policies [Text Block] Earnings Per Share [Abstract] Net Earnings (Loss) per share Earnings Per Share [Text Block] Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract] Other Current Assets Other Current Assets [Text Block] Property Plant And Equipment [Abstract] Property and equipment, net Property Plant And Equipment Disclosure [Text Block] Goodwill And Intangible Assets Disclosure [Abstract] Intangible Assets Intangible Assets Disclosure [Text Block] Equity Method Investments And Joint Ventures [Abstract] Investments in and loans to equity accounted investees Equity Method Investments Disclosure [Text Block] Payables And Accruals [Abstract] Accounts Payable and Other Liabilities Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Shareholders’ Equity Shareholders Equity And Share Based Payments [Text Block] Revenue From Contract With Customer [Abstract] Revenue Revenue From Contract With Customer [Text Block] Investments All Other Investments [Abstract] Financial instruments Financial Instruments Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and contingencies Commitments And Contingencies Disclosure [Text Block] Basis of presentation Basis Of Accounting Policy Policy [Text Block] Use of estimates Use Of Estimates Disclosure of accounting policy for unusual or infrequent items. COVID-19 Pandemic Unusual Or Infrequent Items Policy [Text Block] Recent accounting pronouncements not yet adopted New Accounting Pronouncements Policy Policy [Text Block] Schedule of Basic and Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Schedule of Potential Common Shares Excluded from Computation of Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Schedule of Other Current Assets Schedule Of Other Current Assets Table [Text Block] Schedule of Property and Equipment, Net Property Plant And Equipment [Text Block] Schedule of Intangible Assets Schedule Of Finite Lived Intangible Assets Table [Text Block] Schedule of Estimated Amortization Expense on Intangible Assets Finite Lived Intangible Assets Amortization Expense Table [Text Block] Schedule of Accounts Payable and Other Liabilities Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Pre-initial public offering plan. Pre-IPO Plan Pre Initial Public Offering Plan [Member] 2020 Share option and incentive plan. 2020 Share Option and Incentive Plan Two Thousand Twenty Share Option And Incentive Plan [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Summary of Stock Options Granted Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Restricted Share Units Granted Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block] Summary of Stock-Based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Summary of Deferred Revenue Outstanding Contract With Customer Asset And Liability Table [Text Block] Changes in Fair Value of Liability for Contingent Consideration Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Basic earnings (loss) per share Earnings Per Share Basic [Abstract] Net earnings (loss) attributable to common shareholders - basic Net Income Loss Available To Common Stockholders Basic Weighted-average common shares outstanding - basic Net earnings (loss) per share attributable to common shareholders - basic Diluted earnings (loss) per share Earnings Per Share Diluted [Abstract] Net earnings (loss) attributable to common shareholders - diluted Net Income Loss Available To Common Stockholders Diluted Stock options and RSUs Incremental Common Shares Attributable To Share Based Payment Arrangements Weighted-average common shares outstanding - diluted Net earnings (loss) per share attributable to common shareholders - diluted Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Convertible Preferred Shares Convertible Preferred Stock [Member] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Options to Purchase Common Shares Employee Stock Option [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Total potential common shares excluded Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Tax and investment tax credit receivable current. Materials and supplies current. Tax and investment tax credit receivable Tax And Investment Tax Credit Receivable Current Prepaid expenses Prepaid Expense Current Materials and supplies Materials And Supplies Current Total other current assets Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Computers Computer Equipment [Member] Laboratory equipment. Laboratory Equipment Laboratory Equipment [Member] Furniture and Fixtures Furniture And Fixtures [Member] Leasehold Improvements Leasehold Improvements [Member] Operating lease right-of-use assets. Operating Lease Right-of-use Assets Operating Lease Right Of Use Assets [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Property and equipment Property Plant And Equipment Gross Less accumulated depreciation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property and equipment, net Depreciation expense on property and equipment Schedule Of Finite Lived Intangible Assets [Table] Schedule Of Finite Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class Finite Lived Intangible Assets By Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name Finite Lived Intangible Assets Major Class Name [Domain] License based intangible assets. License License Based Intangible Assets [Member] Technology Technology Based Intangible Assets [Member] IPR&D In Process Research And Development [Member] Finite Lived Intangible Assets [Line Items] Finite Lived Intangible Assets [Line Items] Gross carrying amount Finite Lived Intangible Assets Gross Accumulated amortization Finite Lived Intangible Assets Accumulated Amortization Net book value 2021 Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year 2022 Finite Lived Intangible Assets Amortization Expense Next Twelve Months 2023 Finite Lived Intangible Assets Amortization Expense Year Two 2024 Finite Lived Intangible Assets Amortization Expense Year Three 2025 Finite Lived Intangible Assets Amortization Expense Year Four Finite lived intangible assets amortization expense Finite Lived Intangible Assets Net Number of joint ventures. Schedule Of Equity Method Investments [Table] Schedule Of Equity Method Investments [Table] Investment, Name Schedule Of Equity Method Investment Equity Method Investee Name [Axis] Investment, Name Equity Method Investee Name [Domain] Dayhu joint venture. Dayhu JV Dayhu Joint Venture [Member] Beedie joint venture. Beedie JV Beedie Joint Venture [Member] Variable Rate Variable Rate [Axis] Variable Rate Variable Rate [Domain] Prime Rate Prime Rate [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Maximum Maximum [Member] Minimum [Member] Minimum [Member] Schedule Of Equity Method Investments [Line Items] Schedule Of Equity Method Investments [Line Items] Number Of Joint Ventures Number Of Joint Ventures Equity investment balance, cash contribution made in joint venture Payments To Acquire Interest In Subsidiaries And Affiliates Equity method investment, commitment amount. Equity method investment, outstanding related party loan. Equity method investment, commitment amount Equity Method Investment Commitment Amount Debt instrument, basis spread on variable rate Debt Instrument Basis Spread On Variable Rate1 Commitment amount, repayment term Debt Instrument Term Commitment amount, maturity date Debt Instrument Maturity Date Debt instrument, repayment description Debt Instrument Payment Terms Equity method investment, outstanding related party loan Equity Method Investment Outstanding Related Party Loan Liability for in-licensing agreement current. Deferred grant funding current. Accounts payable and accrued liabilities Accounts Payable And Accrued Liabilities Current Liability for in-licensing agreement Liability For In Licensing Agreement Current Operating lease liability Operating Lease Liability Current Liability classified options Deferred Compensation Share Based Arrangements Liability Current Government remittances payable Taxes Payable Current Current portion of deferred grant funding Deferred Grant Funding Current Current portion of long-term debt Long Term Debt Current Total accounts payable and other liabilities Accounts Payable And Other Accrued Liabilities Current Conversion of liability classified options to equity. Two thousand twenty employee share purchase plan. 2020 Employee Share Purchase Plan Two Thousand Twenty Employee Share Purchase Plan [Member] Conversion of liability classified options to equity Conversion Of Liability Classified Options To Equity Number of shares available for issuance Common Stock Capital Shares Reserved For Future Issuance Shares reserved for employee stock purchase plan. Shares reserved for ESPP Shares Reserved For Employee Stock Purchase Plan Number of Shares Outstanding, Beginning Balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Number of Shares, Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Number of Shares, Exercised Number of Shares, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Number of Shares Outstanding, Ending Balance Number of Options exercisable as of March 31, 2021 Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Weighted-Average Exercise Price, Beginning Balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Weighted-Average Exercise Price, Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Weighted-Average Exercise Price, Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Weighted-Average Exercise Price, Forfeited Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Weighted-Average Exercise Price, Ending Balance Weighted-Average Exercise Price, Options exercisable as of March 31, 2021 Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Restricted Share Units (RSUs) Restricted Stock Units R S U [Member] Number of Shares Outstanding, Beginning Balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Number of Shares, Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Number of Shares, Exercised Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Number of Shares, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Number of Shares Outstanding, Ending Balance Weighted-Average Grant Date Fair Value, Beginning Balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Exercised Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value, Ending Balance Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development Research And Development Expense [Member] General and Administrative General And Administrative Expense [Member] Sales and Marketing Selling And Marketing Expense [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Stock-based compensation expense Allocated Share Based Compensation Expense Deferred compensation share-based arrangements, liability, classified, noncurrent outstanding. Options outstanding Deferred Compensation Share Based Arrangements Liability Classified Noncurrent Outstanding Stock options liability included in other liabilities Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent Deferred revenue Contract With Customer Liability Disaggregation Of Revenue [Table] Disaggregation Of Revenue [Table] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Research, collaboration and license agreement. Research, Collaboration and License Agreement Research Collaboration And License Agreement [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Eli Lilly. Eli Lilly Eli Lilly [Member] Various other agreements. Various Other Agreements Various Other Agreements [Member] License Revenue Disaggregation Of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Contract with customer liability, revenue recognized Contract With Customer Liability Revenue Recognized Milestone payment threshold amount. Low to mid-teens royalty threshold sales amount. Mid-teens to mid-twenties royalty threshold sales amount. Milestone payment threshold amount Milestone Payment Threshold Amount Low to mid-teens royalty threshold sales amount Low To Mid Teens Royalty Threshold Sales Amount Mid-teens to mid-twenties royalty threshold sales amount Mid Teens To Mid Twenties Royalty Threshold Sales Amount Upfront payment received. Upfront received Upfront Payment Received Deferred revenue Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis] Revenue, remaining performance obligation Revenue Remaining Performance Obligation Revenue, remaining performance obligation, expected timing of satisfaction period Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 Revenue Fair Value By Balance Sheet Grouping [Table] Fair Value By Balance Sheet Grouping [Table] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 2 Fair Value Inputs Level2 [Member] Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Other long term liabilities. Other Long-term Liabilities Other Long Term Liabilities [Member] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Fair value of long-term debt Long Term Debt Fair Value Carrying value of long term debt Debt Instrument Carrying Amount Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Liability Class Fair Value By Liability Class [Axis] Fair Value by Liability Class Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain] Contingent consideration. Contingent Consideration Contingent Consideration [Member] Level 3 Fair Value Inputs Level3 [Member] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Liability at beginning of the period Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Increase (decrease) in fair value of liability for contingent consideration Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease Liability at end of the period Lessee Lease Description [Table] Lessee Lease Description [Table] Office and laboratory space. Office and Laboratory Space Office And Laboratory Space [Member] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] Sydney, Australia AUSTRALIA Vancouver, Canada CANADA Lessee Lease Description [Line Items] Lessee Lease Description [Line Items] Royalty expensed Lessee, operating lease liability payments due after year four. Future lease payments for remainder of fiscal 2021 Lessee Operating Lease Liability Payments Remainder Of Fiscal Year Future lease payments for 2022 Lessee Operating Lease Liability Payments Due Next Twelve Months Future lease payments for 2023 Lessee Operating Lease Liability Payments Due Year Two Future lease payments for 2024 Lessee Operating Lease Liability Payments Due Year Three Future lease payments for 2025 Lessee Operating Lease Liability Payments Due Year Four Future lease payments thereafter Lessee Operating Lease Liability Payments Due After Year Four Lease liability Lease not yet commenced, term of contract Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1 Lease not yet commenced, discount rate Lessee Operating Lease Lease Not Yet Commenced Discount Rate Ownership percentage in joint venture agreement Equity Method Investment Ownership Percentage Future lease payments for 2026 Lessee Operating Lease Liability Payments Due Year Five Future lease payments thereafter Lessee Operating Lease Liability Payments Due After Year Five EX-101.PRE 11 abcl-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 abcl-10q_20210331_htm.xml IDEA: XBRL DOCUMENT 0001703057 2021-01-01 2021-03-31 0001703057 2021-05-10 0001703057 2020-12-31 0001703057 2021-03-31 0001703057 2020-01-01 2020-12-31 0001703057 abcl:ResearchFeesMember 2020-01-01 2020-03-31 0001703057 abcl:ResearchFeesMember 2021-01-01 2021-03-31 0001703057 us-gaap:LicenseMember 2021-01-01 2021-03-31 0001703057 abcl:MilestonePaymentsMember 2021-01-01 2021-03-31 0001703057 us-gaap:RoyaltyMember 2021-01-01 2021-03-31 0001703057 2020-01-01 2020-03-31 0001703057 us-gaap:CommonStockMember 2020-12-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001703057 us-gaap:RetainedEarningsMember 2020-12-31 0001703057 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001703057 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001703057 us-gaap:CommonStockMember 2021-03-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001703057 us-gaap:RetainedEarningsMember 2021-03-31 0001703057 abcl:SeriesA1PreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001703057 us-gaap:CommonStockMember 2019-12-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001703057 us-gaap:RetainedEarningsMember 2019-12-31 0001703057 2019-12-31 0001703057 abcl:SeriesA2PreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0001703057 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001703057 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001703057 abcl:SeriesA1PreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0001703057 abcl:SeriesA2PreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0001703057 us-gaap:CommonStockMember 2020-03-31 0001703057 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001703057 us-gaap:RetainedEarningsMember 2020-03-31 0001703057 2020-03-31 0001703057 abcl:PreInitialPublicOfferingPlanMember 2021-01-01 2021-03-31 0001703057 abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember 2021-01-01 2021-03-31 0001703057 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001703057 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001703057 us-gaap:ComputerEquipmentMember 2020-12-31 0001703057 us-gaap:ComputerEquipmentMember 2021-03-31 0001703057 abcl:LaboratoryEquipmentMember 2020-12-31 0001703057 abcl:LaboratoryEquipmentMember 2021-03-31 0001703057 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001703057 us-gaap:FurnitureAndFixturesMember 2021-03-31 0001703057 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001703057 us-gaap:LeaseholdImprovementsMember 2021-03-31 0001703057 abcl:OperatingLeaseRightOfUseAssetsMember 2020-12-31 0001703057 abcl:OperatingLeaseRightOfUseAssetsMember 2021-03-31 0001703057 abcl:LicenseBasedIntangibleAssetsMember 2021-03-31 0001703057 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-03-31 0001703057 us-gaap:InProcessResearchAndDevelopmentMember 2021-03-31 0001703057 abcl:DayhuJointVentureMember 2020-01-01 2020-12-31 0001703057 abcl:BeedieJointVentureMember 2021-01-01 2021-03-31 0001703057 srt:MaximumMember abcl:DayhuJointVentureMember 2021-01-01 2021-03-31 0001703057 abcl:DayhuJointVentureMember us-gaap:PrimeRateMember 2021-01-01 2021-03-31 0001703057 abcl:DayhuJointVentureMember 2021-01-01 2021-03-31 0001703057 abcl:DayhuJointVentureMember 2021-03-31 0001703057 2021-03-01 2021-03-31 0001703057 abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember 2021-03-31 0001703057 abcl:TwoThousandTwentyEmployeeSharePurchasePlanMember 2020-12-31 0001703057 abcl:PreInitialPublicOfferingPlanMember 2020-12-31 0001703057 abcl:PreInitialPublicOfferingPlanMember 2021-03-31 0001703057 abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember 2020-12-31 0001703057 us-gaap:RestrictedStockUnitsRSUMember abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember 2021-01-01 2021-03-31 0001703057 us-gaap:RestrictedStockUnitsRSUMember abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember 2021-03-31 0001703057 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001703057 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001703057 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001703057 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001703057 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-03-31 0001703057 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-03-31 0001703057 abcl:EliLillyMember srt:MaximumMember abcl:ResearchCollaborationAndLicenseAgreementMember 2020-03-31 0001703057 abcl:EliLillyMember srt:MinimumMember abcl:ResearchCollaborationAndLicenseAgreementMember 2020-03-31 0001703057 abcl:EliLillyMember abcl:ResearchCollaborationAndLicenseAgreementMember 2020-01-01 2020-12-31 0001703057 abcl:EliLillyMember abcl:ResearchCollaborationAndLicenseAgreementMember 2021-01-01 2021-03-31 0001703057 abcl:EliLillyMember abcl:ResearchCollaborationAndLicenseAgreementMember 2020-01-01 2021-03-31 0001703057 abcl:EliLillyMember abcl:ResearchCollaborationAndLicenseAgreementMember 2020-12-31 0001703057 abcl:EliLillyMember 2021-04-01 abcl:ResearchCollaborationAndLicenseAgreementMember 2021-03-31 0001703057 abcl:VariousOtherAgreementsMember 2021-03-31 0001703057 2021-04-01 abcl:VariousOtherAgreementsMember 2021-03-31 0001703057 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001703057 us-gaap:FairValueInputsLevel2Member 2021-03-31 0001703057 abcl:OtherLongTermLiabilitiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001703057 abcl:OtherLongTermLiabilitiesMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001703057 us-gaap:FairValueInputsLevel3Member abcl:ContingentConsiderationMember 2020-12-31 0001703057 us-gaap:FairValueInputsLevel3Member abcl:ContingentConsiderationMember 2021-01-01 2021-03-31 0001703057 us-gaap:FairValueInputsLevel3Member abcl:ContingentConsiderationMember 2021-03-31 0001703057 country:AU abcl:OfficeAndLaboratorySpaceMember 2021-03-31 0001703057 country:CA abcl:OfficeAndLaboratorySpaceMember 2021-03-31 shares iso4217:USD iso4217:USD shares abcl:JointVenture iso4217:CAD pure false Q1 --12-31 0001703057 00-0000000 Unlimited Unlimited 10-Q true 2021-03-31 2021 false 001-39781 AbCellera Biologics Inc. A1 2215 Yukon Street Vancouver BC V5Y 0A1 604 559-9005 Common shares, no par value per share ABCL NASDAQ Yes Yes Non-accelerated Filer false true false false false 270925888 594116000 685795000 903000 23371000 212336000 193071000 5970000 5745000 813325000 907982000 17923000 34618000 115153000 112688000 31500000 31500000 19247000 32187000 8388000 9548000 192211000 220541000 1005536000 1128523000 20195000 13287000 13411000 13762000 36152000 30030000 27143000 20010000 6589000 11306000 103490000 88395000 3715000 16973000 25894000 28730000 9148000 9378000 26161000 26992000 6620000 931000 71538000 83004000 175028000 171399000 269497768 269497768 270925930 270925930 710387000 711139000 5919000 14562000 114202000 231423000 830508000 957124000 1005536000 1128523000 4657000 3986000 20259000 7000000 171496000 4657000 202741000 20010000 4118000 12352000 437000 2578000 1650000 6422000 574000 3305000 6779000 44667000 -2122000 158074000 -1001000 265000 1030000 3148000 29000 3413000 -2093000 161487000 44266000 -2093000 117221000 -0.01 0.43 -0.01 0.37 151859924 269697212 151859924 320282747 269497768 710387000 5919000 114202000 830508000 1428162 752000 -579000 173000 4021000 4021000 5201000 5201000 117221000 117221000 270925930 711139000 14562000 231423000 957124000 2105264 7546000 151681382 5122000 2300000 -4716000 10252000 6017784 74662000 74662000 535000 235000 -111000 124000 744000 744000 -2093000 -2093000 2105264 7546000 6017784 74662000 152216382 5357000 2933000 -6809000 83689000 -2093000 117221000 415000 840000 158000 2465000 73000 661000 1237000 5427000 623000 28000 191000 26611000 30073000 -26861000 -6123000 -156000 -5194000 27676000 6086000 -7134000 1435000 1924000 -764000 109545000 583000 3644000 5000000 12195000 -5583000 -15839000 2033000 1716000 16171000 799000 387000 124000 173000 74662000 87738000 -1543000 -484000 81391000 91679000 7553000 594116000 88944000 685795000 95000 423000 741000 14188000 9060000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of operations </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">AbCellera Biologics Inc.’s (the “Company”) mission is to improve health with technologies that transform the way that antibody-based therapies are discovered. The Company aims to become the centralized operating system for next generation antibody discovery. The Company’s full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The Company believes its technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable. Rather than advancing its own clinical pipeline of drug candidates, the Company forges partnerships with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies. </span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Basis of presentation</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2020.</p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended March 31, 2021 and 2020 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2020, except for the new accounting guidance adopted during the period (Note 3).</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All amounts expressed in the consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share and per share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” and “CAD” are to Canadian dollars.</p> Basis of presentation <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2020.</p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended March 31, 2021 and 2020 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2020, except for the new accounting guidance adopted during the period (Note 3).</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All amounts expressed in the consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share and per share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” and “CAD” are to Canadian dollars.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Significant accounting policies </p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:5.15%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of estimates</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and determining whether an option for additional goods or services represents a material right, recoverability of investment tax credits receivable, value of contingent consideration payable and the fair value of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.</p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.15%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19 Pandemic</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the global spread of the ongoing COVID-19 pandemic, the Company has implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on its employees and its business. The Company has taken measures to secure its research and development activities, while work in its laboratories and facilities has been re-organized to reduce risk of COVID-19 transmission. Given the global economic impact, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company’s business, financial condition, and results of operations could be materially adversely affected. The Company continues to closely monitor the COVID-19 pandemic as it evolves its business continuity plans and response strategy. As of the date of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Company’s financial statements.</p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.15%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent accounting pronouncements not yet adopted</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the consolidated financial statements as a result of future adoption.</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:5.15%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of estimates</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and determining whether an option for additional goods or services represents a material right, recoverability of investment tax credits receivable, value of contingent consideration payable and the fair value of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.</p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.15%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19 Pandemic</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the global spread of the ongoing COVID-19 pandemic, the Company has implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on its employees and its business. The Company has taken measures to secure its research and development activities, while work in its laboratories and facilities has been re-organized to reduce risk of COVID-19 transmission. Given the global economic impact, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company’s business, financial condition, and results of operations could be materially adversely affected. The Company continues to closely monitor the COVID-19 pandemic as it evolves its business continuity plans and response strategy. As of the date of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Company’s financial statements.</p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.15%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent accounting pronouncements not yet adopted</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the consolidated financial statements as a result of future adoption.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Net Earnings (Loss) per share </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Basic and diluted net earnings (loss) per share attributable to common shareholders was calculated as follows:</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.52%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basic earnings (loss) per share</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,093</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,221</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss) attributable to common shareholders - basic</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2,093</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">117,221</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding - basic</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">151,859,924</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">269,697,212</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss) per share attributable to common shareholders - basic</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.01</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0.43</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Diluted earnings (loss) per share</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss) attributable to common shareholders - diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2,093</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">117,221</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding - basic</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,859,924</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269,697,212</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options and RSUs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,585,535</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding - diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">151,859,924</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">320,282,747</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss) per share attributable to common shareholders - diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.01</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0.37</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s potentially dilutive securities, which include convertible preferred shares and stock options have been excluded from the computation of diluted net loss per share for the three months ended March 31, 2020 as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding for the three months ended March 31, 2020 used to calculate both basic and diluted net loss per share attributable to common shareholders is the same.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net earnings (loss) per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common shares</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,310,018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,640,178</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total potential common shares excluded</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,950,196</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Basic and diluted net earnings (loss) per share attributable to common shareholders was calculated as follows:</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.52%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basic earnings (loss) per share</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,093</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,221</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss) attributable to common shareholders - basic</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2,093</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">117,221</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding - basic</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">151,859,924</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">269,697,212</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss) per share attributable to common shareholders - basic</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.01</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0.43</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Diluted earnings (loss) per share</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss) attributable to common shareholders - diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2,093</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">117,221</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding - basic</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,859,924</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269,697,212</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options and RSUs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,585,535</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding - diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">151,859,924</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">320,282,747</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net earnings (loss) per share attributable to common shareholders - diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(0.01</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0.37</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> -2093000 117221000 -2093000 117221000 151859924 269697212 -0.01 0.43 -2093000 117221000 151859924 269697212 50585535 151859924 320282747 -0.01 0.37 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net earnings (loss) per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.76%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common shares</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,310,018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,640,178</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.76%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total potential common shares excluded</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,950,196</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 13310018 2640178 15950196 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Other current assets </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Other current assets consisted of the following:</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax and investment tax credit receivable</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">489</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,073</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,287</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Materials and supplies</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,408</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,209</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,970</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,745</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Other current assets consisted of the following:</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax and investment tax credit receivable</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">489</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,073</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,287</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Materials and supplies</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,408</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,209</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,970</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,745</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 489000 249000 4073000 4287000 1408000 1209000 5970000 5745000 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Property and equipment, net</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Property and equipment, net consisted of the following:</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,324</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,309</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,423</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,035</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,708</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,977</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,935</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,463</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,509</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,903</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,586</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,285</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,923</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,618</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Depreciation expense on property and equipment for the three months ended March 31, 2020 and 2021 was $0.4 million and $0.8 million, respectively. </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Property and equipment, net consisted of the following:</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,324</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,309</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,423</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,035</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,708</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,977</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,935</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,463</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,509</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,903</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,586</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,285</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,923</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,618</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 6324000 6309000 9423000 13035000 119000 119000 3708000 3977000 3935000 17463000 23509000 40903000 5586000 6285000 17923000 34618000 400000 800000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Intangible assets:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Intangible assets consisted of the following:</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">carrying</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net book</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,873</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,125</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,748</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Technology</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,400</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">860</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,540</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IPR&amp;D</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,400</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,400</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.64%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,673</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,985</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,688</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March 31, 2021, amortization expense on intangible assets is estimated to be as follows for each of the next five years:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,860</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,860</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,834</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,476</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,476</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,506</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Intangible assets consisted of the following:</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">carrying</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net book</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,873</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,125</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,748</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Technology</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,400</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">860</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,540</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IPR&amp;D</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,400</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,400</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.64%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,673</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,985</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,688</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 35873000 4125000 31748000 41400000 860000 40540000 40400000 40400000 117673000 4985000 112688000 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March 31, 2021, amortization expense on intangible assets is estimated to be as follows for each of the next five years:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,860</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,860</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,834</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,476</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,476</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,506</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 9860000 9860000 9834000 3476000 3476000 36506000 <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. Investments in and loans to equity accounted investees</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into two joint ventures as part of the construction of future office and laboratory headquarters. <span style="Background-color:#FFFFFF;color:#000000;">During 2020, the Company entered into a joint venture with Dayhu (Dayhu JV). To date, the equity investment balance of $19.3 million represents the cash contribution made since inception. </span> <span style="Background-color:#FFFFFF;color:#000000;"> In the three months ended March 31, 2021 the Company entered into the Beedie joint venture (Beedie JV). To date we have contributed $11.7 million into the Beedie JV. To date, the Company has not recorded any amount of proportionate income or loss with respect to either venture. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the three months ended March 31, 2021, th<span style="Background-color:#FFFFFF;color:#000000;">e Company made a commitment up to CAD$</span></p> <p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82.7<span style="Background-color:#FFFFFF;color:#000000;"> million</span><span style="Background-color:#FFFFFF;color:#000000;"> ($</span>61.5<span style="Background-color:#FFFFFF;color:#000000;"> million</span><span style="Background-color:#FFFFFF;color:#000000;">) </span><span style="Background-color:#FFFFFF;color:#000000;">to the </span><span style="Background-color:#FFFFFF;color:#000000;">Dayhu</span><span style="Background-color:#FFFFFF;color:#000000;"> JV </span><span style="Background-color:#FFFFFF;color:#000000;">to fund the construction at a rate </span><span style="Background-color:#FFFFFF;color:#000000;">referenced to an applicable Canadian </span><span style="Background-color:#FFFFFF;color:#000000;">b</span><span style="Background-color:#FFFFFF;color:#000000;">ank prime rate</span><span style="Background-color:#FFFFFF;color:#000000;"> plus </span><span style="Background-color:#FFFFFF;color:#000000;">0.6</span><span style="Background-color:#FFFFFF;color:#000000;">%</span><span style="Background-color:#FFFFFF;color:#000000;">, and </span><span style="Background-color:#FFFFFF;color:#000000;">repayment on the earlier of </span><span style="Background-color:#FFFFFF;color:#000000;">thirty months</span><span style="Background-color:#FFFFFF;color:#000000;"> from the date of initial advancement and </span><span style="Background-color:#FFFFFF;color:#000000;">September 1, 2023</span><span style="Background-color:#FFFFFF;color:#000000;">, or upon the trigger of certain liquidity events as </span><span style="Background-color:#FFFFFF;color:#000000;">defined in the agreement</span><span style="Background-color:#FFFFFF;color:#000000;">.</span><span style="Background-color:#FFFFFF;color:#000000;"> </span><span style="Background-color:#FFFFFF;color:#000000;">The loan is secured by the underlying land and future assets of the joint venture. </span><span style="Background-color:#FFFFFF;color:#000000;">At</span><span style="Background-color:#FFFFFF;color:#000000;"> March 31, 2021, the outstanding related party loan balance was $</span>1.2<span style="Background-color:#FFFFFF;color:#000000;"> million</span><span style="Background-color:#FFFFFF;color:#000000;"> </span><span style="Background-color:#FFFFFF;color:#000000;">to the </span><span style="Background-color:#FFFFFF;color:#000000;">joint venture</span><span style="Background-color:#FFFFFF;color:#000000;">. </span></p> 2 19300 11700000 82700000 61500000 0.006 repayment on the earlier of thirty months from the date of initial advancement and September 1, 2023, or upon the trigger of certain liquidity events as defined in the agreement. P30M 2023-09-01 1200000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Accounts payable and other liabilities </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Accounts payable and other liabilities consisted of the following:</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,130</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,585</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability for in-licensing agreement</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,545</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">675</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,533</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability classified options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,270</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">474</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government remittances payable</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,988</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,207</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of deferred grant funding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">942</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,943</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of long-term debt</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable and other liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,195</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,287</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Accounts payable and other liabilities consisted of the following:</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,130</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,585</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability for in-licensing agreement</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,545</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">675</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,533</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability classified options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,270</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">474</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government remittances payable</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,988</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,207</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of deferred grant funding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">942</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,943</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of long-term debt</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable and other liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,195</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,287</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 7130000 3585000 5000000 4545000 675000 1533000 4270000 474000 1988000 1207000 942000 1943000 190000 20195000 13287000 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10. Shareholders’ equity</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Sixth Amended and Restated Stock Option Plan:</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains the AbCellera Biologics Inc. Sixth Amended and Restated Stock Option Plan and our Pre-IPO Plan. Any awards granted under the Pre-IPO Plan will remain subject to the terms of our Pre-IPO Plan and applicable award agreements.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, substantially all employee option holders whose awards were liability-classified elected to convert the currency of their option exercise price from Canadian dollars to U.S. dollars for administrative convenience. As a result of the modification, $5.2 million was reclassified from liability to equity.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:5.15%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">2020 Share Option and Incentive Plan:</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our 2020 Share Option and Incentive Plan, or 2020 Plan, was approved by our<span style="Background-color:#FFFFFF;"> board of directors on November 18, 2020 and approved by our shareholders on December 1, 2020.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, the number of shares available for issuance under the 2020 Plan was 20,075,196, which includes awards granted and outstanding under the Pre-IPO Plan that are forfeited after December 10, 2020. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:5.15%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">2020 Employee Share Purchase Plan:</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company’s Board of Directors approved the 2020 Employee Share Purchase Plan, or the 2020 ESPP. A total of 2,700,000 shares of common stock was initially reserved for issuance under the ESPP. At March 31, 2020 the Company had not yet commenced the ESPP. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company’s stock options granted in Canadian dollars under the Pre-IPO Plan since December 31, 2020:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,204,810</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.71</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,428,120</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.12</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.41</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of March 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,735,690</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.72</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of March 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,038,995</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.29</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company’s stock options granted under the 2020 Plan since December 31, 2020:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,260,840</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.00</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321,356</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52.06</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(900</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52.30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of March 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,581,296</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.50</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of March 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the 2020 Plan, restricted share units (RSUs) were available to be granted and offer holders are subject to a one year cliff vesting followed by monthly vesting thereafter. <span style="color:#000000;">The following table summarizes the Company’s restricted share units granted under the 2020 Plan since December 31, 2020:</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Grant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185,108</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52.02</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(600</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52.30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of March 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,508</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52.02</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Stock-based compensation:</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was classified in the consolidated statements of income (loss) and comprehensive income (loss) as follows:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">616</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,158</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">608</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,316</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">953</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,237</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,427</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">At December 31, 2020, there were 1,012,000 liability classified options outstanding, of which $4.3 million was included in other liabilities. At March 31, 2021 there were 60,000 liability classified options outstanding, of which $0.5 million was included in other liabilities. </span></p> 5200000 20075196 2700000 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company’s stock options granted in Canadian dollars under the Pre-IPO Plan since December 31, 2020:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,204,810</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.71</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,428,120</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.12</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.41</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of March 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,735,690</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.72</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of March 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,038,995</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.29</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 53204810 0.71 1428120 0.12 41000 10.41 51735690 0.72 25038995 0.29 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company’s stock options granted under the 2020 Plan since December 31, 2020:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,260,840</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.00</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321,356</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52.06</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(900</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52.30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of March 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,581,296</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.50</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of March 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 1260840 20.00 321356 52.06 900 52.30 1581296 26.50 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the 2020 Plan, restricted share units (RSUs) were available to be granted and offer holders are subject to a one year cliff vesting followed by monthly vesting thereafter. <span style="color:#000000;">The following table summarizes the Company’s restricted share units granted under the 2020 Plan since December 31, 2020:</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Grant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185,108</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52.02</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(600</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52.30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of March 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,508</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52.02</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 185108 52.02 600 52.30 184508 52.02 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was classified in the consolidated statements of income (loss) and comprehensive income (loss) as follows:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">616</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,158</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">608</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,316</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">953</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,237</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,427</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 616000 3158000 608000 1316000 13000 953000 1237000 5427000 1012000 4300000 60000 500000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. Revenue</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The disaggregated revenue categories are presented on the face of the statement of income (loss) and comprehensive income (loss).</p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.19%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred revenue</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue represents payments received for performance obligations not yet satisfied and are presented as current or long-term in the accompanying balance sheets based on the expected timing of satisfaction of the underlying goods and/or services. <span style="font-size:1pt;"> </span></p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue outstanding in each respective period is as follows:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,544</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,983</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,230</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,375</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2020 and 2021, the Company recognized $1.4 million and $1.3 million, respectively, of revenue that had been included in deferred revenue in the previous year.</p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March of 2020, the Company entered into a research collaboration and license agreement with Eli Lilly pursuant to which the Company will perform discovery research for several targets for Eli Lilly to develop and commercialize. Under the agreement, the Company is entitled to receive an aggregate of up to $29.0 million of milestone payments as well as royalties in the low single digits based on net sales for non-COVID-19 targets and in the low- to mid-teens for aggregate sales below $125.0 million and mid-teens to mid-twenties on aggregate sales above $125.0 million.</p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement resulted in initial upfront of $26.7 million, of which $21.9 million was included in deferred revenue at December 31, 2020. In the three months ended March 31, 2021 the Company received an additional $1.1 million in payments, for total payments received in respect of this agreement of $27.8 million. The Company expects to recognize approximately $9.4 million  in revenue in the next 12 months related to these payments under the agreement.</p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the remaining deferred revenue balance of $10.3 million which is related to various other agreements, approximately $1.9 million is expected to be recognized in revenue in the next 12 months. <span style="color:#000000;"> </span> </p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:4.19%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License revenue</p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the licenses to our intellectual property the Company recognizes revenue from non-refundable, up-front fees when the license is transferred to the customer and the customer is able to use and benefit from the license. For the three months ended March 31, 2021, the Company recognized $20.3 million from license revenue relating to license of the Trianni platform. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue outstanding in each respective period is as follows:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,544</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,983</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,230</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,375</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> 5544000 28983000 26230000 32375000 1400000 1300000 29000000.0 125000000.0 125000000.0 26700000 21900000 1100000 27800000 9400000 P12M 10300000 1900000 P12M 20300000 <p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.15%;text-indent:-5.15%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12. Financial instruments </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company categorizes its financial assets and liabilities measured at fair value into a three-level hierarchy established by U.S. GAAP that prioritizes those inputs to valuation techniques used to measure fair value based on the degree to which they are observable. The three levels of the fair value hierarchy are as follows: Level 1 inputs are quoted prices in active markets for identical assets and liabilities; Level 2 inputs, other than quoted prices included within Level 1, are observable for the asset or liability either directly or indirectly; and Level 3 inputs are not observable in the market.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, loans to related parties, accounts payable and accrued liabilities and royalties payable, operating lease obligations, long-term debt, and contingent consideration payable. The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, and bank indebtedness approximate their fair values due to the immediate and short-term maturity of these financial instruments. The fair value of loans to related party approximate the carrying value as the interest rates approximate the rates applicable for non-related party loans.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<span style="Background-color:#FFFFFF;color:#000000;">t December 31, 2020 and March 31, 2021, the carrying value of long-term debt was $2.2 million and $0.9 million, respectively, and have been included in Other long-term liabilities on the balance sheet. The estimated fair value of long-term debt of $2.3 million and $1.2 million at December 31, 2020 and March 31, 2021, respectively, are classified as Level 2 and have been determined by discounting future principal and interest amounts at estimated interest rates expected to be available to the Company at period end.  </span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Contingent consideration related to business acquisitions are recorded at fair value on the acquisition date and adjusted on a recurring basis for changes in its fair value. Changes in the fair value of contingent consideration liabilities can result from changes in anticipated payments and changes in assumed discount periods and rates. These inputs are unobservable in the market and therefore categorized as Level 3 inputs.  </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the changes in fair value of the liability for contingent consideration:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability at</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">beginning of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">the period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(decrease) in fair</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value of liability</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for contingent</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">consideration</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability at</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">end of the</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Three months ended March 31, 2021</p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,559</p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">581</p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,140</p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 2200000 900000 2300000 1200000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the changes in fair value of the liability for contingent consideration:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability at</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">beginning of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">the period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(decrease) in fair</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value of liability</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for contingent</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">consideration</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability at</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">end of the</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Three months ended March 31, 2021</p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,559</p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">581</p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,140</p></td> <td style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 22559000 581000 23140000 <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">13</span><span style="color:#000000;">. Commitments and contingencies </span></p> <p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company does not have contingency reserves established for any litigation liabilities and any of the costs related to such legal proceedings are expensed as incurred.</span></p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company may enter into certain agreements with strategic partners in the ordinary course of operations that may include contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements.</span></p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Pursuant to the agreements, the Company may be obligated to make research and development and regulatory milestone payments upon the occurrence of certain events and upon receipt of royalty payments in the low single-digits to mid-twenties based on certain net sales targets. During the three months ended March 31, 2021, the Company has expensed approximately $20.0 million related to such obligations, of which that same amount is included in current liabilities. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the quarter ended March 31, 2021 the Company entered into a lease for office and laboratory space in Sydney, Australia representing future lease payments of $0.7 million for the current year, approximately $1.5 million for each of the next four years and $9.7 million thereafter. In the three months ended March 31, 2021, the Company recognized a lease liability of $13.9 million , with a corresponding right of use asset</span><span style="color:#000000;"> </span><span style="Background-color:#FFFFFF;">, utilizing a ten year term and 3.0% discount rate. </span><span style="color:#000000;"> </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company entered into a lease for office and laboratory space in Vancouver, Canada, in conjunction with our 50% owned joint venture agreement, representing future lease payments of $1.5 million due in four years, $5.9 million due in five years, and approximately $135.0 million thereafter.  The lease liability and corresponding right of use asset will be recognized on lease commencement date after completion of construction of the office and laboratory space. </span></p> 20000000.0 700000 1500000 1500000 1500000 1500000 9700000 13900000 P10Y 0.030 0.50 1500000 5900000 135000000.0 Exclusive of depreciation and amortization XML 13 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2021
May 10, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Document Period End Date Mar. 31, 2021  
Current Fiscal Year End Date --12-31  
Entity Registrant Name AbCellera Biologics Inc.  
Entity Central Index Key 0001703057  
Entity Tax Identification Number 00-0000000  
Entity File Number 001-39781  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Incorporation, State or Country Code A1  
Entity Address, Address Line One 2215 Yukon Street  
Entity Address, City or Town Vancouver  
Entity Address, State or Province BC  
Entity Address, Postal Zip Code V5Y 0A1  
City Area Code 604  
Local Phone Number 559-9005  
Title of 12(b) Security Common shares, no par value per share  
Trading Symbol ABCL  
Security Exchange Name NASDAQ  
Document Quarterly Report true  
Document Transition Report false  
Entity Common Stock, Shares Outstanding   270,925,888
Entity Bankruptcy Proceedings Reporting Current false  

XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 685,795 $ 594,116
Accounts receivable 23,371 903
Accrued accounts receivable 193,071 212,336
Other current assets 5,745 5,970
Total current assets 907,982 813,325
Long term assets:    
Property and equipment, net 34,618 17,923
Intangible assets 112,688 115,153
Goodwill 31,500 31,500
Investments in and loans to equity accounted investees 32,187 19,247
Other long-term assets 9,548 8,388
Total long-term assets 220,541 192,211
Total assets 1,128,523 1,005,536
Current liabilities:    
Accounts payable and other liabilities 13,287 20,195
Current portion of contingent consideration payable 13,762 13,411
Income taxes payable 30,030 36,152
Accrued royalties payable 20,010 27,143
Deferred revenue 11,306 6,589
Total current liabilities 88,395 103,490
Long-term liabilities:    
Operating lease liability 16,973 3,715
Deferred revenue and grant funding 28,730 25,894
Contingent consideration payable 9,378 9,148
Deferred tax liability 26,992 26,161
Other long-term liabilities 931 6,620
Total long-term liabilities 83,004 71,538
Total liabilities 171,399 175,028
Commitments and contingencies
Shareholders' equity:    
Common shares: no par value, unlimited authorized shares at December 31, 2020 and March 31, 2021: 269,497,768 and 270,925,930 shares issued and outstanding at December 31, 2020 and March 31, 2021 respectively 711,139 710,387
Additional paid-in capital 14,562 5,919
Accumulated earnings 231,423 114,202
Total shareholders' equity 957,124 830,508
Total liabilities and shareholders' equity $ 1,128,523 $ 1,005,536
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Statement Of Financial Position [Abstract]    
Common stock, no par value
Common stock, shares authorized Unlimited Unlimited
Common stock, shares issued 270,925,930 269,497,768
Common stock, shares outstanding 270,925,930 269,497,768
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenue:    
Total revenue $ 202,741 $ 4,657
Operating expenses:    
Royalty fees 20,010  
Research and development [1] 12,352 4,118
Sales and marketing [1] 2,578 437
General and administrative [1] 6,422 1,650
Depreciation and amortization 3,305 574
Total operating expenses 44,667 6,779
Income (loss) from operations 158,074 (2,122)
Other (income) expense    
Other (income) expense (265) 1,001
Grants and incentives (3,148) (1,030)
Total other income (3,413) (29)
Net earnings (loss) before income tax 161,487 (2,093)
Provision for income tax 44,266  
Net earnings (loss) and comprehensive income (loss) for the period $ 117,221 $ (2,093)
Net earnings (loss) per share attributable to common shareholders    
Basic $ 0.43 $ (0.01)
Diluted $ 0.37 $ (0.01)
Weighted-average common shares outstanding    
Basic 269,697,212 151,859,924
Diluted 320,282,747 151,859,924
Research Fees    
Revenue:    
Total revenue $ 3,986 $ 4,657
Licensing Revenue    
Revenue:    
Total revenue 20,259  
Milestone Payments    
Revenue:    
Total revenue 7,000  
Royalty Revenue    
Revenue:    
Total revenue $ 171,496  
[1] Exclusive of depreciation and amortization
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Preferred Shares
Series A1
Preferred Shares
Series A2
Common Shares
Additional Paid-in Capital
Accumulated Earnings (Deficit)
Beginning balances at Dec. 31, 2019 $ 10,252 $ 7,546   $ 5,122 $ 2,300 $ (4,716)
Beginning balances, Shares at Dec. 31, 2019   2,105,264   151,681,382    
Issuance of Series A2 preferred shares 74,662   $ 74,662      
Issuance of Series A2 preferred shares, Shares     6,017,784      
Shares issued under stock option plan 124     $ 235 (111)  
Shares issued under stock option plan, Shares       535,000    
Stock-based compensation expense 744       744  
Net earnings (loss) (2,093)         (2,093)
Ending balances at Mar. 31, 2020 83,689 $ 7,546 $ 74,662 $ 5,357 2,933 (6,809)
Ending balances, Shares at Mar. 31, 2020   2,105,264 6,017,784 152,216,382    
Beginning balances at Dec. 31, 2020 830,508     $ 710,387 5,919 114,202
Beginning balances, Shares at Dec. 31, 2020       269,497,768    
Shares issued under stock option plan 173     $ 752 (579)  
Shares issued under stock option plan, Shares       1,428,162    
Stock-based compensation expense 4,021       4,021  
Reclassification of liability classified options 5,201       5,201  
Net earnings (loss) 117,221         117,221
Ending balances at Mar. 31, 2021 $ 957,124     $ 711,139 $ 14,562 $ 231,423
Ending balances, Shares at Mar. 31, 2021       270,925,930    
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities:    
Net income (loss) $ 117,221 $ (2,093)
Cash flows from operating activities:    
Depreciation of property and equipment 840 415
Amortization of intangible assets 2,465 158
Amortization of operating lease right-of-use-assets 661 73
Stock-based compensation 5,427 1,237
Deferred tax expense 623  
Other (191) (28)
Changes in operating assets and liabilities:    
Accounts and accrued research fees receivable (30,073) (26,611)
Accrued royalties receivable 26,861  
Income taxes payable (6,123)  
Accounts payable and accrued liabilities (5,194) (156)
Deferred revenue 6,086 27,676
Accrued royalties payable (7,134)  
Other assets and liabilities (1,924) (1,435)
Net cash (used in) provided by operating activities 109,545 (764)
Cash flows from investing activities:    
Purchases of property and equipment (3,644) (583)
Purchase of intangible assets   (5,000)
Investment in equity investees (12,195)  
Net cash used in investing activities (15,839) (5,583)
Cash flows from financing activities:    
Repayment of long-term debt (1,716) (2,033)
Proceeds from long-term debt   16,171
Payment of deferred financing fees   (799)
Short-term borrowings   (387)
Issuance of common shares pursuant to exercise of stock options 173 124
Proceeds from issuance of preferred shares - series A2 financing   74,662
Net cash provided by (used in) financing activities (1,543) 87,738
Effect of exchange rate changes on cash and cash equivalents (484)  
Increase in cash and cash equivalents 91,679 81,391
Cash and cash equivalents, beginning of period 594,116 7,553
Cash and cash equivalents, end of period 685,795 88,944
Supplemental disclosure of non-cash investing and financing activities    
Property plant and equipment in accounts payable 423 95
Right-of-use assets obtained in exchange for operating lease obligation $ 14,188 741
Purchase of intangible assets in exchange for in-licensing agreement payable   $ 9,060
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Nature of Operations
3 Months Ended
Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Nature of Operations

1. Nature of operations

AbCellera Biologics Inc.’s (the “Company”) mission is to improve health with technologies that transform the way that antibody-based therapies are discovered. The Company aims to become the centralized operating system for next generation antibody discovery. The Company’s full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The Company believes its technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable. Rather than advancing its own clinical pipeline of drug candidates, the Company forges partnerships with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies. 

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Basis of Presentation
3 Months Ended
Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Basis of presentation

2. Basis of presentation

The accompanying interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2020.

These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended March 31, 2021 and 2020 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2020, except for the new accounting guidance adopted during the period (Note 3).

All amounts expressed in the consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share and per share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” and “CAD” are to Canadian dollars.

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Significant Accounting Policies
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Significant accounting policies

3. Significant accounting policies

Use of estimates

The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and determining whether an option for additional goods or services represents a material right, recoverability of investment tax credits receivable, value of contingent consideration payable and the fair value of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.

COVID-19 Pandemic

With the global spread of the ongoing COVID-19 pandemic, the Company has implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on its employees and its business. The Company has taken measures to secure its research and development activities, while work in its laboratories and facilities has been re-organized to reduce risk of COVID-19 transmission. Given the global economic impact, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company’s business, financial condition, and results of operations could be materially adversely affected. The Company continues to closely monitor the COVID-19 pandemic as it evolves its business continuity plans and response strategy. As of the date of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Company’s financial statements.

Recent accounting pronouncements not yet adopted

The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the consolidated financial statements as a result of future adoption.

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Net Earnings (Loss) Per Share
3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Net Earnings (Loss) per share

4. Net Earnings (Loss) per share

Basic and diluted net earnings (loss) per share attributable to common shareholders was calculated as follows:

 

 

 

Three months ended March 31,

 

 

 

2020

 

 

2021

 

 

 

(in thousands, except share and per share data)

 

Basic earnings (loss) per share

 

 

 

 

 

 

 

 

Net earnings (loss)

 

$

(2,093

)

 

$

117,221

 

Net earnings (loss) attributable to common shareholders - basic

 

$

(2,093

)

 

$

117,221

 

Weighted-average common shares outstanding - basic

 

 

151,859,924

 

 

 

269,697,212

 

Net earnings (loss) per share attributable to common shareholders - basic

 

$

(0.01

)

 

$

0.43

 

 

 

 

 

 

 

 

 

 

Diluted earnings (loss) per share

 

 

 

 

 

 

 

 

Net earnings (loss) attributable to common shareholders - diluted

 

$

(2,093

)

 

$

117,221

 

Weighted-average common shares outstanding - basic

 

 

151,859,924

 

 

 

269,697,212

 

Stock options and RSUs

 

 

-

 

 

 

50,585,535

 

Weighted-average common shares outstanding - diluted

 

 

151,859,924

 

 

 

320,282,747

 

Net earnings (loss) per share attributable to common shareholders - diluted

 

$

(0.01

)

 

$

0.37

 

 

The Company’s potentially dilutive securities, which include convertible preferred shares and stock options have been excluded from the computation of diluted net loss per share for the three months ended March 31, 2020 as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding for the three months ended March 31, 2020 used to calculate both basic and diluted net loss per share attributable to common shareholders is the same.

The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net earnings (loss) per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:

 

 

 

Three months ended March 31,

 

 

 

2020

 

 

2021

 

Options to purchase common shares

 

 

13,310,018

 

 

 

-

 

Convertible preferred shares

 

 

2,640,178

 

 

 

-

 

Total potential common shares excluded

 

 

15,950,196

 

 

 

-

 

 

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Other Current Assets
3 Months Ended
Mar. 31, 2021
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]  
Other Current Assets

5. Other current assets

Other current assets consisted of the following:

 

 

 

 

 

December 31,

2020

 

 

March 31,

2021

 

 

 

 

 

(in thousands)

 

Tax and investment tax credit receivable

 

 

 

$

489

 

 

$

249

 

Prepaid expenses

 

 

 

 

4,073

 

 

 

4,287

 

Materials and supplies

 

 

 

 

1,408

 

 

 

1,209

 

Total other current assets

 

 

 

$

5,970

 

 

$

5,745

 

 

 

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment, Net
3 Months Ended
Mar. 31, 2021
Property Plant And Equipment [Abstract]  
Property and equipment, net

6. Property and equipment, net

Property and equipment, net consisted of the following:

 

 

 

 

 

December 31,

2020

 

 

March 31,

2021

 

 

 

 

 

(in thousands)

 

Computers

 

 

 

$

6,324

 

 

$

6,309

 

Laboratory equipment

 

 

 

 

9,423

 

 

 

13,035

 

Furniture and fixtures

 

 

 

 

119

 

 

 

119

 

Leasehold improvements

 

 

 

 

3,708

 

 

 

3,977

 

Operating lease right-of-use assets

 

 

 

 

3,935

 

 

 

17,463

 

Property and equipment

 

 

 

 

23,509

 

 

 

40,903

 

Less accumulated depreciation

 

 

 

 

(5,586

)

 

 

(6,285

)

Property and equipment, net

 

 

 

$

17,923

 

 

$

34,618

 

 

Depreciation expense on property and equipment for the three months ended March 31, 2020 and 2021 was $0.4 million and $0.8 million, respectively.

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets
3 Months Ended
Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]  
Intangible Assets

7. Intangible assets:

 

Intangible assets consisted of the following:

 

 

 

March 31, 2021

 

 

 

Gross

carrying

amount

 

 

Accumulated

amortization

 

 

Net book

value

 

 

 

(in thousands)

 

License

 

$

35,873

 

 

$

4,125

 

 

$

31,748

 

Technology

 

 

41,400

 

 

 

860

 

 

 

40,540

 

IPR&D

 

 

40,400

 

 

 

-

 

 

 

40,400

 

 

 

$

117,673

 

 

$

4,985

 

 

$

112,688

 

 

At March 31, 2021, amortization expense on intangible assets is estimated to be as follows for each of the next five years:

 

 

 

Amortization

Expense

 

 

 

(in thousands)

 

2021

 

$

9,860

 

2022

 

 

9,860

 

2023

 

 

9,834

 

2024

 

 

3,476

 

2025

 

 

3,476

 

 

 

$

36,506

 

 

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Investments in and Loans to Equity Accounted Investees
3 Months Ended
Mar. 31, 2021
Equity Method Investments And Joint Ventures [Abstract]  
Investments in and loans to equity accounted investees

8. Investments in and loans to equity accounted investees

The Company has entered into two joint ventures as part of the construction of future office and laboratory headquarters. During 2020, the Company entered into a joint venture with Dayhu (Dayhu JV). To date, the equity investment balance of $19.3 million represents the cash contribution made since inception.   In the three months ended March 31, 2021 the Company entered into the Beedie joint venture (Beedie JV). To date we have contributed $11.7 million into the Beedie JV. To date, the Company has not recorded any amount of proportionate income or loss with respect to either venture.

In the three months ended March 31, 2021, the Company made a commitment up to CAD$

82.7 million ($61.5 million) to the Dayhu JV to fund the construction at a rate referenced to an applicable Canadian bank prime rate plus 0.6%, and repayment on the earlier of thirty months from the date of initial advancement and September 1, 2023, or upon the trigger of certain liquidity events as defined in the agreement. The loan is secured by the underlying land and future assets of the joint venture. At March 31, 2021, the outstanding related party loan balance was $1.2 million to the joint venture.

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Accounts Payable and Other Liabilities
3 Months Ended
Mar. 31, 2021
Payables And Accruals [Abstract]  
Accounts Payable and Other Liabilities

9. Accounts payable and other liabilities

Accounts payable and other liabilities consisted of the following:

 

 

 

 

 

December 31,

2020

 

 

March 31,

2021

 

 

 

 

 

(in thousands)

 

Accounts payable and accrued liabilities

 

 

 

$

7,130

 

 

$

3,585

 

Liability for in-licensing agreement

 

 

 

 

5,000

 

 

 

4,545

 

Operating lease liability

 

 

 

 

675

 

 

 

1,533

 

Liability classified options

 

 

 

 

4,270

 

 

 

474

 

Government remittances payable

 

 

 

 

1,988

 

 

 

1,207

 

Current portion of deferred grant funding

 

 

 

 

942

 

 

 

1,943

 

Current portion of long-term debt

 

 

 

 

190

 

 

 

-

 

Total accounts payable and other liabilities

 

 

 

$

20,195

 

 

$

13,287

 

 

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Shareholders’ Equity
3 Months Ended
Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Shareholders’ Equity

10. Shareholders’ equity

Sixth Amended and Restated Stock Option Plan:

The Company maintains the AbCellera Biologics Inc. Sixth Amended and Restated Stock Option Plan and our Pre-IPO Plan. Any awards granted under the Pre-IPO Plan will remain subject to the terms of our Pre-IPO Plan and applicable award agreements.

In March 2021, substantially all employee option holders whose awards were liability-classified elected to convert the currency of their option exercise price from Canadian dollars to U.S. dollars for administrative convenience. As a result of the modification, $5.2 million was reclassified from liability to equity.

2020 Share Option and Incentive Plan:

Our 2020 Share Option and Incentive Plan, or 2020 Plan, was approved by our board of directors on November 18, 2020 and approved by our shareholders on December 1, 2020.

As of March 31, 2021, the number of shares available for issuance under the 2020 Plan was 20,075,196, which includes awards granted and outstanding under the Pre-IPO Plan that are forfeited after December 10, 2020.

2020 Employee Share Purchase Plan:

In December 2020, the Company’s Board of Directors approved the 2020 Employee Share Purchase Plan, or the 2020 ESPP. A total of 2,700,000 shares of common stock was initially reserved for issuance under the ESPP. At March 31, 2020 the Company had not yet commenced the ESPP.

The following table summarizes the Company’s stock options granted in Canadian dollars under the Pre-IPO Plan since December 31, 2020:

 

 

 

Number of

Shares

 

 

Weighted-

Average Exercise

Price

 

Outstanding as of December 31, 2020

 

 

53,204,810

 

 

$

0.71

 

Granted

 

 

-

 

 

 

-

 

Exercised

 

 

(1,428,120

)

 

 

0.12

 

Forfeited

 

 

(41,000

)

 

 

10.41

 

Outstanding as of March 31, 2021

 

 

51,735,690

 

 

 

0.72

 

Options exercisable as of March 31, 2021

 

 

25,038,995

 

 

$

0.29

 

 

 

The following table summarizes the Company’s stock options granted under the 2020 Plan since December 31, 2020:

 

 

 

Number of

Shares

 

 

Weighted-

Average Exercise

Price

 

Outstanding as of December 31, 2020

 

 

1,260,840

 

 

$

20.00

 

Granted

 

 

321,356

 

 

 

52.06

 

Exercised

 

 

-

 

 

 

-

 

Forfeited

 

 

(900

)

 

 

52.30

 

Outstanding as of March 31, 2021

 

 

1,581,296

 

 

$

26.50

 

Options exercisable as of March 31, 2021

 

 

-

 

 

 

-

 

 

As part of the 2020 Plan, restricted share units (RSUs) were available to be granted and offer holders are subject to a one year cliff vesting followed by monthly vesting thereafter. The following table summarizes the Company’s restricted share units granted under the 2020 Plan since December 31, 2020:

 

 

 

Number of

Shares

 

 

Weighted-

Average Grant

Date Fair Value

 

Outstanding as of December 31, 2020

 

 

-

 

 

$

-

 

Granted

 

 

185,108

 

 

 

52.02

 

Exercised

 

 

-

 

 

 

-

 

Forfeited

 

 

(600

)

 

 

52.30

 

Outstanding as of March 31, 2021

 

 

184,508

 

 

$

52.02

 

 

Stock-based compensation:

Stock-based compensation expense was classified in the consolidated statements of income (loss) and comprehensive income (loss) as follows:

 

 

 

Three months ended March 31,

 

 

 

2020

 

 

2021

 

 

 

(in thousands)

 

Research and development

 

$

616

 

 

$

3,158

 

General and administrative

 

 

608

 

 

 

1,316

 

Sales and marketing

 

 

13

 

 

 

953

 

 

 

$

1,237

 

 

$

5,427

 

 

At December 31, 2020, there were 1,012,000 liability classified options outstanding, of which $4.3 million was included in other liabilities. At March 31, 2021 there were 60,000 liability classified options outstanding, of which $0.5 million was included in other liabilities.

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue
3 Months Ended
Mar. 31, 2021
Revenue From Contract With Customer [Abstract]  
Revenue

11. Revenue

The disaggregated revenue categories are presented on the face of the statement of income (loss) and comprehensive income (loss).

Deferred revenue

Deferred revenue represents payments received for performance obligations not yet satisfied and are presented as current or long-term in the accompanying balance sheets based on the expected timing of satisfaction of the underlying goods and/or services.  

Deferred revenue outstanding in each respective period is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in thousands)

 

December 31, 2019

 

 

March 31, 2020

 

 

December 31, 2020

 

March 31, 2021

 

Deferred revenue

 

$

(5,544

)

 

$

(28,983

)

 

$

(26,230

)

$

(32,375

)

 

 

During the three months ended March 31, 2020 and 2021, the Company recognized $1.4 million and $1.3 million, respectively, of revenue that had been included in deferred revenue in the previous year.

In March of 2020, the Company entered into a research collaboration and license agreement with Eli Lilly pursuant to which the Company will perform discovery research for several targets for Eli Lilly to develop and commercialize. Under the agreement, the Company is entitled to receive an aggregate of up to $29.0 million of milestone payments as well as royalties in the low single digits based on net sales for non-COVID-19 targets and in the low- to mid-teens for aggregate sales below $125.0 million and mid-teens to mid-twenties on aggregate sales above $125.0 million.

The agreement resulted in initial upfront of $26.7 million, of which $21.9 million was included in deferred revenue at December 31, 2020. In the three months ended March 31, 2021 the Company received an additional $1.1 million in payments, for total payments received in respect of this agreement of $27.8 million. The Company expects to recognize approximately $9.4 million  in revenue in the next 12 months related to these payments under the agreement.

Of the remaining deferred revenue balance of $10.3 million which is related to various other agreements, approximately $1.9 million is expected to be recognized in revenue in the next 12 months.  

License revenue

For the licenses to our intellectual property the Company recognizes revenue from non-refundable, up-front fees when the license is transferred to the customer and the customer is able to use and benefit from the license. For the three months ended March 31, 2021, the Company recognized $20.3 million from license revenue relating to license of the Trianni platform.

 

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Financial Instruments
3 Months Ended
Mar. 31, 2021
Investments All Other Investments [Abstract]  
Financial instruments

12. Financial instruments

The Company categorizes its financial assets and liabilities measured at fair value into a three-level hierarchy established by U.S. GAAP that prioritizes those inputs to valuation techniques used to measure fair value based on the degree to which they are observable. The three levels of the fair value hierarchy are as follows: Level 1 inputs are quoted prices in active markets for identical assets and liabilities; Level 2 inputs, other than quoted prices included within Level 1, are observable for the asset or liability either directly or indirectly; and Level 3 inputs are not observable in the market.

The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, loans to related parties, accounts payable and accrued liabilities and royalties payable, operating lease obligations, long-term debt, and contingent consideration payable. The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, and bank indebtedness approximate their fair values due to the immediate and short-term maturity of these financial instruments. The fair value of loans to related party approximate the carrying value as the interest rates approximate the rates applicable for non-related party loans.

At December 31, 2020 and March 31, 2021, the carrying value of long-term debt was $2.2 million and $0.9 million, respectively, and have been included in Other long-term liabilities on the balance sheet. The estimated fair value of long-term debt of $2.3 million and $1.2 million at December 31, 2020 and March 31, 2021, respectively, are classified as Level 2 and have been determined by discounting future principal and interest amounts at estimated interest rates expected to be available to the Company at period end.  

Contingent consideration related to business acquisitions are recorded at fair value on the acquisition date and adjusted on a recurring basis for changes in its fair value. Changes in the fair value of contingent consideration liabilities can result from changes in anticipated payments and changes in assumed discount periods and rates. These inputs are unobservable in the market and therefore categorized as Level 3 inputs.  

The following table presents the changes in fair value of the liability for contingent consideration:

 

(in thousands)

 

Liability at

beginning of

the period

 

 

Increase

(decrease) in fair

value of liability

for contingent

consideration

 

Liability at

end of the

period

 

Three months ended March 31, 2021

 

$

22,559

 

 

581

 

$

23,140

 

 

 

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]  
Commitments and contingencies

13. Commitments and contingencies

From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company does not have contingency reserves established for any litigation liabilities and any of the costs related to such legal proceedings are expensed as incurred.

The Company may enter into certain agreements with strategic partners in the ordinary course of operations that may include contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements.

Pursuant to the agreements, the Company may be obligated to make research and development and regulatory milestone payments upon the occurrence of certain events and upon receipt of royalty payments in the low single-digits to mid-twenties based on certain net sales targets. During the three months ended March 31, 2021, the Company has expensed approximately $20.0 million related to such obligations, of which that same amount is included in current liabilities.

During the quarter ended March 31, 2021 the Company entered into a lease for office and laboratory space in Sydney, Australia representing future lease payments of $0.7 million for the current year, approximately $1.5 million for each of the next four years and $9.7 million thereafter. In the three months ended March 31, 2021, the Company recognized a lease liability of $13.9 million , with a corresponding right of use asset , utilizing a ten year term and 3.0% discount rate.  

The Company entered into a lease for office and laboratory space in Vancouver, Canada, in conjunction with our 50% owned joint venture agreement, representing future lease payments of $1.5 million due in four years, $5.9 million due in five years, and approximately $135.0 million thereafter.  The lease liability and corresponding right of use asset will be recognized on lease commencement date after completion of construction of the office and laboratory space.

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Basis of presentation Basis of presentation

The accompanying interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2020.

These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended March 31, 2021 and 2020 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2020, except for the new accounting guidance adopted during the period (Note 3).

All amounts expressed in the consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share and per share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” and “CAD” are to Canadian dollars.

Use of estimates

Use of estimates

The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and determining whether an option for additional goods or services represents a material right, recoverability of investment tax credits receivable, value of contingent consideration payable and the fair value of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.

COVID-19 Pandemic

COVID-19 Pandemic

With the global spread of the ongoing COVID-19 pandemic, the Company has implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on its employees and its business. The Company has taken measures to secure its research and development activities, while work in its laboratories and facilities has been re-organized to reduce risk of COVID-19 transmission. Given the global economic impact, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company’s business, financial condition, and results of operations could be materially adversely affected. The Company continues to closely monitor the COVID-19 pandemic as it evolves its business continuity plans and response strategy. As of the date of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Company’s financial statements.

Recent accounting pronouncements not yet adopted

Recent accounting pronouncements not yet adopted

The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the consolidated financial statements as a result of future adoption.

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Net Earnings (Loss) Per Share (Tables)
3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders

Basic and diluted net earnings (loss) per share attributable to common shareholders was calculated as follows:

 

 

 

Three months ended March 31,

 

 

 

2020

 

 

2021

 

 

 

(in thousands, except share and per share data)

 

Basic earnings (loss) per share

 

 

 

 

 

 

 

 

Net earnings (loss)

 

$

(2,093

)

 

$

117,221

 

Net earnings (loss) attributable to common shareholders - basic

 

$

(2,093

)

 

$

117,221

 

Weighted-average common shares outstanding - basic

 

 

151,859,924

 

 

 

269,697,212

 

Net earnings (loss) per share attributable to common shareholders - basic

 

$

(0.01

)

 

$

0.43

 

 

 

 

 

 

 

 

 

 

Diluted earnings (loss) per share

 

 

 

 

 

 

 

 

Net earnings (loss) attributable to common shareholders - diluted

 

$

(2,093

)

 

$

117,221

 

Weighted-average common shares outstanding - basic

 

 

151,859,924

 

 

 

269,697,212

 

Stock options and RSUs

 

 

-

 

 

 

50,585,535

 

Weighted-average common shares outstanding - diluted

 

 

151,859,924

 

 

 

320,282,747

 

Net earnings (loss) per share attributable to common shareholders - diluted

 

$

(0.01

)

 

$

0.37

 

Schedule of Potential Common Shares Excluded from Computation of Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders

The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net earnings (loss) per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:

 

 

 

Three months ended March 31,

 

 

 

2020

 

 

2021

 

Options to purchase common shares

 

 

13,310,018

 

 

 

-

 

Convertible preferred shares

 

 

2,640,178

 

 

 

-

 

Total potential common shares excluded

 

 

15,950,196

 

 

 

-

 

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Other Current Assets (Tables)
3 Months Ended
Mar. 31, 2021
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]  
Schedule of Other Current Assets

Other current assets consisted of the following:

 

 

 

 

 

December 31,

2020

 

 

March 31,

2021

 

 

 

 

 

(in thousands)

 

Tax and investment tax credit receivable

 

 

 

$

489

 

 

$

249

 

Prepaid expenses

 

 

 

 

4,073

 

 

 

4,287

 

Materials and supplies

 

 

 

 

1,408

 

 

 

1,209

 

Total other current assets

 

 

 

$

5,970

 

 

$

5,745

 

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment, Net (Tables)
3 Months Ended
Mar. 31, 2021
Property Plant And Equipment [Abstract]  
Schedule of Property and Equipment, Net

Property and equipment, net consisted of the following:

 

 

 

 

 

December 31,

2020

 

 

March 31,

2021

 

 

 

 

 

(in thousands)

 

Computers

 

 

 

$

6,324

 

 

$

6,309

 

Laboratory equipment

 

 

 

 

9,423

 

 

 

13,035

 

Furniture and fixtures

 

 

 

 

119

 

 

 

119

 

Leasehold improvements

 

 

 

 

3,708

 

 

 

3,977

 

Operating lease right-of-use assets

 

 

 

 

3,935

 

 

 

17,463

 

Property and equipment

 

 

 

 

23,509

 

 

 

40,903

 

Less accumulated depreciation

 

 

 

 

(5,586

)

 

 

(6,285

)

Property and equipment, net

 

 

 

$

17,923

 

 

$

34,618

 

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets (Tables)
3 Months Ended
Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets

Intangible assets consisted of the following:

 

 

 

March 31, 2021

 

 

 

Gross

carrying

amount

 

 

Accumulated

amortization

 

 

Net book

value

 

 

 

(in thousands)

 

License

 

$

35,873

 

 

$

4,125

 

 

$

31,748

 

Technology

 

 

41,400

 

 

 

860

 

 

 

40,540

 

IPR&D

 

 

40,400

 

 

 

-

 

 

 

40,400

 

 

 

$

117,673

 

 

$

4,985

 

 

$

112,688

 

Schedule of Estimated Amortization Expense on Intangible Assets

At March 31, 2021, amortization expense on intangible assets is estimated to be as follows for each of the next five years:

 

 

 

Amortization

Expense

 

 

 

(in thousands)

 

2021

 

$

9,860

 

2022

 

 

9,860

 

2023

 

 

9,834

 

2024

 

 

3,476

 

2025

 

 

3,476

 

 

 

$

36,506

 

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Accounts Payable and Other Liabilities (Tables)
3 Months Ended
Mar. 31, 2021
Payables And Accruals [Abstract]  
Schedule of Accounts Payable and Other Liabilities

Accounts payable and other liabilities consisted of the following:

 

 

 

 

 

December 31,

2020

 

 

March 31,

2021

 

 

 

 

 

(in thousands)

 

Accounts payable and accrued liabilities

 

 

 

$

7,130

 

 

$

3,585

 

Liability for in-licensing agreement

 

 

 

 

5,000

 

 

 

4,545

 

Operating lease liability

 

 

 

 

675

 

 

 

1,533

 

Liability classified options

 

 

 

 

4,270

 

 

 

474

 

Government remittances payable

 

 

 

 

1,988

 

 

 

1,207

 

Current portion of deferred grant funding

 

 

 

 

942

 

 

 

1,943

 

Current portion of long-term debt

 

 

 

 

190

 

 

 

-

 

Total accounts payable and other liabilities

 

 

 

$

20,195

 

 

$

13,287

 

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Shareholders’ Equity (Tables)
3 Months Ended
Mar. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Summary of Restricted Share Units Granted

As part of the 2020 Plan, restricted share units (RSUs) were available to be granted and offer holders are subject to a one year cliff vesting followed by monthly vesting thereafter. The following table summarizes the Company’s restricted share units granted under the 2020 Plan since December 31, 2020:

 

 

 

Number of

Shares

 

 

Weighted-

Average Grant

Date Fair Value

 

Outstanding as of December 31, 2020

 

 

-

 

 

$

-

 

Granted

 

 

185,108

 

 

 

52.02

 

Exercised

 

 

-

 

 

 

-

 

Forfeited

 

 

(600

)

 

 

52.30

 

Outstanding as of March 31, 2021

 

 

184,508

 

 

$

52.02

 

Summary of Stock-Based Compensation Expense

Stock-based compensation expense was classified in the consolidated statements of income (loss) and comprehensive income (loss) as follows:

 

 

 

Three months ended March 31,

 

 

 

2020

 

 

2021

 

 

 

(in thousands)

 

Research and development

 

$

616

 

 

$

3,158

 

General and administrative

 

 

608

 

 

 

1,316

 

Sales and marketing

 

 

13

 

 

 

953

 

 

 

$

1,237

 

 

$

5,427

 

Pre-IPO Plan  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Summary of Stock Options Granted

The following table summarizes the Company’s stock options granted in Canadian dollars under the Pre-IPO Plan since December 31, 2020:

 

 

 

Number of

Shares

 

 

Weighted-

Average Exercise

Price

 

Outstanding as of December 31, 2020

 

 

53,204,810

 

 

$

0.71

 

Granted

 

 

-

 

 

 

-

 

Exercised

 

 

(1,428,120

)

 

 

0.12

 

Forfeited

 

 

(41,000

)

 

 

10.41

 

Outstanding as of March 31, 2021

 

 

51,735,690

 

 

 

0.72

 

Options exercisable as of March 31, 2021

 

 

25,038,995

 

 

$

0.29

 

2020 Share Option and Incentive Plan  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Summary of Stock Options Granted

The following table summarizes the Company’s stock options granted under the 2020 Plan since December 31, 2020:

 

 

 

Number of

Shares

 

 

Weighted-

Average Exercise

Price

 

Outstanding as of December 31, 2020

 

 

1,260,840

 

 

$

20.00

 

Granted

 

 

321,356

 

 

 

52.06

 

Exercised

 

 

-

 

 

 

-

 

Forfeited

 

 

(900

)

 

 

52.30

 

Outstanding as of March 31, 2021

 

 

1,581,296

 

 

$

26.50

 

Options exercisable as of March 31, 2021

 

 

-

 

 

 

-

 

XML 39 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2021
Revenue From Contract With Customer [Abstract]  
Summary of Deferred Revenue Outstanding

Deferred revenue outstanding in each respective period is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in thousands)

 

December 31, 2019

 

 

March 31, 2020

 

 

December 31, 2020

 

March 31, 2021

 

Deferred revenue

 

$

(5,544

)

 

$

(28,983

)

 

$

(26,230

)

$

(32,375

)

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2021
Investments All Other Investments [Abstract]  
Changes in Fair Value of Liability for Contingent Consideration

The following table presents the changes in fair value of the liability for contingent consideration:

 

(in thousands)

 

Liability at

beginning of

the period

 

 

Increase

(decrease) in fair

value of liability

for contingent

consideration

 

Liability at

end of the

period

 

Three months ended March 31, 2021

 

$

22,559

 

 

581

 

$

23,140

 

 

 

XML 41 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Net Earnings (Loss) Per Share - Schedule of Basic and Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Basic earnings (loss) per share    
Net earnings (loss) $ 117,221 $ (2,093)
Net earnings (loss) attributable to common shareholders - basic $ 117,221 $ (2,093)
Weighted-average common shares outstanding - basic 269,697,212 151,859,924
Net earnings (loss) per share attributable to common shareholders - basic $ 0.43 $ (0.01)
Diluted earnings (loss) per share    
Net earnings (loss) attributable to common shareholders - diluted $ 117,221 $ (2,093)
Weighted-average common shares outstanding - basic 269,697,212 151,859,924
Stock options and RSUs 50,585,535  
Weighted-average common shares outstanding - diluted 320,282,747 151,859,924
Net earnings (loss) per share attributable to common shareholders - diluted $ 0.37 $ (0.01)
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Net Earnings (Loss) Per Share - Schedule of Potential Common Shares Excluded from Computation of Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders (Details)
3 Months Ended
Mar. 31, 2020
shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]  
Total potential common shares excluded 15,950,196
Options to Purchase Common Shares  
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]  
Total potential common shares excluded 13,310,018
Convertible Preferred Shares  
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]  
Total potential common shares excluded 2,640,178
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Other Current Assets - Schedule of Other Current Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]    
Tax and investment tax credit receivable $ 249 $ 489
Prepaid expenses 4,287 4,073
Materials and supplies 1,209 1,408
Total other current assets $ 5,745 $ 5,970
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Property Plant And Equipment [Line Items]    
Property and equipment $ 40,903 $ 23,509
Less accumulated depreciation (6,285) (5,586)
Property and equipment, net 34,618 17,923
Computers    
Property Plant And Equipment [Line Items]    
Property and equipment 6,309 6,324
Laboratory Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment 13,035 9,423
Furniture and Fixtures    
Property Plant And Equipment [Line Items]    
Property and equipment 119 119
Leasehold Improvements    
Property Plant And Equipment [Line Items]    
Property and equipment 3,977 3,708
Operating Lease Right-of-use Assets    
Property Plant And Equipment [Line Items]    
Property and equipment $ 17,463 $ 3,935
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment, Net - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Property Plant And Equipment [Abstract]    
Depreciation expense on property and equipment $ 840 $ 415
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Finite Lived Intangible Assets [Line Items]    
Gross carrying amount $ 117,673  
Accumulated amortization 4,985  
Net book value 112,688 $ 115,153
License    
Finite Lived Intangible Assets [Line Items]    
Gross carrying amount 35,873  
Accumulated amortization 4,125  
Net book value 31,748  
Technology    
Finite Lived Intangible Assets [Line Items]    
Gross carrying amount 41,400  
Accumulated amortization 860  
Net book value 40,540  
IPR&D    
Finite Lived Intangible Assets [Line Items]    
Gross carrying amount 40,400  
Net book value $ 40,400  
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details)
$ in Thousands
Mar. 31, 2021
USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]  
2021 $ 9,860
2022 9,860
2023 9,834
2024 3,476
2025 3,476
Finite lived intangible assets amortization expense $ 36,506
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Investments in and Loans to Equity Accounted Investees - Additional Information (Details)
3 Months Ended 12 Months Ended
Mar. 31, 2021
USD ($)
JointVenture
Mar. 31, 2021
CAD ($)
JointVenture
Dec. 31, 2020
USD ($)
Schedule Of Equity Method Investments [Line Items]      
Number Of Joint Ventures | JointVenture 2 2  
Dayhu JV      
Schedule Of Equity Method Investments [Line Items]      
Equity investment balance, cash contribution made in joint venture     $ 19,300
Commitment amount, repayment term 30 months 30 months  
Commitment amount, maturity date Sep. 01, 2023 Sep. 01, 2023  
Debt instrument, repayment description repayment on the earlier of thirty months from the date of initial advancement and September 1, 2023, or upon the trigger of certain liquidity events as defined in the agreement. repayment on the earlier of thirty months from the date of initial advancement and September 1, 2023, or upon the trigger of certain liquidity events as defined in the agreement.  
Equity method investment, outstanding related party loan $ 1,200,000    
Dayhu JV | Maximum      
Schedule Of Equity Method Investments [Line Items]      
Equity method investment, commitment amount $ 61,500,000 $ 82,700,000  
Dayhu JV | Prime Rate      
Schedule Of Equity Method Investments [Line Items]      
Debt instrument, basis spread on variable rate 0.60% 0.60%  
Beedie JV      
Schedule Of Equity Method Investments [Line Items]      
Equity investment balance, cash contribution made in joint venture $ 11,700,000    
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Accounts Payable and Other Liabilities - Schedule of Accounts Payable and Other Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Payables And Accruals [Abstract]    
Accounts payable and accrued liabilities $ 3,585 $ 7,130
Liability for in-licensing agreement 4,545 5,000
Operating lease liability 1,533 675
Liability classified options 474 4,270
Government remittances payable 1,207 1,988
Current portion of deferred grant funding 1,943 942
Current portion of long-term debt   190
Total accounts payable and other liabilities $ 13,287 $ 20,195
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Shareholders' Equity - Additional Information (Details) - USD ($)
$ in Millions
1 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Conversion of liability classified options to equity $ 5.2  
Options outstanding 60,000 1,012,000
Stock options liability included in other liabilities $ 0.5 $ 4.3
2020 Share Option and Incentive Plan    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Number of shares available for issuance 20,075,196  
2020 Employee Share Purchase Plan    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Shares reserved for ESPP   2,700,000
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Shareholders' Equity - Summary of Stock Options Granted (Details)
3 Months Ended
Mar. 31, 2021
$ / shares
shares
Pre-IPO Plan  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Number of Shares Outstanding, Beginning Balance | shares 53,204,810
Number of Shares, Exercised | shares (1,428,120)
Number of Shares, Forfeited | shares (41,000)
Number of Shares Outstanding, Ending Balance | shares 51,735,690
Number of Options exercisable as of March 31, 2021 | shares 25,038,995
Weighted-Average Exercise Price, Beginning Balance | $ / shares $ 0.71
Weighted-Average Exercise Price, Exercised | $ / shares 0.12
Weighted-Average Exercise Price, Forfeited | $ / shares 10.41
Weighted-Average Exercise Price, Ending Balance | $ / shares 0.72
Weighted-Average Exercise Price, Options exercisable as of March 31, 2021 | $ / shares $ 0.29
2020 Share Option and Incentive Plan  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Number of Shares Outstanding, Beginning Balance | shares 1,260,840
Number of Shares, Granted | shares 321,356
Number of Shares, Forfeited | shares (900)
Number of Shares Outstanding, Ending Balance | shares 1,581,296
Weighted-Average Exercise Price, Beginning Balance | $ / shares $ 20.00
Weighted-Average Exercise Price, Granted | $ / shares 52.06
Weighted-Average Exercise Price, Forfeited | $ / shares 52.30
Weighted-Average Exercise Price, Ending Balance | $ / shares $ 26.50
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Shareholders' Equity - Summary of Restricted Share Units Granted (Details) - 2020 Share Option and Incentive Plan - Restricted Share Units (RSUs)
3 Months Ended
Mar. 31, 2021
$ / shares
shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Number of Shares, Granted | shares 185,108
Number of Shares, Forfeited | shares (600)
Number of Shares Outstanding, Ending Balance | shares 184,508
Weighted-Average Grant Date Fair Value, Granted | $ / shares $ 52.02
Weighted-Average Grant Date Fair Value, Forfeited | $ / shares 52.30
Weighted-Average Grant Date Fair Value, Ending Balance | $ / shares $ 52.02
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Shareholders' Equity - Summary of Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Stock-based compensation expense $ 5,427 $ 1,237
Research and Development    
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Stock-based compensation expense 3,158 616
General and Administrative    
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Stock-based compensation expense 1,316 608
Sales and Marketing    
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Stock-based compensation expense $ 953 $ 13
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue - Summary of Deferred Revenue Outstanding (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Mar. 31, 2020
Dec. 31, 2019
Revenue From Contract With Customer [Abstract]        
Deferred revenue $ (32,375) $ (26,230) $ (28,983) $ (5,544)
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue - Additional Information (Details) - USD ($)
3 Months Ended 12 Months Ended 15 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Mar. 31, 2021
Dec. 31, 2019
Disaggregation Of Revenue [Line Items]          
Contract with customer liability, revenue recognized $ 1,300,000 $ 1,400,000      
Deferred revenue 32,375,000 28,983,000 $ 26,230,000 $ 32,375,000 $ 5,544,000
Revenue 202,741,000 4,657,000      
License Revenue          
Disaggregation Of Revenue [Line Items]          
Revenue 20,259,000        
Research, Collaboration and License Agreement | Eli Lilly          
Disaggregation Of Revenue [Line Items]          
Upfront received 1,100,000   26,700,000 27,800,000  
Deferred revenue     $ 21,900,000    
Research, Collaboration and License Agreement | Maximum | Eli Lilly          
Disaggregation Of Revenue [Line Items]          
Milestone payment threshold amount   29,000,000.0      
Low to mid-teens royalty threshold sales amount   125,000,000.0      
Research, Collaboration and License Agreement | Minimum [Member] | Eli Lilly          
Disaggregation Of Revenue [Line Items]          
Mid-teens to mid-twenties royalty threshold sales amount   $ 125,000,000.0      
Various Other Agreements          
Disaggregation Of Revenue [Line Items]          
Deferred revenue $ 10,300,000     $ 10,300,000  
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue - Additional Information (Details1) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-04-01
$ in Millions
Mar. 31, 2021
USD ($)
Research, Collaboration and License Agreement | Eli Lilly  
Disaggregation Of Revenue [Line Items]  
Revenue, remaining performance obligation $ 9.4
Revenue, remaining performance obligation, expected timing of satisfaction period 12 months
Various Other Agreements  
Disaggregation Of Revenue [Line Items]  
Revenue, remaining performance obligation $ 1.9
Revenue, remaining performance obligation, expected timing of satisfaction period 12 months
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Financial Instruments - Additional Information (Details) - Level 2 - USD ($)
$ in Millions
Mar. 31, 2021
Dec. 31, 2020
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Fair value of long-term debt $ 1.2 $ 2.3
Other Long-term Liabilities    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Carrying value of long term debt $ 0.9 $ 2.2
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details) - Contingent Consideration - Level 3
$ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]  
Liability at beginning of the period $ 22,559
Increase (decrease) in fair value of liability for contingent consideration 581
Liability at end of the period $ 23,140
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Lessee Lease Description [Line Items]    
Royalty expensed $ 20,010  
Lease liability 16,973 $ 3,715
Office and Laboratory Space | Sydney, Australia    
Lessee Lease Description [Line Items]    
Future lease payments for remainder of fiscal 2021 700  
Future lease payments for 2022 1,500  
Future lease payments for 2023 1,500  
Future lease payments for 2024 1,500  
Future lease payments for 2025 1,500  
Future lease payments thereafter 9,700  
Lease liability $ 13,900  
Lease not yet commenced, term of contract 10 years  
Lease not yet commenced, discount rate 3.00%  
Office and Laboratory Space | Vancouver, Canada    
Lessee Lease Description [Line Items]    
Future lease payments for 2025 $ 1,500  
Ownership percentage in joint venture agreement 50.00%  
Future lease payments for 2026 $ 5,900  
Future lease payments thereafter $ 135,000  
EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 90 294 1 true 43 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) (Unaudited) Sheet http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 100060 - Disclosure - Nature of Operations Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureNatureOfOperations Nature of Operations Notes 7 false false R8.htm 100070 - Disclosure - Basis of Presentation Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureBasisOfPresentation Basis of Presentation Notes 8 false false R9.htm 100080 - Disclosure - Significant Accounting Policies Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - Net Earnings (Loss) Per Share Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShare Net Earnings (Loss) Per Share Notes 10 false false R11.htm 100100 - Disclosure - Other Current Assets Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssets Other Current Assets Notes 11 false false R12.htm 100110 - Disclosure - Property and Equipment, Net Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNet Property and Equipment, Net Notes 12 false false R13.htm 100120 - Disclosure - Intangible Assets Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssets Intangible Assets Notes 13 false false R14.htm 100130 - Disclosure - Investments in and Loans to Equity Accounted Investees Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvestees Investments in and Loans to Equity Accounted Investees Notes 14 false false R15.htm 100140 - Disclosure - Accounts Payable and Other Liabilities Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilities Accounts Payable and Other Liabilities Notes 15 false false R16.htm 100150 - Disclosure - Shareholders??? Equity Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquity Shareholders??? Equity Notes 16 false false R17.htm 100160 - Disclosure - Revenue Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenue Revenue Notes 17 false false R18.htm 100170 - Disclosure - Financial Instruments Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstruments Financial Instruments Notes 18 false false R19.htm 100180 - Disclosure - Commitments and Contingencies Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 19 false false R20.htm 100190 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.abcellera.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies 20 false false R21.htm 100200 - Disclosure - Net Earnings (Loss) Per Share (Tables) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareTables Net Earnings (Loss) Per Share (Tables) Tables http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShare 21 false false R22.htm 100210 - Disclosure - Other Current Assets (Tables) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssetsTables Other Current Assets (Tables) Tables http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssets 22 false false R23.htm 100220 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNet 23 false false R24.htm 100230 - Disclosure - Intangible Assets (Tables) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) Tables http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssets 24 false false R25.htm 100240 - Disclosure - Accounts Payable and Other Liabilities (Tables) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesTables Accounts Payable and Other Liabilities (Tables) Tables http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilities 25 false false R26.htm 100250 - Disclosure - Shareholders??? Equity (Tables) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityTables Shareholders??? Equity (Tables) Tables http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquity 26 false false R27.htm 100260 - Disclosure - Revenue (Tables) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueTables Revenue (Tables) Tables http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenue 27 false false R28.htm 100270 - Disclosure - Financial Instruments (Tables) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstruments 28 false false R29.htm 100280 - Disclosure - Net Earnings (Loss) Per Share - Schedule of Basic and Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails Net Earnings (Loss) Per Share - Schedule of Basic and Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders (Details) Details http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareTables 29 false false R30.htm 100290 - Disclosure - Net Earnings (Loss) Per Share - Schedule of Potential Common Shares Excluded from Computation of Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails Net Earnings (Loss) Per Share - Schedule of Potential Common Shares Excluded from Computation of Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders (Details) Details http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareTables 30 false false R31.htm 100300 - Disclosure - Other Current Assets - Schedule of Other Current Assets (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssetsScheduleOfOtherCurrentAssetsDetails Other Current Assets - Schedule of Other Current Assets (Details) Details 31 false false R32.htm 100310 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) Details 32 false false R33.htm 100320 - Disclosure - Property and Equipment, Net - Additional Information (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails Property and Equipment, Net - Additional Information (Details) Details 33 false false R34.htm 100330 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails Intangible Assets - Schedule of Intangible Assets (Details) Details 34 false false R35.htm 100340 - Disclosure - Intangible Assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails Intangible Assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details) Details 35 false false R36.htm 100350 - Disclosure - Investments in and Loans to Equity Accounted Investees - Additional Information (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails Investments in and Loans to Equity Accounted Investees - Additional Information (Details) Details 36 false false R37.htm 100360 - Disclosure - Accounts Payable and Other Liabilities - Schedule of Accounts Payable and Other Liabilities (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails Accounts Payable and Other Liabilities - Schedule of Accounts Payable and Other Liabilities (Details) Details 37 false false R38.htm 100370 - Disclosure - Shareholders' Equity - Additional Information (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails Shareholders' Equity - Additional Information (Details) Details 38 false false R39.htm 100380 - Disclosure - Shareholders' Equity - Summary of Stock Options Granted (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails Shareholders' Equity - Summary of Stock Options Granted (Details) Details 39 false false R40.htm 100390 - Disclosure - Shareholders' Equity - Summary of Restricted Share Units Granted (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails Shareholders' Equity - Summary of Restricted Share Units Granted (Details) Details 40 false false R41.htm 100400 - Disclosure - Shareholders' Equity - Summary of Stock-Based Compensation Expense (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails Shareholders' Equity - Summary of Stock-Based Compensation Expense (Details) Details 41 false false R42.htm 100410 - Disclosure - Revenue - Summary of Deferred Revenue Outstanding (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueSummaryOfDeferredRevenueOutstandingDetails Revenue - Summary of Deferred Revenue Outstanding (Details) Details 42 false false R43.htm 100420 - Disclosure - Revenue - Additional Information (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails Revenue - Additional Information (Details) Details 43 false false R44.htm 100430 - Disclosure - Revenue - Additional Information (Details1) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1 Revenue - Additional Information (Details1) Details 44 false false R45.htm 100440 - Disclosure - Financial Instruments - Additional Information (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails Financial Instruments - Additional Information (Details) Details 45 false false R46.htm 100450 - Disclosure - Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details) Details 46 false false R47.htm 100460 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 47 false false All Reports Book All Reports abcl-10q_20210331.htm abcl-20210331.xsd abcl-20210331_cal.xml abcl-20210331_def.xml abcl-20210331_lab.xml abcl-20210331_pre.xml abcl-ex311_11.htm abcl-ex312_10.htm abcl-ex321_8.htm abcl-ex322_9.htm gv4rnzlkpfex000001.jpg http://xbrl.sec.gov/dei/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abcl-10q_20210331.htm": { "axisCustom": 0, "axisStandard": 19, "contextCount": 90, "dts": { "calculationLink": { "local": [ "abcl-20210331_cal.xml" ] }, "definitionLink": { "local": [ "abcl-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "abcl-10q_20210331.htm" ] }, "labelLink": { "local": [ "abcl-20210331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "abcl-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "abcl-20210331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 370, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 6, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 11 }, "keyCustom": 22, "keyStandard": 272, "memberCustom": 18, "memberStandard": 25, "nsprefix": "abcl", "nsuri": "http://www.abcellera.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Net Earnings (Loss) Per Share", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShare", "shortName": "Net Earnings (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Other Current Assets", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssets", "shortName": "Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Property and Equipment, Net", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Intangible Assets", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Investments in and Loans to Equity Accounted Investees", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvestees", "shortName": "Investments in and Loans to Equity Accounted Investees", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Accounts Payable and Other Liabilities", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilities", "shortName": "Accounts Payable and Other Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Shareholders\u2019 Equity", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquity", "shortName": "Shareholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Revenue", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Financial Instruments", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Commitments and Contingencies", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Net Earnings (Loss) Per Share (Tables)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareTables", "shortName": "Net Earnings (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Other Current Assets (Tables)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssetsTables", "shortName": "Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Property and Equipment, Net (Tables)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Intangible Assets (Tables)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Accounts Payable and Other Liabilities (Tables)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesTables", "shortName": "Accounts Payable and Other Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Shareholders\u2019 Equity (Tables)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityTables", "shortName": "Shareholders\u2019 Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Revenue (Tables)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Financial Instruments (Tables)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Net Earnings (Loss) Per Share - Schedule of Basic and Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails", "shortName": "Net Earnings (Loss) Per Share - Schedule of Basic and Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20200101_20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Net Earnings (Loss) Per Share - Schedule of Potential Common Shares Excluded from Computation of Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails", "shortName": "Net Earnings (Loss) Per Share - Schedule of Potential Common Shares Excluded from Computation of Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20200101_20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210331", "decimals": "-3", "first": true, "lang": null, "name": "abcl:TaxAndInvestmentTaxCreditReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Other Current Assets - Schedule of Other Current Assets (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssetsScheduleOfOtherCurrentAssetsDetails", "shortName": "Other Current Assets - Schedule of Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210331", "decimals": "-3", "first": true, "lang": null, "name": "abcl:TaxAndInvestmentTaxCreditReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails", "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Property and Equipment, Net - Additional Information (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "shortName": "Property and Equipment, Net - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Intangible Assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails", "shortName": "Intangible Assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": "INF", "first": true, "lang": null, "name": "abcl:NumberOfJointVentures", "reportCount": 1, "unitRef": "U_abclJointVenture", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Investments in and Loans to Equity Accounted Investees - Additional Information (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails", "shortName": "Investments in and Loans to Equity Accounted Investees - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abclDayhuJointVentureMember_20200101_20201231", "decimals": "-2", "lang": null, "name": "us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Accounts Payable and Other Liabilities - Schedule of Accounts Payable and Other Liabilities (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails", "shortName": "Accounts Payable and Other Liabilities - Schedule of Accounts Payable and Other Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210301_20210331", "decimals": "-5", "first": true, "lang": null, "name": "abcl:ConversionOfLiabilityClassifiedOptionsToEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Shareholders' Equity - Additional Information (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "shortName": "Shareholders' Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210301_20210331", "decimals": "-5", "first": true, "lang": null, "name": "abcl:ConversionOfLiabilityClassifiedOptionsToEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_us-gaapPlanNameAxis_abclPreInitialPublicOfferingPlanMember_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Shareholders' Equity - Summary of Stock Options Granted (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails", "shortName": "Shareholders' Equity - Summary of Stock Options Granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_us-gaapPlanNameAxis_abclPreInitialPublicOfferingPlanMember_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) (Unaudited)", "role": "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited", "shortName": "Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_abclTwoThousandTwentyShareOptionAndIncentivePlanMember_20210101_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Shareholders' Equity - Summary of Restricted Share Units Granted (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails", "shortName": "Shareholders' Equity - Summary of Restricted Share Units Granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_abclTwoThousandTwentyShareOptionAndIncentivePlanMember_20210101_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Shareholders' Equity - Summary of Stock-Based Compensation Expense (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails", "shortName": "Shareholders' Equity - Summary of Stock-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Revenue - Summary of Deferred Revenue Outstanding (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueSummaryOfDeferredRevenueOutstandingDetails", "shortName": "Revenue - Summary of Deferred Revenue Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R43": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Revenue - Additional Information (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "shortName": "Revenue - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_srtCounterpartyNameAxis_abclEliLillyMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-04-01_us-gaapTypeOfArrangementAxis_abclResearchCollaborationAndLicenseAgreementMember_20210331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Revenue - Additional Information (Details1)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1", "shortName": "Revenue - Additional Information (Details1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_srtCounterpartyNameAxis_abclEliLillyMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-04-01_us-gaapTypeOfArrangementAxis_abclResearchCollaborationAndLicenseAgreementMember_20210331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20210331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Financial Instruments - Additional Information (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails", "shortName": "Financial Instruments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20210331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_abclContingentConsiderationMember_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails", "shortName": "Financial Instruments - Changes in Fair Value of Liability for Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_abclContingentConsiderationMember_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RoyaltyExpense", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_srtStatementGeographicalAxis_countryAU_us-gaapPropertyPlantAndEquipmentByTypeAxis_abclOfficeAndLaboratorySpaceMember_20210331", "decimals": "-5", "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - Nature of Operations", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNatureOfOperations", "shortName": "Nature of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Basis of Presentation", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureBasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Significant Accounting Policies", "role": "http://www.abcellera.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abcl-10q_20210331.htm", "contextRef": "C_0001703057_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 43, "tag": { "abcl_AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital, reclassification of liability classified options.", "label": "Adjustments To Additional Paid In Capital Reclassification Of Liability Classified Options", "terseLabel": "Reclassification of liability classified options" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedOptions", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_BeedieJointVentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beedie joint venture.", "label": "Beedie Joint Venture [Member]", "terseLabel": "Beedie JV" } } }, "localname": "BeedieJointVentureMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abcl_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent consideration.", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent Consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "abcl_ConversionOfLiabilityClassifiedOptionsToEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of liability classified options to equity.", "label": "Conversion Of Liability Classified Options To Equity", "terseLabel": "Conversion of liability classified options to equity" } } }, "localname": "ConversionOfLiabilityClassifiedOptionsToEquity", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_DayhuJointVentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dayhu joint venture.", "label": "Dayhu Joint Venture [Member]", "terseLabel": "Dayhu JV" } } }, "localname": "DayhuJointVentureMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abcl_DeferredCompensationShareBasedArrangementsLiabilityClassifiedNoncurrentOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred compensation share-based arrangements, liability, classified, noncurrent outstanding.", "label": "Deferred Compensation Share Based Arrangements Liability Classified Noncurrent Outstanding", "verboseLabel": "Options outstanding" } } }, "localname": "DeferredCompensationShareBasedArrangementsLiabilityClassifiedNoncurrentOutstanding", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "abcl_DeferredGrantFundingCurrent": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails": { "order": 10060.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred grant funding current.", "label": "Deferred Grant Funding Current", "terseLabel": "Current portion of deferred grant funding" } } }, "localname": "DeferredGrantFundingCurrent", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abcl_DeferredRevenueAndGrantFundingNoncurrent": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10100.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred revenue and grant funding noncurrent.", "label": "Deferred Revenue And Grant Funding Noncurrent", "terseLabel": "Deferred revenue and grant funding" } } }, "localname": "DeferredRevenueAndGrantFundingNoncurrent", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_EliLillyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eli Lilly.", "label": "Eli Lilly [Member]", "terseLabel": "Eli Lilly" } } }, "localname": "EliLillyMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "domainItemType" }, "abcl_EquityMethodInvestmentCommitmentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity method investment, commitment amount.", "label": "Equity Method Investment Commitment Amount", "terseLabel": "Equity method investment, commitment amount" } } }, "localname": "EquityMethodInvestmentCommitmentAmount", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity method investment, outstanding related party loan.", "label": "Equity Method Investment Outstanding Related Party Loan", "terseLabel": "Equity method investment, outstanding related party loan" } } }, "localname": "EquityMethodInvestmentOutstandingRelatedPartyLoan", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_GrantsAndIncentives": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10060.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Grants and Incentives.", "label": "Grants And Incentives", "negatedLabel": "Grants and incentives" } } }, "localname": "GrantsAndIncentives", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in accounts payable and accrued liabilities excluding royalties payable.", "label": "Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in accrued royalties receivable.", "label": "Increase Decrease In Accrued Royalties Receivable", "negatedLabel": "Accrued royalties receivable" } } }, "localname": "IncreaseDecreaseInAccruedRoyaltiesReceivable", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "abcl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, operating lease liability payments due after year four.", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "terseLabel": "Future lease payments thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_LiabilityForInLicensingAgreementCurrent": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails": { "order": 10020.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability for in-licensing agreement current.", "label": "Liability For In Licensing Agreement Current", "terseLabel": "Liability for in-licensing agreement" } } }, "localname": "LiabilityForInLicensingAgreementCurrent", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abcl_LicenseBasedIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License based intangible assets.", "label": "License Based Intangible Assets [Member]", "terseLabel": "License" } } }, "localname": "LicenseBasedIntangibleAssetsMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "abcl_LowToMidTeensRoyaltyThresholdSalesAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Low to mid-teens royalty threshold sales amount.", "label": "Low To Mid Teens Royalty Threshold Sales Amount", "terseLabel": "Low to mid-teens royalty threshold sales amount" } } }, "localname": "LowToMidTeensRoyaltyThresholdSalesAmount", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_MaterialsAndSuppliesCurrent": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssetsScheduleOfOtherCurrentAssetsDetails": { "order": 10030.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Materials and supplies current.", "label": "Materials And Supplies Current", "terseLabel": "Materials and supplies" } } }, "localname": "MaterialsAndSuppliesCurrent", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssetsScheduleOfOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "abcl_MidTeensToMidTwentiesRoyaltyThresholdSalesAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Mid-teens to mid-twenties royalty threshold sales amount.", "label": "Mid Teens To Mid Twenties Royalty Threshold Sales Amount", "terseLabel": "Mid-teens to mid-twenties royalty threshold sales amount" } } }, "localname": "MidTeensToMidTwentiesRoyaltyThresholdSalesAmount", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_MilestonePaymentThresholdAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payment threshold amount.", "label": "Milestone Payment Threshold Amount", "terseLabel": "Milestone payment threshold amount" } } }, "localname": "MilestonePaymentThresholdAmount", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_MilestonePaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone payments.", "label": "Milestone Payments [Member]", "terseLabel": "Milestone Payments" } } }, "localname": "MilestonePaymentsMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "domainItemType" }, "abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash or Part Noncash Acquisition Right-of-use assets obtained in exchange for operating lease obligation.", "label": "Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation", "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligation" } } }, "localname": "NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abcl_NumberOfJointVentures": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of joint ventures.", "label": "Number Of Joint Ventures", "terseLabel": "Number Of Joint Ventures" } } }, "localname": "NumberOfJointVentures", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "abcl_OfficeAndLaboratorySpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office and laboratory space.", "label": "Office And Laboratory Space [Member]", "terseLabel": "Office and Laboratory Space" } } }, "localname": "OfficeAndLaboratorySpaceMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abcl_OperatingLeaseRightOfUseAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease right-of-use assets.", "label": "Operating Lease Right Of Use Assets [Member]", "terseLabel": "Operating Lease Right-of-use Assets" } } }, "localname": "OperatingLeaseRightOfUseAssetsMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "abcl_OtherLongTermLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other long term liabilities.", "label": "Other Long Term Liabilities [Member]", "terseLabel": "Other Long-term Liabilities" } } }, "localname": "OtherLongTermLiabilitiesMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abcl_PreInitialPublicOfferingPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pre-initial public offering plan.", "label": "Pre Initial Public Offering Plan [Member]", "terseLabel": "Pre-IPO Plan" } } }, "localname": "PreInitialPublicOfferingPlanMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "domainItemType" }, "abcl_ResearchCollaborationAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research, collaboration and license agreement.", "label": "Research Collaboration And License Agreement [Member]", "terseLabel": "Research, Collaboration and License Agreement" } } }, "localname": "ResearchCollaborationAndLicenseAgreementMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "domainItemType" }, "abcl_ResearchFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research fees.", "label": "Research Fees [Member]", "terseLabel": "Research Fees" } } }, "localname": "ResearchFeesMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "domainItemType" }, "abcl_SeriesA1PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A1 preferred stock.", "label": "Series A1 Preferred Stock [Member]", "terseLabel": "Series A1" } } }, "localname": "SeriesA1PreferredStockMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "abcl_SeriesA2PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A2 preferred stock.", "label": "Series A2 Preferred Stock [Member]", "terseLabel": "Series A2" } } }, "localname": "SeriesA2PreferredStockMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "abcl_SharesReservedForEmployeeStockPurchasePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares reserved for employee stock purchase plan.", "label": "Shares Reserved For Employee Stock Purchase Plan", "terseLabel": "Shares reserved for ESPP" } } }, "localname": "SharesReservedForEmployeeStockPurchasePlan", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "abcl_TaxAndInvestmentTaxCreditReceivableCurrent": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssetsScheduleOfOtherCurrentAssetsDetails": { "order": 10010.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax and investment tax credit receivable current.", "label": "Tax And Investment Tax Credit Receivable Current", "terseLabel": "Tax and investment tax credit receivable" } } }, "localname": "TaxAndInvestmentTaxCreditReceivableCurrent", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssetsScheduleOfOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "abcl_TwoThousandTwentyEmployeeSharePurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty employee share purchase plan.", "label": "Two Thousand Twenty Employee Share Purchase Plan [Member]", "terseLabel": "2020 Employee Share Purchase Plan" } } }, "localname": "TwoThousandTwentyEmployeeSharePurchasePlanMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Share option and incentive plan.", "label": "Two Thousand Twenty Share Option And Incentive Plan [Member]", "terseLabel": "2020 Share Option and Incentive Plan" } } }, "localname": "TwoThousandTwentyShareOptionAndIncentivePlanMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "domainItemType" }, "abcl_UnusualOrInfrequentItemsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for unusual or infrequent items.", "label": "Unusual Or Infrequent Items Policy [Text Block]", "terseLabel": "COVID-19 Pandemic" } } }, "localname": "UnusualOrInfrequentItemsPolicyTextBlock", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "abcl_UpfrontPaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront payment received.", "label": "Upfront Payment Received", "terseLabel": "Upfront received" } } }, "localname": "UpfrontPaymentReceived", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abcl_VariousOtherAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Various other agreements.", "label": "Various Other Agreements [Member]", "terseLabel": "Various Other Agreements" } } }, "localname": "VariousOtherAgreementsMember", "nsuri": "http://www.abcellera.com/20210331", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "domainItemType" }, "country_AU": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AUSTRALIA", "terseLabel": "Sydney, Australia" } } }, "localname": "AU", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA", "terseLabel": "Vancouver, Canada" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings Reporting Current", "terseLabel": "Entity Bankruptcy Proceedings Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r50", "r81" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investee Name [Domain]", "terseLabel": "Investment, Name" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r219", "r220", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r335", "r338" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r219", "r220", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r335", "r338" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r143", "r198", "r202", "r308", "r334", "r336" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r143", "r198", "r202", "r308", "r334", "r336" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r210", "r219", "r220", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r335", "r338" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r210", "r219", "r220", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r335", "r338" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "label": "Schedule Of Equity Method Investment Equity Method Investee Name [Axis]", "terseLabel": "Investment, Name" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r144", "r145", "r198", "r203", "r337", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r144", "r145", "r198", "r203", "r337", "r344", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]", "terseLabel": "Accounts Payable and Other Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails": { "order": 10010.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable And Accrued Liabilities Current", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.", "label": "Accounts Payable And Other Accrued Liabilities", "terseLabel": "Accounts payable and other liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable And Other Accrued Liabilities Current", "totalLabel": "Total accounts payable and other liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r27", "r147", "r148" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10270.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable Net Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r21", "r314", "r325" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10160.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r8", "r9", "r40" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10170.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties Current", "terseLabel": "Accrued royalties payable" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r36", "r172" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r28" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r83", "r84", "r85", "r243", "r244", "r245" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r221", "r223", "r248", "r249" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r223", "r240", "r247" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r71", "r160", "r166" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization Of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Total potential common shares excluded" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r79", "r132", "r135", "r141", "r152", "r268", "r272", "r286", "r313", "r324" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r49", "r79", "r152", "r268", "r272", "r286" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r13", "r14", "r15", "r16", "r17", "r18", "r19", "r20", "r79", "r152", "r268", "r272", "r286" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets Noncurrent", "totalLabel": "Total long-term assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Noncurrent [Abstract]", "terseLabel": "Long term assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r224", "r241" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r264", "r265" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination Contingent Consideration Liability Current", "terseLabel": "Current portion of contingent consideration payable" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r264", "r265" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10110.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination Contingent Consideration Liability Noncurrent", "terseLabel": "Contingent consideration payable" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r1", "r82", "r128" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description And Basis Of Presentation [Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r33", "r73" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10260.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r68", "r73", "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r68", "r287" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r78", "r79", "r99", "r103", "r104", "r107", "r109", "r117", "r118", "r119", "r152", "r286" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r45", "r179", "r317", "r329" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r176", "r177", "r178", "r180" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Number of shares available for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r83", "r84" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock No Par Value", "terseLabel": "Common stock, no par value" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorizedUnlimited": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\".", "label": "Common Stock Shares Authorized Unlimited", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorizedUnlimited", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "authorizedUnlimitedItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r26", "r182" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r26" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common shares: no par value, unlimited authorized shares at December 31, 2020 and March 31, 2021: 269,497,768 and 270,925,930 shares issued and outstanding at December 31, 2020 and March 31, 2021 respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computers" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract With Customer Asset And Liability Table [Text Block]", "terseLabel": "Summary of Deferred Revenue Outstanding" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r185", "r186", "r199" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract With Customer Liability", "negatedLabel": "Deferred revenue", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueSummaryOfDeferredRevenueOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r185", "r186", "r199" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10180.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract With Customer Liability Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r200" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract With Customer Liability Revenue Recognized", "terseLabel": "Contract with customer liability, revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Shares" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument Basis Spread On Variable Rate1", "verboseLabel": "Debt instrument, basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r22", "r181", "r315", "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Debt Instrument Carrying Amount", "terseLabel": "Carrying value of long term debt" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r42", "r280" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.", "label": "Debt Instrument Maturity Date", "verboseLabel": "Commitment amount, maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r43", "r322" ], "lang": { "en-us": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Debt Instrument Payment Terms", "verboseLabel": "Debt instrument, repayment description" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument Term", "verboseLabel": "Commitment amount, repayment term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails": { "order": 10040.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).", "label": "Deferred Compensation Share Based Arrangements Liability Current", "terseLabel": "Liability classified options" } } }, "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).", "label": "Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent", "terseLabel": "Stock options liability included in other liabilities" } } }, "localname": "DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r71", "r80", "r255", "r259", "r260", "r261" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense Benefit", "terseLabel": "Deferred tax expense" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r252", "r253" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10120.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r71", "r170" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation of property and equipment", "verboseLabel": "Depreciation expense on property and equipment" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r71", "r170" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10130.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation Of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r198", "r202", "r203", "r204", "r205", "r206", "r207", "r208" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r55", "r88", "r89", "r90", "r91", "r92", "r96", "r99", "r107", "r108", "r109", "r113", "r114", "r320", "r331" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share Basic", "terseLabel": "Basic", "verboseLabel": "Net earnings (loss) per share attributable to common shareholders - basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share Basic [Abstract]", "terseLabel": "Basic earnings (loss) per share" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share Basic And Diluted [Abstract]", "terseLabel": "Net earnings (loss) per share attributable to common shareholders" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r55", "r88", "r89", "r90", "r91", "r92", "r99", "r107", "r108", "r109", "r113", "r114", "r320", "r331" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Diluted", "terseLabel": "Diluted", "verboseLabel": "Net earnings (loss) per share attributable to common shareholders - diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share Diluted [Abstract]", "terseLabel": "Diluted earnings (loss) per share" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r110", "r111", "r112", "r115" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Earnings (Loss) per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r287" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "verboseLabel": "Options to Purchase Common Shares" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r83", "r84", "r85", "r87", "r93", "r95", "r116", "r154", "r182", "r183", "r243", "r244", "r245", "r256", "r257", "r288", "r289", "r290", "r291", "r292", "r293", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment Ownership Percentage", "terseLabel": "Ownership percentage in joint venture agreement" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments And Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments Disclosure [Text Block]", "terseLabel": "Investments in and loans to equity accounted investees" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvestees" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]", "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r278", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value By Balance Sheet Grouping [Table]", "terseLabel": "Fair Value By Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r279", "r298", "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Fair Value By Liability Class [Axis]", "terseLabel": "Liability Class" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r211", "r212", "r217", "r218", "r279", "r299" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r279", "r300" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r281", "r283" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r281", "r283" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]", "terseLabel": "Changes in Fair Value of Liability for Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease", "terseLabel": "Increase (decrease) in fair value of liability for contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r281" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value", "periodEndLabel": "Liability at end of the period", "periodStartLabel": "Liability at beginning of the period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r298", "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsChangesInFairValueOfLiabilityForContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Financial instruments" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r165" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails": { "order": 10020.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Accumulated Amortization", "terseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r167" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails": { "order": 10020.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Next Twelve Months", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails": { "order": 10010.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite Lived Intangible Assets Amortization Expense Table [Text Block]", "terseLabel": "Schedule of Estimated Amortization Expense on Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r167" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails": { "order": 10050.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r167" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails": { "order": 10040.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r167" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails": { "order": 10030.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r161", "r162", "r165", "r168", "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite Lived Intangible Assets By Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r165", "r310" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails": { "order": 10010.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Gross", "terseLabel": "Gross carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite Lived Intangible Assets [Line Items]", "terseLabel": "Finite Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r161", "r164" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r165", "r309" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Net", "totalLabel": "Finite lived intangible assets amortization expense" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfEstimatedAmortizationExpenseOnIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r58" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10120.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r157", "r158", "r312" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10230.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill And Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research And Development [Member]", "terseLabel": "IPR&D" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r53", "r132", "r134", "r137", "r140", "r142", "r311", "r318", "r321", "r332" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10010.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Net earnings (loss) before income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r80", "r94", "r95", "r131", "r254", "r258", "r262", "r333" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10020.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "terseLabel": "Provision for income tax" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r70" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase Decrease In Accrued Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r70" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase Decrease In Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r70" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10270.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase Decrease In Other Operating Capital Net", "negatedLabel": "Other assets and liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r70" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase Decrease In Receivables", "negatedLabel": "Accounts and accrued research fees receivable" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInRoyaltiesPayable": { "auth_ref": [ "r70" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.", "label": "Increase Decrease In Royalties Payable", "terseLabel": "Accrued royalties payable" } } }, "localname": "IncreaseDecreaseInRoyaltiesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r100", "r101", "r102", "r109" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails": { "order": 10020.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable To Share Based Payment Arrangements", "terseLabel": "Stock options and RSUs" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r159", "r163" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10220.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets Net Excluding Goodwill", "terseLabel": "Intangible assets", "totalLabel": "Net book value" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments All Other Investments [Abstract]" } } }, "localname": "InvestmentsAllOtherInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "auth_ref": [ "r34" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10240.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.", "label": "Investments In Affiliates Subsidiaries Associates And Joint Ventures", "terseLabel": "Investments in and loans to equity accounted investees" } } }, "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee Lease Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee Lease Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDiscountRate": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments for lease that has not yet commenced.", "label": "Lessee Operating Lease Lease Not Yet Commenced Discount Rate", "terseLabel": "Lease not yet commenced, discount rate" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedDiscountRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1", "terseLabel": "Lease not yet commenced, term of contract" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Five", "terseLabel": "Future lease payments thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "Future lease payments for 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "Future lease payments for 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "Future lease payments for 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "Future lease payments for 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "Future lease payments for 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year", "terseLabel": "Future lease payments for remainder of fiscal 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r39", "r79", "r136", "r152", "r269", "r272", "r273", "r286" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r32", "r79", "r152", "r286", "r316", "r327" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r41", "r79", "r152", "r269", "r272", "r273", "r286" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10070.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r10", "r11", "r12", "r22", "r23", "r79", "r152", "r269", "r272", "r273", "r286" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "Licensing Revenue", "verboseLabel": "License Revenue" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails": { "order": 10070.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt Current", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long Term Debt Fair Value", "terseLabel": "Fair value of long-term debt" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r120", "r128" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature Of Operations", "terseLabel": "Nature of Operations" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r68" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r68" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r68", "r69", "r72" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r51", "r52", "r54", "r72", "r79", "r86", "r88", "r89", "r90", "r91", "r94", "r95", "r105", "r132", "r134", "r137", "r140", "r142", "r152", "r286", "r319", "r330" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net earnings (loss)", "totalLabel": "Net earnings (loss) and comprehensive income (loss) for the period" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r88", "r89", "r90", "r91", "r96", "r97", "r106", "r109", "r132", "r134", "r137", "r140", "r142" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income Loss Available To Common Stockholders Basic", "terseLabel": "Net earnings (loss) attributable to common shareholders - basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r98", "r106", "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income Loss Available To Common Stockholders Diluted", "terseLabel": "Net earnings (loss) attributable to common shareholders - diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recent accounting pronouncements not yet adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r74", "r75", "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash Or Part Noncash Acquisition Fixed Assets Acquired1", "terseLabel": "Property plant and equipment in accounts payable" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "auth_ref": [ "r74", "r75", "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash Or Part Noncash Acquisition Intangible Assets Acquired1", "terseLabel": "Purchase of intangible assets in exchange for in-licensing agreement payable" } } }, "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r59" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10040.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income Expense", "negatedTotalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income Expense [Abstract]", "terseLabel": "Other (income) expense" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10080.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r132", "r134", "r137", "r140", "r142" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10030.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r294" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails": { "order": 10030.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r294" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating lease liability", "verboseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease Right Of Use Asset Amortization Expense", "terseLabel": "Amortization of operating lease right-of-use-assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssetsScheduleOfOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10290.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets Current", "terseLabel": "Other current assets", "totalLabel": "Total other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssetsScheduleOfOtherCurrentAssetsDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10250.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "Other Current Assets [Text Block]", "terseLabel": "Other Current Assets" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income Expense", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r60" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10050.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income Expense", "negatedLabel": "Other (income) expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables And Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r66" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments Of Financing Costs", "negatedLabel": "Payment of deferred financing fees" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r61" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments To Acquire Equity Method Investments", "negatedLabel": "Investment in equity investees" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r62" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments To Acquire Intangible Assets", "negatedLabel": "Purchase of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": { "auth_ref": [ "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).", "label": "Payments To Acquire Interest In Subsidiaries And Affiliates", "terseLabel": "Equity investment balance, cash contribution made in joint venture" } } }, "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r62" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r224", "r241" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Shares" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r155", "r156" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssetsScheduleOfOtherCurrentAssetsDetails": { "order": 10020.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssetsScheduleOfOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]", "terseLabel": "Prime Rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r64" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds From Issuance Of Long Term Debt", "terseLabel": "Proceeds from long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r63" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds From Issuance Of Preferred Stock And Preference Stock", "terseLabel": "Proceeds from issuance of preferred shares - series A2 financing" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r63", "r242" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Issuance of common shares pursuant to exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r51", "r52", "r67", "r79", "r86", "r94", "r95", "r132", "r134", "r137", "r140", "r142", "r152", "r267", "r270", "r271", "r274", "r275", "r286", "r321" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r36", "r173" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r175", "r345", "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Disclosure [Text Block]", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r35", "r171" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r16", "r17", "r173", "r328" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10210.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r16", "r173" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Schedule of Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r16", "r171" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r65" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments Of Long Term Debt", "negatedLabel": "Repayment of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r65" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments Of Short Term Debt", "negatedLabel": "Short-term borrowings" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r251", "r357" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10100.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Share Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r183", "r246", "r326", "r342", "r343" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r83", "r84", "r85", "r87", "r93", "r95", "r154", "r243", "r244", "r245", "r256", "r257", "r339", "r341" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Earnings (Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue From Contract With Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r129", "r130", "r133", "r138", "r139", "r143", "r144", "r146", "r197", "r198", "r308" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10070.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Total revenue", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r187", "r188", "r189", "r190", "r191", "r192", "r195", "r196", "r201", "r209" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue From Contract With Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r193" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue Remaining Performance Obligation", "terseLabel": "Revenue, remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1", "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r57" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10090.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty fees", "verboseLabel": "Royalty expensed" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalty Revenue" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]", "terseLabel": "Schedule of Accounts Payable and Other Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Schedule of Potential Common Shares Excluded from Computation of Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Schedule of Basic and Diluted Net Earnings (Loss) Per Share Attributable to Common Shareholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r223", "r239", "r247" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r223", "r239", "r247" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Equity Method Investments [Line Items]", "terseLabel": "Schedule Of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r0", "r79", "r151", "r152", "r286" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule Of Equity Method Investments [Table]", "terseLabel": "Schedule Of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r161", "r164", "r309" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule Of Finite Lived Intangible Assets [Table]", "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r161", "r164" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule Of Finite Lived Intangible Assets Table [Text Block]", "terseLabel": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule Of Other Current Assets Table [Text Block]", "terseLabel": "Schedule of Other Current Assets" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r36", "r173" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r224", "r241" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]", "terseLabel": "Summary of Restricted Share Units Granted" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r226", "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of Stock Options Granted" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited": { "order": 10110.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling And Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling And Marketing Expense [Member]", "terseLabel": "Sales and Marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r70" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period", "negatedLabel": "Number of Shares, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Number of Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "periodEndLabel": "Number of Shares Outstanding, Ending Balance", "periodStartLabel": "Number of Shares Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value, Ending Balance", "periodStartLabel": "Weighted-Average Grant Date Fair Value, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period", "negatedLabel": "Number of Shares, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquityTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Number of Options exercisable as of March 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options exercisable as of March 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Number of Shares, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Number of Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r228", "r241" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Number of Shares Outstanding, Ending Balance", "periodStartLabel": "Number of Shares Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price, Ending Balance", "periodStartLabel": "Weighted-Average Exercise Price, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r222", "r225" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfRestrictedShareUnitsGrantedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r184", "r250" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders Equity And Share Based Payments [Text Block]", "terseLabel": "Shareholders\u2019 Equity" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Ending balances, Shares", "periodStartLabel": "Beginning balances, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant accounting policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r24", "r25", "r26", "r78", "r79", "r99", "r103", "r104", "r107", "r109", "r117", "r118", "r119", "r152", "r182", "r286" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationOfDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r47", "r83", "r84", "r85", "r87", "r93", "r95", "r116", "r154", "r182", "r183", "r243", "r244", "r245", "r256", "r257", "r288", "r289", "r290", "r291", "r292", "r293", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r83", "r84", "r85", "r116", "r308" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r25", "r26", "r182", "r183" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of Series A2 preferred shares, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r25", "r26", "r182", "r183", "r230" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Number of Shares, Exercised", "terseLabel": "Shares issued under stock option plan, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureShareholdersEquitySummaryOfStockOptionsGrantedDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r25", "r26", "r182", "r183" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of Series A2 preferred shares" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r47", "r182", "r183" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Shares issued under stock option plan" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r26", "r30", "r31", "r79", "r149", "r152", "r286" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Ending balances", "periodStartLabel": "Beginning balances", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Shareholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails": { "order": 10050.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable Current", "terseLabel": "Government remittances payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureAccountsPayableAndOtherLiabilitiesScheduleOfAccountsPayableAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology Based Intangible Assets [Member]", "terseLabel": "Technology" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails", "http://www.abcellera.com/20210331/taxonomy/role/DisclosureRevenueAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_UnbilledReceivablesCurrent": { "auth_ref": [], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10280.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.", "label": "Unbilled Receivables Current", "terseLabel": "Accrued accounts receivable" } } }, "localname": "UnbilledReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r121", "r122", "r123", "r124", "r125", "r126", "r127" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureInvestmentsInAndLoansToEquityAccountedInvesteesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r98", "r109" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number Of Diluted Shares Outstanding", "terseLabel": "Diluted", "totalLabel": "Weighted-average common shares outstanding - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Shares Outstanding [Abstract]", "terseLabel": "Weighted-average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r96", "r109" ], "calculation": { "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails": { "order": 10010.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number Of Shares Outstanding Basic", "terseLabel": "Basic", "verboseLabel": "Weighted-average common shares outstanding - basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.abcellera.com/20210331/taxonomy/role/DisclosureNetEarningsLossPerShareScheduleOfBasicAndDilutedNetEarningsLossPerShareAttributableToCommonShareholdersDetails", "http://www.abcellera.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeLossAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5227-128473" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r358": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r359": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r361": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r362": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r363": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r364": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r365": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" } }, "version": "2.1" } ZIP 67 0001564590-21-028008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-028008-xbrl.zip M4$L#!!0 ( +: KE(3XE\0^#0! -EH&P 5 86)C;"TQ,'%?,C R,3 S M,S$N:'1M[+UM=^)(LB[Z^=RU[G_(ZYG>NVI=&2/Q[NKV612VNSF[RO88N_>> M^\4KD1*C*2'1>G'9\^MO9DK"8, &(5!(BCYG3QD0(I5/1#P1D9D1O_[OYXE% MR!-S/=.Q?SM2*]4CPFS=,4S[\;>CP!\=MX_^]]G__7_]^O\<'Y/SR_X5Z>J^ M^<3.34^W'"]PV:?!]\^D;UNFS\BNY,3LCQ<7SCGLNH^("<4Y\1^=\IT:J:>EQM'*OU.[5]JK5/ M5:W2;C7;C7;K_ZU63ZO5N1O\&3X F?OOE#0JU8I:::J-N0MOJ/Z#/C+2/Y^[ MD-5::KO1,&J->JU>8]7.<$@-8S2L-O1:@U6-^9$ZTQ?7?!S[Y)/^60Z1/Z]M M,\MB+^32M*FMF]0B@_A)%3XU>H5T+8O>A:YF]'<[,FWJDX[N.)5JW63O@,^OP'V-'<]<;K%^8O;IZ$'\:7TJ%N+=R9 MOR$&[5*)A7B0:JVFQI<'WK'_,F7>["LCZ@WEO>-/Q%>JQU7U>.%+CY1.5WY' M?+#B*YX_=1?'[S&]\N@\G8A/^!?4]ILON/ZZDL_OK:KZVX7 ]DY=4UOOF8;PBMF8/7/5B/FEZLG_?/\VT,=L0H_?VA/S M>=TOJ,+X"!,O+/SKY?[JZU\O/?%=:GLCQYU(^R[NU#BN:L=:<^XFQQR#A1O% MF'QTG_8K2NOQ$?;U2!I:1@WQ[X3Y5#+3,?LK,)]^.^HYMB^D\XYKQ1'1PU>_ M'?GLV3^1WR8GXGN^Z5N,_R%,Z;%:_>LA-IH5?A'__"2^X->3^*<$8US]SDG# MY@SK,Y<\"4[2*HV8NX:.\7+VJV$^$<]_L=AO1X;I32WZ(C28B5'_KU_-YU-Q M.^:*5^%+TS"8+5_*U_S:JU"/BM]TX_J%N.8C&_"!ZTBQ$8_@GH^Z%;0AG8[LQ'!^K&I>Y+0?2 MFA_(A?^UR8?'-DZE*U^->& MS-UV0,?5\+_M!M29011Y"*<]9S)Q[('OZ#\&8^HRKQOX8\VX,)J;/ MC/?'5HW'5E4U,;;9U[8<6C/]H;V=MHV&=NE27;K&@6V&M[U_B(S]_>#\0;J, MGAS/T?SP:^\,_\JYH>Z?U H^D/YP!@GGDE/;Y-ZC[_)OG,6#C0>6QFCK*8PV M]E]3&^W\"-OJJA&:OK!K7M/UO\#@LI./I&31+KXB>+@YG_X?B]:!(7)E9HB9S5 M^P6#L_@4$T9%]N(L&J*\)+YI_-G"+XF[;H%?0ZWF +8P O#/9KF6ZNS>T2<[ M0S!GJ%8C$%UPRJ](#X"(_?,$0#5V+M, X'WAS(=-613.6FISLU(XWS$5/#SC M#_-F<.(FTE^COA,_X=:BO2C<2[>;^ZES9CL3TW[OQSZT9(N_MGS'^-/YYTVF M?&]\U:W9ZXWF[L9>:R?6<_T;US$"W;]V!\Q],G76?3:]!^$IB:0R M=XS&EXQYWYF(X!9QR$;C9]/+'H4#NBBX!A_"\]0R==,/1TP,DU\5KD/P9SU= M];!'9^)I3Y3E?=\*_B+(SF\G*3HY:0H)UE[F\66DXR]X:WE)(H*+25QE+SPL"@C&]F2[Z;%/-^QV0U]D?F%8HN*-"AKGADE9E.K?>17C5QZZ,-HY<&S/-L(0M83BW0E 9G>,I^:-C,NJ&N;]J-7'LE8_>0H$JO)([^N7#Y8)!>^7:K,4QJ) M D!!A9.N];15&K'*DK\*)T]K.*_8$I1]P)3JTN^A:*O80@& K4 +R'O,4VS) M !(P92,2/8MZWO5(&LO9*LF _PKSNNJ-W!?H,F.>0+81JI4WX!%X)_,*?FVW\16U?_F+F*^\'2[%@HCCB#]#H+)T4? M;W)1)D8 ):$#8(,HHM% !B"] "\EZ<4&S)@)$./Y!(Y.B 4U;J MM8V[G_R17V2YONNIH*.NS;E(%_/PQ$H@3]M/!6?@8C*UG!?&I \=HE.DO.$>9_#5K5@[AYAXW#Q#,PMC9;UB/BO+Z*X]IM4"5=YYLXN*<"IT@T>?R%M MLFH",@B$#KCW)1T!R:^+EDAF^DT$1+BVW^C0D;427TIG0*1GO_;YT7Y\ M*![%-A_ Q .<]8@NO0QXE.$'+N.779K/XJ\B%+;8BF'6SP%:D8W$I-B6!*"8 M0+4FWQCUV-BQC/YDZCI/,JXLG3EY9Q+0GFPF*.4P*) $!9Q%$?[;]504@C?M M1SE3LG'D]>C>8UW/8^6Q*]*3W60JT+IL(S3%MC%PA>:@EN;2Y"X;^V8^,:-O M\]]Y%$GL\/&_OGRG_W)7$/!V[PS]D3LYRB9/,2"=-& MTY)O89IKSR0L\?]Q3-O_DX\J<-F:#F+28,]?%]]^QSYBGNN+3LE&8+'K4;BK M\3OSQP['ZXEY_NM>Q_EW&5O8C71.7\;!_-A6K:'GS8T7I>]WF9F(8]?,34[6 MU0_4\VEG"?S*F&&RU2*8WUUO*8G@NLDIWSZXY:YXO>Y'+1OY%>F9VEM.@:'4 M\A??Z;,Y"2:1I.[9$)=>"Y(9X@W'-\/UZ$R\7$"VU&HFWYBN=VNB&^?#GXD< MU#^I:U+NQ][R&5H\KLF%0KR)6K=_K8N#A;=@S)_?7("C?&J8E<^/0@_&YR^M M!*+@'5SP#IYX"X'.U-3LK)TUB-J9]JFSG"EC#@^;9;;8_Z&(S,XLB8FZ"5Q] M3+TW I*[U. V O+!\Q=\63_9N>IV+58I#H-[\S% M@JQ\-!LYV55R0 .:GI3EWT/(L90!I^D-I.QW9C.76GQ:N\;$M$UN]ZD@F[): MLXWF ^W9/B6M)!8-JJ3EWZ8-F&69]B.?V>_4_<'$8:2RFK./I@(MV9[DJR1& M#*!\0;5?GNOWG(!_Z$[YB%X6DB 7EOG-M*R7USVW[^S(C8]\\:C]>M1U77&E MF+W9W6)?N>=85EB,)LPD1.?JNH\N8XL'>7)K!%=.0I17V6X:=L^IB,TRJQ". MAK.(<3H_E_W^WH.7KMY%C;B7A6J$:O2A&LW+":K17A0EK\?OBJXQ4#S^ YWP MRU '\A\AH Z4*BK9)P^@#I1 ![;G@5+H +I A13]@^]9VUZ,;]D3LP-VRR;4 M%'T_;I@[)G2!WYH1?]$=7%9X-8A>4/A0I; MYRJ^'W\)*0*4GLQ^SNA8ME[>O_>0Q=[?UV&G(.2MIVD MH8%' [^Q7E]2T_V36@'[^C+[\P\NY,*[>?DFMNPMU/:/+^G;T\#WY.=: 6*B MS69AKK[_^GDH:)2R#W')K>'.L[@Y^*6"7I;O3L)Z:S.KL7NZ"P"[[1[7V+1[751=/,KNKUN M7D77?#YUF24YS1N;4V*9]H];QUJ4 /'%BN,^GHBC("E=J3[5#PC_4:OR' M&O^AQ7_4XC_J1V>_GKQY&OF,T;N>$[@Z\\1;\ITQHX;$Y]<3PWP2_TZ)Y[^( MAYE0]]&TCX>.[SN3T^K4_Q*]XSM3^5+,W[%I"\$_K?[R9<1G]'A$)Z;U#AW+^#(WQOI6 M0]SYE^Q4A.;;%P:84W]UUJ>V(ED[]KL_"J)U&CGO\BB2X\.KN_ MZM]=G)/!7??N8E"@YQI<].YO^W?]BP'I7IV3B__I_=&]^OV"]*Z_?^\/!OWK MJ\,^K+;/A_WO[N"/_M7O=]=7"CGO$:W:J'_T-:[==?.2L(]BDB MO5>@/XF3\.3:9I^C)^"L&3]#..MB8KX(=_-77[0((>'T_W;$94!GEN5QOXQ/ M^>QU!(%\'=TG DP7NT:G'CN-__A"?IJ&/^84RB<@_ 7)W+Y!GN1O<_2=Z>PV MX<7UZ-+-:7T>8/%Z<>K%&ZLG/YKN 7MT&+GOD\'+A'_XEOIWFOVU&J:U5FG8 M/P+J<@VP7F[9U'']K92-R(U!_F]')A\=]_WY@SK6D%J6XP^=9R'&G5:]^665 M.OYZXAL?XM)I'AJ8#WRRG8#YQWWW]N[B]ML_R>W%S?7M';FYOQW<=Z_NR-TU MX?Q\QTF8<"_U^I:HC4_&9W)]2>[^N"!SU#VC[6[O3GRL=FKU^=D\"87]1&K5 MV;*[NB_V.,#L73HN\<>,_!7+*PDC%L+XV(QW>*6^2NIOY'+3X3WZ;2_Z.MQWMB;^6]6Q; M&LR--%S?YIQ:UD]Q+JFEO=)Y$SA+!D%R M24XN_DQB8W81F2;R$/]'?.?U18',:<^93$Q/Y#')IF(7-/WV&PSKS" M7\BDI/AF^,7MJ(M_>%SKM-HK^*L08=M>0W:MOL](;CW^S67\;]FC+.%H^^), MW78RT!WV.!DSEY*OIF,YCZ;ND;ZM5Q*[,#LFJ0Z@.3[I3L1PIE&B%UY<#<3] 8I-( MJ27<6W3$QF3RK\ U/<.4Q]ZX$4^!G> ^O#FOO7(*W$=JF_^6KS_G1ID.("7] MRFUE4"%1@T'WUZ%+3L[ZT=Z'<(L[N7(JG_.I9IFR2GN95;J&X3+/B_[Y9MI, MW3)UIJD-\L_@!T=EX+N,^7MP.G,YV2MBO&B6>_S/:_?.^6EO-]5_4FY$@B>Q MW69QBM])EFK5M<.0UOC:O>&\SZW3EB''UQXZ!$E2?>I:.&X@F&C&1> X=;GLFU-J$?;,]$ T4.!OB[UN'K+RW)1Q MN21",%?1;A%SFJ\)A?_X6UM36U\\XC.+33J%<-&Q A$0$^HRRE76 M8*?DTWKE7UBX$BS0Y5_;7MV;U?I;5?_\#@/4YG]5G!*T;L13)$DV-AJ=XTZU MVBAHKG$KZ6Q4:K7Y&WKZ?R22^F<5YR=SX"=LH(RX56EGHK$RXRO]I M.U>O^-*/%O(L7EB2!I(]ZV-1&HTX-ODY-OD[KXR[29"U8F/+W R+RC-Q M7];[JPM;SB(OYT75AI*TMO-7Q]_*($MHN];+4G.5[;J(Z&/KC1W+ M"[7\3N+^8H'VCL=Q5]0SZ%]$-EDGWV4'O0V2@&OS-;F*?_NV(9:#>'3Y0O0Q MXQ,P$04?0LMOTY;K3M+PJ?YT+O&%L14HN/Q;8_8O!/[4=YZ=1E.I,I(E4C MH;/"J&V03YI MX3,.N7SPSX?_XD\@KI>7\B^)443WD45[S&?O[H-^)7U:B/:X!6$YXW)X/B.?!(8M;YH-:T2 M7>"/38^/F$[%/J]]:V XWIEB,>]S$K59L18T-UMBLB(M0K4IEMIP2:7$X@_$ M"-5U)G9N"MD7DN0*4[[R7?YC]O&*#SP^ OY'Q 5"SG5GPB?T11&\Q6_&C;V8 MND?RZ#H__7'\<873&),C,]C(M.6^;;DD)A8\M.J7=>.3'ZM?XLL^O&#]^.(+ M!7=%%Z\9:WRE:8=&@4>#QUK,QO,47"EB4CO^_CB45[5:"1,['R49U$ZEMJ\C M@)EHV3SNVNW("5AZL M2G4"(B[9< ;42K6($K"E'&C52KU=J&GHHEW8P2YH%54KNEF8)>G?T&HMW(T M@%:U]8DY[B8(9_FW(^WH/?/>K-3W:]YW'J*F5AK[5;7=AUAI[5<9UHUP\V6D MPGEXZX-E;?612;?'3?VCX[[LF%B5-Y1T6K+C"8%Z6O@F3;SMELL2:'@!R"W MXQW?+3O-232H_9->HF'MG8D2C6K_S% G0 C2!OLZ"F# M6[Z>M% M_/A/D_\T_UEB\\=UQ)+YD^G)M)--;=VDEEB.%R5:Q,6B#8%!7<,CHG*+::P^ M_$74VB?Z>>52^=;[-=;;U<8*N_K\6L PK!=ZF'BFE'M)O#&SK%AHR24"]K(="?A,,3A[<#U#ZH+M17;9K]2^X<;3'W]Y<9U=";W+7JS3;1)M@.B MDNQMJX'<+?>=OA"UJA QX7)6=*D))_]2;OWD8AO89@CN_8/L)10> M8#J:/VFPHKQ,>-I)'@88R"]?"PZ@HX^/GRE$.=UD$N[]Q*<&TGDL>ZW M!]!N'8L.]Y/CV9:(*7UDQT.7T1_'=,2G_91:/^D+%\"3C(8&JV54HD%D4MA: M[E3E5DITUQ2):1CBH&BLVU3_P:,ZSOWB;HY[^K=+^=], MMV<1=OS&K03J3762.S$AX5OQ""J)3X)O%?PW*^W&!_'_1D>A#[6H=Z#Y;VN5 MMG80 #[*OI1K]N.WOK[.70A(JU+%JADWG#DW62W)#J;0;A6G,=!-]_:.]"O@ MU"&R3WNT.Z]S=ZC=>92,71$__$U,^D/_LG_5O>KUN]\>>+QP??N]*_ID\,OF M(QYY>QXW1*5O3V4,;IG\1X[.9M\G<]^?A89TP]/SF9FX[0^_R_IDJ9FW+91K MK^Q3+AN7S:SW?38A*EJY@UJY_MW%]P?UX=7,R<:VWR^N[@;;6+G9ZLVLP;5' M/MW;-#!,GQF?X1N\0MLSM>"F[/WP$0J'@)CK0ANSWO75^<75X.+\@?\UN/[6 M/^>V[/SA:_<;-VX7#X,_+BZV,FL]1SRA6)[F?TDW2!Z1^$HM;NT8&8P9$_DF MM&UHV]"V93_79;1MK^X:#U![U]\O=C=O[@CX?+M U?CWIC=\AL(8&LL7VK MUA_0[F6J@XV"VSUP$RZ73S5_6#0O[YZX.]^ M^^>@/]C*O?M.;?HH3=BL+=^YZ>F!YXEM\R(!U[6I]>*9TL][M7S"-(8'[\0U MM\P+K- 5O)ZR\&?0)&:\5%'T_!RX&9W&]A$_\ACOR:W+43*P["O/$WK/BUL(Z6XP4N?[[NT G\J$T( MN36]'VCRLEV1*'J>#]R,2Y-77V?RY@LWH+U+T=[518Q[=WO];?!P*)8'HPUA$%#\X7FJW0''?"D0Q8G'?K7MPG/.%S?_7%QFZ_S M#:"L%AXXP ,'I3$VT8&#;Q>_=[^%KM+%>?_J]VU\I6_LD5IDKGH(VIMLO23, M]6=BN;IHNC(P7=V'V_[@OQXNN[V[Z]MMS)9(1Y%+JON.BQ8++58)+1:N3F:R M.GE_=7OQ>W]P=W$K=IYUOUT,'B[^<=^_^^?#X*)W?]N_V\*(W=MA[2\F"MT- MJ,7D$F.XI7:^DIU(8]U[LC!/Y*BAS__M;O!P M?W-]Q>W:NOU5F_IR-J-Q*<3\5G;F9;3KNG*5#JX96K7Q6;>T"(UJU M?:XQ?N]?77 /[O*"^V[Q-HKMUAF_\W^XWS9BW%V;VSB!5@RM6/FL6 .MV.&M M6.,A^4*C+,W>M\.JS?Q3-%MHMLIGMIIHM@YOMIH/%__S1_]K?ZL"0A?/8W-H MXEFDK.U4"^T45L6 9U@&?'*I+^*O+6S*ZY?0JF1K5=I[[T.7NT82&?SDG%0M MUE87/RE;."P/*ODHTA8B$QN3) )WNT%DL)=9-C)ZMX9XN-E9'O+4OJRI$[ZV M=]06@IW5P[];6CC:>[GRY/[F/9+$3#03343$?U$U\P--RUEWV&.6Q5Q*OII\ M (^F[HD">OMJ"I7Y TLYV+ JZT;%5DE19^KLT\7SE/MT7MC0TA\[@4=M0^ZN MN*\,*L00W8%MG; V*1VYW)]!\BZ\&CVK O;Q(]V=NL[XE5@$SZ;KR]OTG?H+?@(2S3 M;J" "3+WAU-]@?>38[6/13\$#Y6L$#B5*:X!,-UPU0+Q29-S$"/4H@4JU56K!YO1>X8MV#4!EAGL)+Q1R,X//H5^TS X;N+0 80C['$!$B M-J@B(&# "+ <4H_3OP4A( 2H 4#",\!K?EJK4FO 9EW9A5*4 M/%'^ROP.2S M'C9G@Y;7P$@MHW12J=S0O\-# (.TH[-?S6?Q^:5+==E!+;!-_U8)KA\D$,MJ8>$9M.^+P$WO$CI=-38>JZMB'^N7BU^)6:JM:JS9:#V(WI*J)^QI,-_FPO-^.CFM')*QU\=N1 M^8@V.[J.I],WR,NTQE7S:'%X*6? M,,PN5]8/84 O9%W,T%TQ/]H+DB#$?O4P.M5::MX%*G/!E1EC M:)3Z\DD]4E@2"JNG1V')XV>MIM1:*A(<-''"M6H(*'"-= -F$)I>&%V _#T4 MC8 Q[:4W3#!@0!\DB0_2>.N#W-M#T[*8\>J#>,F#Z,T\$%53:C5 )W<*0V4]""4^G8(U585/7:""[V=!6^G]=;;D78T++6WYRB^H71:U5PL M(Z"= &4GH-)KGH)_5)?2J O2ZN%IM;TKK29/'C245CV]S>UH)W*87L 5_%U0 MN'-\:J6422C D@8458 Q[7#K%B).ZUT;K#N=DE_36=J >(A,05NM*34M'R?V MT#SDP3S@A@!4"U0+9,V#L&:]N@-K)D\$=*HMI=/6D#5S)V%0MAGL,0\ ORCX M-\=^)#YS)U@6'(P:P)CVTF]Z@@$#;F^$BPVJ" @8,,Q%J2^?U",QP,6F]"J" M*[J'1^'&=:;,]5]D#7%1/GPZX8-4B,U\>,D0#.KP)$MY84#N3I)@7BHC'EN\ M&XO?NFL;%['1NV)[6Z556TI'2Z_P&:IZP54=@U.4^O))/1)<$H);JB">G."2 M+ZC6ZDI3;2/!01.G$BR7YB#([ML^M1_-H<4R/GT-P.. H@AY)/(^EDN+[CJ-KJM*HIE=[#-6ZX&J-831*??FD'LDL"9DMU0_?=ZB, M9 93='!9&@(*??N)>;[8&>(1TY8[P"V'?Y'XCMP*+G:%AZVZF,$O$! M&7"'"%Y3U#8R(#AY@[+6C>V^UK3[LAP^47,UNK+*>4'M2 )%;:#D'['C0$Z@ MPLXD^_*(EBIXSW4FN7)L?<^5O)5:BIOZT%24QE1 9=@\Y0A074JC+LBL!V?6 MQE*5[P3,ND.U;Z511V;-I:A!V2APZ#0#_!K@82NPM+(,1>U["D5KH.1(/VQF M@!8P)UANV \%O:GTO:FEDG:'2E&H'4W15#47JS%H:?)E:: R>)ZR&*A/J$_( MW("9>ZE6WZ%2()I651IU9.ZR6!IXFS$,)Q#U[[3*WDE\?G:'CF7LB--N"1*P MFR]*AP?458?M#=X"=*4T>'^'!V,RKRH9E.A5+7A52W4(0Z]J;UD0A?^FTJ@U M<[6DA,8E'T0!@K)SG@=!?8*D3TC62-:O9+U42G$3LMZA6**B:FVED9/F.VA< M\KI!9"VJNU>2 !U5?S/IT+1,W^2_( I(>&/NDHSY>)CK_6=410)>DG$_YV2! M0 )UW6'1O*'I@HK3LG.$CD]NP$,ERP=.6*D!U0+5 KFG2."ADL%Z@=+&&+9U?+"@ 6K+)_5(#'"Q*;V* M%&ZA,0>U[;IA/7J/3.D+E?W4;8,X8<&[UP /7FH$XSLLR@EXIQ76YH6U26JI MZUML]VY"L]>UC;""CJZ[ 3/F-F'L:].S5E743B,7Y\=*I?)0+2_&JRCU2'1( M=!\0W5)'N)2(;H<-PS5%PX+S\&2K!(NI.8B_X]74J>-*#7=&4@WYA(AW^9^> M:3"7RL^B$!U>Y@J#<4P8EA<&=%22."I+_>*^!IYI,\_K.9.A:4N+UYM9PMZ\ M(8R=EI?>GJNSU91ZBL79T! 4W!!@B(Y27SZI1_I+0G]+S>+V17\[!>ZMIH;T M!TW8<.$< @I]6W63>F2W!.S67.JA<4SMF(>2T)KRT53MN6UY*'T^VV4DNQ M%"@J.+!P&O"Z-?QP^IO#G]QG[B25AE,%2.9#T048TUYZDP0#!O0YX&*#*@(" M!@Q&4>K+)_5(#'"Q*;V*%&YU- ?;D*^GLHR=_4@L1CTVB^I>X*4[,*3#+%-Y M84#F3I)&7BIK/;-WWX2YF^W0NG)L?<]%M)26BDEE<"(%5=TQ/$6I+Y_4(\DE M(;FEXM4[DMP..Y&;2J>%Y2S R50)EDYS$&N_/?(KFSL_\J_Z9,0GF4\,O*04 M!MV8"RPO#.B/)/%'9A6KZ5"W3F.K=QL:O:YM_"Y,WF5H\?8?>&L-I=VIX^DH M:'(%5>?4-Z 58*H"@#C&DOO4V" M 0.Z)TG5-2FBFL%T"0*JK9C"(Y27SZI1XY+ MPG%+Q;%WXK@=UL.;2J>C(<=!DR@HZ^$+(349.J[!W'B&/<2.1C3:E( M"!4\]+[VQ\PEUJHB7UDEI^8=D . E#O=@9(H? ^;>.)*;N9@0!4Z-:G A8[/ M@N.S5(Q;FM-Y9V?O*^M-I:GEHR0WV@M0]@(JS>8I'X#J4AIU07H]/+TNU01/ M2J\K4PISB_.U]!+C:!)RF%C8-=.#B84U;;A232RD@Q(\CP>*[D#)C<;8B$E= M:>/0#N8$RT77:+]XHN^TX#LM%<([:%:BI2J-6GK['=':0!+&;*T-5!;/4]X" M]0GU"=D;,'LO5?A+*^FQ64.TFE*MYJ."#EH;W(Q1"%BB? ENOX %"]1%![1\ MQ<$2_:S,_*S..W[6WMJHMQI*5LYD8OH3/C!/=DD06FR*BBUZAAM& )R. MA:(/,*9] ]M6WX28\]IA^;S\=CT^!#/8T\'?458G%Q M/E=@4",!X(3E'% M4"V0J/9$5!H25!B@RH" @8,+5'JRR?U2 QPL2F]BA1N]3('!][% M"J9C$T]$==XI^3AITJEMDEKIU(_.;&>65I'_D"EU!:8!4TA@6^:$"[M!:."/ M'9<_GQ$-@E"?G#.=38;,)355(6+;HEQ=_4Y=?1R_I9Z& A2)T?KM&,]#US+# M6\_OQ^@L'34-IV+@._H/&>1Z?<\+F+'EALK^U>5[FS/>VSBR;J1+VSV71GH= M^)Y/9?_.E(>K-3M*O=-26LU56S_?O"%12O" 2^>&$D&QM$TF=2C4ZM(FGN10 M;#U'75ENAQ/]=:713*]9)"H\L' ;>SJD'X/K M>C )+"IVFS#JVGS&L)D#"&2@YJ"Q9TUNH,(V5OMR>I;VQ]TRGYHV,RXB&SIG M5\_9R-3-O?5E4+G7PV^0BT4&M!R@+ =4PLU35@#5I33J@D1[>*)=VOV\*]$F MSRYP@E;J6@V)-H^2!V7%_] I"+56:<%&)NR2X*VHG( 5ER'@ S5;CT51BX,E M5E[.S,%:.C\G5V@B2WPA[?"^,A?M6E5I5+%K MJ:\G!XGE(;J$^H3\C=<+F[ MLW3@>EON3IX,Z31:BJJEUU 2;0TD4 M55W;.%S^1%6JU8;2J#5SM22%9B04%]@J1/2.-(XZ\TKJ5+XSN< M6E%4K:TTK$5U]V(3\'>9#(*AQ_X*^, (>Q(M*>$E*K'$!(#\ M,)HKJ#@MNTJ(%52L$*=\X(24@^J!."'E% KN#B%6+S)5ZY$[1!!YXE/^75G9T/6),R+^F'E,9)#XT#UFB+]D^D167AB9-K5U M4YR#\/D;$Q&@5K::+17Z=*G1XXS=^'FF])$=#UU&?QS3$7^<4VK]I"_>$3G) M1BXWFNOMAI']-H3NL,.8/[8G),FUNSYS XW,A9^B^ M,J@0P[$LZGJ$/>N,LZ[DF_@2R];&/EU_W.ZT] >TV*$ VT7\)27L3 M+SQ5:/A(1'^WWXZ:1P#6[VK52OT#Z.))*PUL=V.7,3+A'XXY=_'AS?7Y@KP MF_5F=1CH;;ZX6EJZ@@H4$A=D:&;$I4$@+K56::=TD*,9=;;"MT!8-->LA9\ &L?2*(O-X]O6[5 K2X5'XI2;9>N,^GQ'Q%W M^F_3'_<"CT\/=2L0 '0]3^[=O*//[Q0R\%S_QG6,0/>OW0%SGTR==9]- M[X$.=2NVHY?%E MR="!R2@Y67)K! ,&]&+.CN&A@LH! H85U%!H38"* ZH#"!B0*Q)$O+5L(M[H MUT+_FZ4:[VI516MTW#P["=]-B7)%M1J;T9;)+:5M,V6/*'F% M+P92Q(O*47#E0&I Z2\O#$@-"0+<>G9+NC-G^R;RM5.-R,UY16746NS9U 0ME44-[TPO64N=3GST[8\U2<6?&P7GGV6@!C MVDN_PPD&#+@]$BPTJ"$@8$!^0.DO+PS(#V"A*;V&%&ZU.#_;P;'0-P@-@#'M MI3=$,&! JL9#T)DC %4YD!I0^LL+ U)#@N7)]M+R9.C\7H1K&0=8>53X37*Q M\%AR)2_,'ODUR&T&[]\L4R;'8_#$:A: M]9Z'* X !"0^EO[PP(.%M3WAJ-47"2^.( MLZ;4&AHR'C3!PO5H " ,N)9X,@? Q_V#B;W&A<@ X$)(P3+PI3>.,&! ARB! M0[34$7O +&X%'[D_]#VVNBF$_W,Q?BT?9YM1I0' @(2&TE]>&)#0$A#:4L?J MI(26QBJ_TFBEE\]&?0<6W>,B_PX@_,YLYE)+QO?4F)BVZ?GB0/$3*T20CZL> M!4NWE]Y&PH !?:($/M%23]/(^'*?J+M@>@^UT*\JS49ZNQ]1Z0NN]$AY*/WE MA0$I+P'E+74YVXGR4L@%-)6ZABO]X"0+RDH_=B=[B\PYF[I)DEF#@\ M3O^W?".K'!KV@\E#XAS[,>0&*NP'LR<':*D?S+P]%5[0G#5-9V6_T:KG8JT# M;0,HVX"4"@<+5)L"0(64NB=*7>H>DIA24\@GU!1^,^3;/$I>"?8? $<@[(WF M+)4PAY>.PZ6/C#LZ8K\%R#AA\Y9].#I+S5MFS1ZBU1)O[SL$FDJKU]YF,7&<29PP<&POD9Z\/,*:]]/NE8," FR3//FWOH"S5_YLY**'Q M^\9-WTZ; Z18'&]\7%)-<8LDJGQ*^OT5:J.=DF5W)5QR7Y _<3]\?,)9],J8R?XQ5Y>'DJ=#WP6%)Y84#7 RPT MJ"$@8$!^0.DO+PS(#V"A*;V&%&[]%/X9[G2#.LPG%RR167J3! ,&).T$^>2E MPNG2UETYMK.85TZC>/I6JZBJPN^&&69H$@95^9'Z4/K+"P-27X)M0]I2C?5= MN._]9=6YW4'-?!QW+I5>?\Y^R10KIRV55N=7^6'G-!YY\_&93]D=;<;R+OE( M#F*5AIQ A>5=]N76S,JDTZ%NG896M&L;_9D-/4!=='ZW7!W60G.QZRYI)-@R M6&W4F-Q A02[+X*M[T:PJ51-4^OI=61#BK0#1R2JHB;7^,,E?JPA M"P$7J,GV#4H\H-7+"9:;%8Q!+VH/7M129??];#IX77A)KPX;VA9(LI?9P6ZD MZSR8>%2IXF")=)T972]5C=_+/HD-LQ]UM89D7DC+ V GQAZ/.@"?_"OF$T9= MFS^]%Q>,&S+^-18E1HA/G^%E&7'O)Y:Z1)QV=)K0(=K2(5JJ+O]:@.?2=28] M_D.F'7!(KF?5-K]*6QI>=T>?F7?QS(?'@3%MZK[T?3;QN%T_$2K<][H9?,?PD$,E M Z9DR$UPL$"U*0!4R$U["ON7.L#,POEH4\)79K.1N?^0O5Y7M&8S5YL3T&JD M'+3OLQ2$X01#BQ&M4A[>7;4K012%X H^==F8:[?Y--N@$+>YX[&]/V9DRES3 M,0">:2TACE 3\=MOTUH KY2F\N_P8$RT-S09DH5VOK;?"E%;:DK$378VG?<* MLWD!+0Z4#0Y(XDCBQ<022;RP)+X]AR\5@MZ"P]/8ZJ"V%$U+K^ S6AI(X@AE M.P0>[9A/HDR92[PQ]U@(]7W7' 8^%7+J.R*U,N%60WXX=BPNRXD+;V+)[X*M M82S:/[1M4'%:2@C= &P%6]YT?;GY>[/E\H?GH6N9,I_F+:3=EWI0741)NAOF#L3ETN0E M74+77E?0SZJ5%/LIHE+G?5D;V0S8M)=,\)'-(**R&YG54B"S]6O)FN"P>C[V M=Y5*E4NPN@L_-#XWKZ8XZ\)**S#P+D6GKEXE"9@07(@->.@2/PW_)6 MS#BF3\RECVQAA[-'G,#W?&J+R8&734*' Y-XY84!O0ZPT*"&@( !^0&EO[PP M(#^ A:;T&H++H/G:(8Q)8TP:(PS(T8?-'*]+%R]U7(V36-TPAW453(;,O1[) MU+%W_9K"VFG+S)WB)C\1)8>YN\:YM-V#[_PK+_,/YLV M]1=^C=FA.JB_16U7[A8\4]\_ONRD+--3/XXCRZU MR)2Z/G%&H@^6)S8\BZ%[3/3-LF75(',G$KUXP&_;K3[4;OWRQ3)L=C\-?4C4^2FZ;8"K)0[1GHQ.'_\Z_Y1O2$,58'A0 M?;IXYL;8$S-CVIS_G<#C%EE.QWUE4"&&8UG4]0A[UMG4CWI \,FCGXL[)?&.@I#7SG2U2; M5Q=(3CUV&O_QA42!1;4:)7@.O/LT_'E-J]3J&3:-SV^2(YWY5RO59H;3OXG2 M2P!:FP2@J0+!1\(?FR/1/(*P*-^H-):;/*]L*K4V%[6I8 M@T4,JCTO]@1G8KT73'5IS' OK'B3K3W:R/C,AZ9H@ YO@#!M\(ZAT@YNJ)J5 M3KU$=JK+IT&L&5*K3/XB-0T^K,S-,II;]/<*;4:3<5N!+4]7UX-)8-'HE$Y) MGCJNO(H&%PUNH2<8#2XTF.XXMY!ZAERV!L'(&!R:?Y M;5O*FGU:N+L$F-YD1;?K*PPL,+"8X)6+/+A:^9:N0*_7[81CF7DMZWSZ6N#* MA !:R+S#VIUP:'RTD+D'$HZ%+(WNH$DL)*SH-!8$2#@F$9U&M) %LI#H-!8$ M2'@6$O./^3"4: =SX2FBF8-EYLHTP6B^@*,&WXU#\X7F"\T7FJ^5J/7HU(QV M7Z']@@P4VB^T7VB_EO>%G;.1J9M^9ON_T(+ESX)AG@PM7>Y0"TLTHIF#CA/X M+EO1AO*"3O]7:E%;%\6_977/RZWC!RMPO]'D@ZG] MN,\V Q\N$/A% 4H#*@MN8 )J0BI*/\( 54NC']0.;*'">.?/**& MI ,=(:#F#TD'E0-A0N8Y8%OZ>O5M6_IM&L]'WYGU$ WWH?2%'15D@]'O6[_>JU9D>I=UI*J]G.1;]ZM"SP+0O2 M+BI']C!AK)='U-YA7--SZIK:NA^<+Q"NND2XU]XC7.+I5&!8 M.SIKJ56EUFXA[>9-1H$2 -(N*D?V,"'MYA&U[6E7.QCM=HVX)9?H4]6WHV.T M:5!P0^FH'23@O$DK4"I D;ER!XF). \HK8] =<.1L"WS*>FS8RX;5D:S*NJ M=87? +DW;X(*E 60>U$YLH<)N3>/J&W/O?6=N'0) MY(FL 0"J&A@^H.R7%06D!:2%K $ JAKE:SJ2_9RCY$- 4DAR6'WQLI]$'VY MPGH>N'RF;YAK.D:X]"H_O)9KK=[%,W-UTV/&/L_FJ57^_\(_:ML=BU>5NM96 MU&9Z&Q31?A3:?F! A;)?5A20.Q-L(6QN2)U_4BM@@)A3;%2<.\/>0(:$)HM MK00R),I^65% ACS[M#U%MJ!09-?XX 3Z!W0II>]XX>!Y*[UCYV@[TI%0>&UM MD3)1[,N* E(FKM)E#0!0U4!:0-DO*PI("PERC>U]!E);9 O55@VC'F#25-H6 MZE D/IV/*11LRBF4VRR!0 '=#YC=F% U M,DG_T! M@RA=8G5'VRXH",B\& M9%D# %0UD!90]LN* M+"]@%9HPHH(,,PJDPV WOQ'A0 KH<6]3QS9.KA85=G M1"R3#DW+]%](_!DS!$0%G8)0!L/_C3H0>_ .P^-97RQ!4%(4T(/#"E19 P!4 M-3"P1]DO*PI("T@+60, 5#7PK"\(&% 9(*" /($\D34 0%4#PP>4_;*B@+2 MM) U $!5 \_ZHN274_*1%) 4L@8 J&I@K("R7U84D!:0%K(& *AJ("V@[)<5 M!:2%!%O+U7AK.1WJUD;[RM_N4;T>?8MWJ/9F&U2C1DDY.MC;4+1J>CO2T=04 MVM0@S:+LEQ4%I%F,OK(& *AJ("V@[)<5!:2%!-&7EE7TA3%3F0Q$-JUK%X[L MDJ'C&LR-)]AS+-,@X85$/M:4NGPFBXO*%?,)HZ[-)RGQ>=9T$ D/KY8>$* % M,M3WH8GGK=P H<>3"EA%]HI 5L%"%8.D8O/1,_(23&N'2I,7I)"7D)>* M E+>>:G("@34_*$6Y04I)"HDJJ* E'>B0BA0:1 IY"7D)52Q@O'2_)3F]: S MJDQ95 99"5D)5:SXK(10H-(4 BGD)>2EHH"$O(10H-(4 RGD)>2EHH"$O(10 MH-(4 RGDI3T=IJN][9)YQ?R^K3L3]LWQTBI%P^[0QI &*H&%,A%3VF_6.[#E8(!+LAZAZZENF-N9'R%K9(-=YND1K(:ZX#W_.I M+J?W7YWN:J,ZU553I:0^G4JKEH!(+6*4?6 M"?D>"!"H4;BJB52?\F;HYA+3"RX>\R=@KA-8) M^1Z!0(U"OD>^3Y_O6P?C^ZZQLG=H&MROUI5&4T/J+YZA0NI'(%"CD/J1^M.G M_O;!J/^]^B1).5^KJ4I=JR'I%\]$(>DC$*A12/I(^NF3?FEBBB.J@G/B4SPM_US"?MGOTA2?]98.ARX<4WYP?#O_)Z)?E0"+4 M?CNJQV)A'R],-!3&OC.EPAS/L46G7KL-/[C"XD$I\I'>I1I M_9^<=F(N2XS2+B=$;(C\IZ0@O(S"AR0SF<&2F,8T)[G M$K;8GFMHS]&>@T4,JCTO]@1G8KT73'5IS'"XR35C>[21\9D/3=$ 9;[4A&F# M>4.E'=Q0->7Z1&GLU.OFO#+YB]0T^+ R-\MH;M'?*[093<9M!;8\75T/)H%% M?6:4R-[&V[_0X*+!+?0$H\&%!M.=XY?*M94)AVA7SW]F;F\Q[P"_<1"F(#Z9 M-O''3N!1V_ 4PIYUQA]<5L,A!O7I9]Q=DCE&<.AV[2)/,]'.UI*O5H)?K]L) MQS+S6M;Y]+7 E0D!M)!YA[4[X=#X:"%S#R0<"UD:W4&36$A8T6DL")!P3"(Z MC6@A"V0AT6DL")#P+"3F'_-A*-$.YL)31#,'R\R5:8+1? %'#;X;A^8+S1>: M+S1?*U&+"OVB_8(.%-HOM%]HOY;WA9VSD:F;?F;[O]""Y<^"89X,+5WN4 OK M/Z*9@XY36KO'>Y>7U'A"+-I07=/J_4HO:.K\?]8@S(N=,E_7,24U5B%95 M.TD5:&]PA%O'L?_W@6=]@V5.;-.>.4P;5J+.I,HT%.BV;QG=K*;9,KIG4<^[ M'LE:U;*Q!!WJ5ECBK*O.RG[-]Y+GF3D*!FG\D752.[&%"TLTC:MN3 M;OU@I-LUXJYPHE5:WXY.,V=P":N0X'TB_1;8+U ^LTC M:MNS;W,G]MTI:E6KBM; O''NA Q*N\6U@.VK8 84 /J>%XB:&:)>1G@$C'0U M,HW/<(5=%@%6:,;"&=G4^RFW<0*!0NB\E-HW2;SY&56CT*J!\2[*?EE10%I M6L@: *"J@4?^0<" R@ !!>2))"=86BMSFR)[PHSSP.4S?<-&I]"&!X,SE/VRHH"DFV ] ML;TAY_Y)K8 5@7(WKXA75YK-])8[T?@4VOB4KW53]G..D@\!!:1=S(EF#0!0 MUZBGPX.=[,24^HG5V^# MN?PIN<829RHU?FI1&]XA>SP0)Y(FL @*H&A@\H^V5% 6D!:2%K ("J!AZN M1,DOI^0C*20H)-2J;E5(2'YX+==:O8MGYNJFQXP]=N[\U: QD2F"P"M1+(D"C[944! M&3)!^\N6!H4BN\;[_:D_HLNX6^9<@R]51=X$)J'8[Q*-=0G%'B@*2)FX1IW.[-6_97X'I\=D?,/?)U%FXH?J6Z\B M]U8#.8\ZUR@JO0W9:& *;6"07%'VRXH"DBO&7%D# %0UD!90]LN* M)"@IBK M 2CFPD@IU\('I9_NPCE5,G1<@[GQ!'N.91HDO)#(QYIR4;;]XJ)RQ7QB.9Z7 MU<'N^4.JI0<#:!4']7UHXGDKMS$#@53HXZ0"5I']()"EFE#%(*G8?+R,O 33 MVJ'2Y 4IY"7DI:* E'=>*K(" 35_J$5Y00J)"HFJ*"#EG:@0"E0:1 IY"7D) M5:Q@O#0_I7D]T(PJ4Q:5059"5D(5*SXK(12H-(5 "GD)>:DH("$O(12H-,5 M"GD)>:DH("$O(12H-,5 "GEI(_0^;7]^KOGV_-P5\_NV[DS8-\?S4BHP]@= MTO;!4#6@0"XZ2_O%% QPWW&EGH>N97JBTH^WX$NUW_I2LAJ0=QWXGD]M M =8668^>13WO>C3P'?V'S'C0H6X-F&LRKZO>N&S$7)<9\N,HZ;%-WF3E#59Y MUI*H]Y$EZ%X!B[O+D-Q313Z$ @D M.A+0P=T^[="N'BKMH,%).S05_@1*JXUI!S1PX'P(! (U"A:0F'8HG;>P.NW0 M5@^6=CB@M[!YVJ&N-)L:^@S%LW#H,R 0J%$E !(=AXS2#%J::8;W:)^_.W'L M73,$:D-3-+6IU-K(]VB=D.^+"01J%.8(D.I3SA'44LT1[$[U&X?W#:76:"'; M%\\V(=LC$*A1R/;(]NFS??U@;-\U5O9,3H/Y-:532^_X*-HI,/*,S(] H$8A M\R/SIU_\H=TX&/6_5Z=IY]H13:5=[2#Y%\]4):[>A+R/O(_*A+Q?!M[?GO:7 M*C-N1?L[Q>GMFM)L(U=G8U[4P_)$5 OJQ*=\7OB[AOFTW:,O/.DO&PQ=/J3X MYOQPUE@!G=^5N?,_J4U7687D@YC')8VZ07=C1JBN<_^:VB]<:ODGOJCSY/*W M;6+RQWETJ46X.^*+RD_^F'E,J#$?NL<,\9<48^ZM&V1DVM3637ZY%[OO7N7M M;$$#2(6.4"UZG+$;/\^4/K+CHF M;@OHD^+<'?:893&7DJ\F'\"CJ7ND;^M+"E24!Y;.0^_ZZOSB:G!Q_L#_&EQ_ MZY]W[_B+P1W_Y_O%U=W@H=<=_/%P>736F]F>HR3\R$:7.#[ 0>M0WY^/>50848CF51U_M+M=AX9EQ*IV]CAQ"^7IAH*G"]RF'CN- M__A"(K>QRD=ZE%D%S&;SPSJY^\]89$.]$-:)5)C5OMN;N/W[AH(/CC\XQX(' MG]F'=[5J9<-ZTFNS")L:YA3CMXV 3!Y=N(R1"?]P[!'&AV>\UHZ%')Z_!QZH MZ'NOZ*V-OLO+0P Q*1TE 09B1D@:!$)2:Y5V>_N<8[DI*\N*YFEFCI&[@-G) MM<"5"0$TD+G'E1M(%0UD[F%,R[G?6U>J13%6/7&="G"ES MJ2]6X,3R]9/IF\P[A=>J2%+:(;),>A>B!.R$%%! ^5#.8:U,'#5# (7#&?F+)Y+_ED.9Z7V?D9= B M3?LOY3)%\,ZZ1%1?;B9/<$1UJ3_YC>N,3#_/S)IOGC=]. MJZNSG')=;6 ^&9JD0-5BY#"4_O+"@!R6@,,ZU>0<]OZ2Z5S-VGH5.0R:I)1@ M330'T7)WXKB^^>]9M&S:/K4?35%HCWH>\SUX625T,C"95UX8T,E(XF2H;YV, M>;MW/>K/K%Y7&KUT0F>UT4[-[4"]+KA>X[YC&#B@.H" 6DN"3"]]C$H/+/3&A>HT0^_7_<@6HQXCTJ =.Z/CP&/'NP7CF/$O6*JY] 8+ M!@SHI23Q4FIOO93KV/)]$X9/PG$]NO="+V7>3%X\3T5;FG3"\Q8>" 8G3% 5 M'6D.I;^\,"#-):&Y^GYI;M/%[V83#P2#DR9<_(: @NR:?#RD87/5B5 ZJ7_P M$E3H?V!>L+PPH/^1Q/]H+#6)'U.7?176KC=G['8)IC>K2J)HM18N D 3**C* MCE2'TE]>&)#JDE!=,PVJ2V&]NZ'4-:0Z< *%Z]T04#AG(^:Z/-3VZ3-A88H+ M7B(*W0_,_Y47!G0_CLZ.X<&"V@$"!N0&E/[RPH#J-0POFC4Z7V06>$6:7/0(VE,[4?^@Z8]WQY)GCV6];,MDPY-:[=629B? M+UABN&0V"BH,Z'? Q095! 0,2! H_>6% 0D"+C:E5Q%<"LV@ I6N\\F,0CNJ MZV[ #.(RCU%7'Y,1XV-QF<[,)SJT$F_5Q31SP?*;I3=5,&! -D^09M:J2^TF M^K;NBGH3H6@-ZN0V52:*B:BP4D6KJJBG2VEX$.% >DN$=TM M-3[8@>Y2."!;JRK5%.LNHM8?@])<7!N2&[<_)\J R#E3I4+=61*F1=WP;.\>O4>M. MVX&EL!QOGJQM8S5E>-*V^6IR=AF%4H2PX39]4>")_^J4ON"Z,0AM@#'MI3=* M,&! ]V2'T!6UH^#:@=R TE]>&) ;$BVR+C6T6QN^SHH^,>\F=(\/%[TV%37% MJE!H"_#(:S&"UMDNZ"A@7=@-/7?@%5Z:!YT5S*Z5%P9T5A(Y*_6/$^W2'$;^ M2=X#ITO MNL3\8L%A0*\ER3:YI4Z'RWY+;/AN0[NW_R/,+:792B].1\4ON.(C[:'TEQ<& MI+TDM+?416E'VDOA*'-3J;:1]<#)5HI[P7%9?<=E]3?'F7?<$([+!P7+6Y?> M,L& 3T2/,NBZE9F"\8M1:WA@C$X,0.P M8+P0G9*AXQK,C2?7Q.)*9>*@0A5Z.:G A9[0HB>TU-5QV1.2)O8Z[C;7HU/3I]85\_>^ M<*TJ]5HC%QE\M"0Y*<^]"5#%106J?4<%R@U42,7[HF)U@\X7R:@XA<5T5>EH MZ>4DT)+D*V^Q:P[IT'D+^'V=? H\9A#3_DRFKO-D&OS%\&6^MS/7 MM*=,C[=C-B,/"P&OV(A)76GUT#+F!,M%'VN_>*(3MNB$+?5CX9:ZQPWU362= MO[[<>Z),T,P)Z\X,=,IGZUO-?"P"H=TIR@']5) LD7F!RA^HD\7!$GV!K,XT MJ-J^7($T\C'5CM*HI[TGYKU)QYS"2W[B5MB,<\YK+5S)K1<,G#9TIBQ?NE/C\W]$68-^_.Z>K#J5E43L*MDR, MY?66H.G+G<_"F^/AJUPO]E^B[= ,CZ3#P AJFA=K<>0&*JSJD^,R]*AE.=$R MK$ '%AK4HMQ A5RUMTSN4O/2I4SNA8P OC-_[!BOL<$!SCMKBMK)UW%G-"1P M%J&Q -W: G11_;F59YRQ@#X$J* FC[&R0W&PQ#(SV7E=2[USU]29Z<<6.N62 MYMQV-$B29A;HLC_7HBD$NJ)/%P1(=A>P08 M/%2R?."$->E@XH+ZDP^EJJ^?@7,$MFX9;B\3!>,OA\^ S=T(, M-DQ<)2&26H,* 3DJ!5J[;4M3TV>9?TNDS)M0,7AS.(5U^7A@TV M8J[+C+GMSJ,="L]AZKQ@.=O2VR<8,"![)TJ=:^OJ[5R/+F-[UW.\W0JFOT:D MK4X^SF652J5Q&1B-:"D%'RH,R&58$SU[!*#41"]W)#H8.ZX?+I8.'==U?O*I MR*SJ.1(VL&DOO4F" 0,2=J+@V&A% M2RGX4&% ,L-UT.P1P'50""C$&]?$0JCN3";^N0W-W$=E! M(YUP5=7JN%@*37R@JC82&TI_>6% 8DM";(V4B>V#(LZOQ-;"8A#@Q ?*VV6O;9D^CGFMD^$(^13VT/Z]LRH1-M"$ !S5WCEWH MBH,E]L;,+(.P:0_MV;'J='IH;Y0U:+>45JV=BS47M$5%L4780+M 8*)B%@=+ M=!*R._*V:0/MK;V$5!MH*XUZ/G9HH%':Z;A=X0[TPT_?7(Q&3)>%Y=BS/J;V M(R,N]1D)__8(MR(RNT-M(_R#_168'!=Q*!9>YA1WG6)'1<1I5T^KW%X45/!0 MR?*!$_;6AHD+ZD\^<$*2VD^HO]1^,W3]KT<7D>-_R_W^:UM$_^+_+E[]_%OF M^:ZI^\P0'W1M8_&-N2M3R0F\!O[U=GHG#M&PY"BD!UPE ?CD]VW=9=1CQ-Q# MX(['10N6>B_]F3(8,.!QT00['&I+;59W25+GIC=U/&K]S@5DRK_!7PM'RK0#9EQSXTQEF:QWO2NUHVI)BSXH MC49Z^S'1 J$%PIH/<*%!+:B(83C!T&)$JY0G&G\G@\+XNSOG3O98 Z.$:$%=S-C^)-D">*4TB'^'!V.R MDZW)H$2';<%A6VJ2 M7M#73]ZT=6Y(?1,< MK$*R4FU6,9,.3>2@F@,D0Y3^\L* 9'AT=@P/EM)KQ[J -[LD1.%C7JAI2B1H MS+F5%X8-"1JA0(TH"0S(!RC]Y84!^0 ,%)G!$$YU/-/O@7*(&.W$%ZM<_%W# M?-KNX1>>]9=M1&Q^.&OR%#J_*W/G?U*;KLI;)!]$VC-\-V;R..ED2NT7L91H M.S[_?>KRMVVQ#,D>76J1*75]L2[ICYG'1#*=#]UC8F^E+:N'49_-ZBWQRSV? MOR'6([W*V]F"!I *':%Z]#AC-WZ>*7UDQT.7T1_'=,0?YY1:/^F+=T1.LIYI M2.!N-XCLZYMUASUF65"W]7UW<7@X>[ZX?ZJ M>W_>O[LX?^A=7YU?7 W"OP;7W_KGW;N+H[,K:9=\A]S;-#!,86]Z,S/4FS=# MES,S-)B9(5+463S[-)N/SY(GPR7(JV#"7%.?7TQ=:E)[1?W 9=>CS0MC+F[^ M8IY.IV(JW8"M]$"D>6UO;%[GY_)0LZ=62#@-@MR5_56@WRE?OE,)J;G MB45]4^JH.9FZSA,C8T8M?TQ^FOQ_?*:/;7E?H<=C&G7'$,,7;@7A%!:^S4=O M#AWCY7A(A6[SS[B/:T9.B2C\R._L,J-"A.\2C8-0<]^% MSZLQ=T;'>_&X39!;J&P^A^21V1'JLQ^>_KJ8S%^V^#_1ZV7?\L9X ]#N1L;[?BRA1ARFV5. M)H'-HF'*1^)NE1&/;39W.H=TR._ GIC%'XY?X,D!>(O3,F26R2_QB,EMX R! M%^[8A5VEPW%X4R;N8,O))ARZ(1V:ENF_B(%Y@:XSSXN\/PX%"WQN698G2Q%W M#>OP$F9S_US\\3H?])&:ML=1Y[HC-K3)QYAPT!UQVY\FGP;^0*; 3)?>?87< M4O&1N)*#8SQ%Q3S%HS@_;:+S'S!UX9R:4_Z8MIQ&"0*?'$.2@:?()XIG@\/Q MR#SIS'+0O;$Y]4+9#*&+YM*5STHM[L9RV>&W&+G.A%ABV/S.4S(=4ZY9NIP& M_NL<(6\BKAZ:SMP,ARXUQZL2^RU"#:,M(0M&^AV;O=3X\FO@\0?UO'-N?%US M*L2V:QM?J6=ZUZ,;ESOGMB^%^8[+]E?+T7^4SZ9K%4+63FECJ:5%-'G=L*8. M%[ ;[DGH+^'_IC&-9%:"NNN_#N-!M_T']>A,_KSL:#2'WI*$1,P>W2DT5_,/ M%=]M'K&UIC[/9+84KXH0U34GV\2DD2F;F84Q?1*VA]D" ]&MR8B+++D&_S(+ M;41(%);U(CYA4W%S.I,9_DUN_,RIQ>1.77'W>ULZJ=('E3_9E5A2\BFBT/O* MH$)^[W9O9B0J+/ T<+U 5'WB=D7X'#+T$@6_DWV\-9,Q@*Q(: M@DB8(%/'E9>\<%(6O<3XG<^9SB9#YH9VNJ8J1&P%7(J[-E&G#9()\/2)2T,P MBZF2J)/+1A;3?2DOU/A7X/F3L%>;^*H9UN/FMV#62UBL6_PT_Y(>N*[?'UL3,97[X8"\1?]LEF2CF5@]L9I9%C6<[/T-_C M!,B=FT?;'/$AB0IS:92.06NE7IT-D&J^D5*_ M4=P#IB9A(OO53W'LN.(CT1^@J]\'X9QQR*841G?X]HE$Y&)$GFOO5B#]7 M?*OW^C5^2?QF]_S-S7K<^AA\EN,;5F9^_+Q+MH5GO]0*=_"JCF]<4:Z,^W)# MZ[4'0WB.-58?-FNL<:PUFO7C>D-M'--:K7;26;6>$5(<@L8H@=;V_.+1)F:D)_L-?Y#1-.GA=, MIJ$G$Z;71B/AK,G8@DT=5P8R$5F(O$=XW%!\U3+#-) 9W6JQZ4IH3A[%+R]< MZ,>I+18_Z]IX8-T87/;$N*$*+Q)>D2TR57.T'GY)ZK D>![BB'263%?-Z?KK M3$0AC4*&@3_SSBQS(ET7WU'BGQ1NJ<-O$ ;8K^FLZ$;\6OX=_H9\?AGN1)CR M<<@@26#U6@ HFC<>%+G\:^*+G-5D3HM3B2-1"9T]PY _R:?HT1&.J2!'YCZ9 MN@RR(C>5WXV(4;AB*N66>$6.]XF[JJ_YNK '3B@1])GH/#PSI9.N,_-)Y-44 ML8\A>(NA]-6-.!4:'2.=H22]Z]G7/)]3492>%=/ \8FBPY_4-=ZF(&6:40SA M%0Y^Z9@'!HXK,V@"8=<4S*R0'[9([?FQ)8CZC.[Q?)N.F_9CYE4E@$G)YCRV?B]H6%CJ1NNGHPX4(IG((*N;8E M+/:C(Y :BL2,,J]@3$Q *$X+3\,QM4-72(I6>$A7*O#"#RARC*]"'3YRA?1> MKY]373>41==X]=PB9Y:_DE&2>.\E3GC+>1.1OA_(X"J,+G09;\^IA"7RM=P MN&%2,W3P9[]:V2H[V6@M5"6XMP./__:UV[='PCSQ&>N+%/:>$VFMT(.A.M/5 MYJA]7!L9C'LP57;<[NC;]>X-GDAW-[UG_WS8[5#;KC, ML8FIEX)Q__O_9^_=F]LVEO3AKS+E37:3*I+A791]CJMDV<[Z_&S+:RE)G?>? MU! 8BHA!@,%%,L^G?[M[!C>"I'@5A\34[HDE"@0&?7MZ>OJ2Q)'N77^(H#.E M:),"HT2]4]I,%6V*1P5C0!-GH@:.@0H.5> ]D4%'=6FX!=BP-I MYD(,J0@FK;T\=5+X0P<;9,.R26@4:P%S^.@'W]"FX-=L27D+V6\7W^"NV[U60 K'_ 0,#A.0\""@ND?HH>*.D%FOJ MY':&9Z%C=:4,).#Y98[925"L=&*\+#.N?-!3_/U\TMAZFJ>QK3A>VRQ*LNJ< M;E-GI1Q@6NJ,#4KI/>(Q%T@*P-BB4231V_<)9]7\JJ_"$G.AI )]R3S.1)1$ MI"OA=LW[)VB=Q:.P:>>YDEIH74'V:(=NJ]0@W-I05-DA9">\F4Z!P;2%*YI9 M1C IOQ5@(A$R(+/)B>\5+/K4";-CE[4#Y!QWXA(^$&I&,660$;/1UUEJV-=3 MY6XI1>$=#S!X$'X1P2T&R2N M18$SC*-$TRU_ LZP_.,89 T3M%#'+>Y:F! AD]_D\6;X,I=G=9S,=%61(I6.A+'D?^*S66SL(SIVDH7B8_O&*R&FC0 M5$6)S]^R0"Z@=]FXZ/\X/RN^,$^>9 F3:KQH>7^/=5.PGZYK#M;D6"C8Z5 MF.LP[SFJ-?7@GD;]='0%)UT996!*'T9H-JWDHM&=&PV_T,P9',L7(#3;39WQ M:BSM!]1M!!$GHG\SW#V*@_REA[< MZ=?1_'A@\@SGK2ILOY\:HP M@^W'6#?8;FB1NOD,QY@+@@QK58#6J4&7=:S8W0IOJ7(LU#>*NFFB9H%UNB5J M/@,GMW:E#GU,\3R,/(2OI0EGMPAFE-I0%%RMJP?NN-03P;\F\WR+32&5=:9, MH5,-=QB#I(_8;AT-,?AN\-VHD\'WJN#[YO#>.RB\:QAK,89('W'5)>.CJJG\ M?] *A%WGV' 7!QOF0BPA\^,(&[8O@\#UY&6L. QE08!)5;T2AK1SS$.+[L94?O(\":SH3N%0YJKW*77K5ZK M-NA=UB[;W9,ZE#+60U_K88#5J(;AD@'69P/6BP,"Z_) Q&I@;?F(BJ$NB1U6C"XMR.C;K[WWD[ [C&VE%='V:G%3YC*;*3LUZZ1-+'9S2 M<)Z%PR:VC1"TLWR)U\U&\S1.3"JDT4=+8C PIA71*R7T!L8T9,IN*%8:GK0% MBBW?CK<1O+JGD<97(3VN[$F]QF4K>L2<3/ND,^[X:=B@KS-A>&-4Y!388 #" M2']UV6 0E_>5%Y%S'GH<^ZAU0AITSI=$WY4.T"LL5G2@PT&N?7EC5$1+=A@ MMG9&^JO+!@,0^O*F\BI2D>,Y3;82V[J3##HIR%3-@>_UH'!3\,.6L8 M:)52>W+'L=I$39ZO_94)P9OXHF'#67DLVO!F\TX;@]* LC-M867T_\SUWZ"? MD?[JLL&@WU;H5QH>=J9]IHS^G]GINAE,7F +Q=*8/T4E"1FH*/MZ^UMH!J?J MP!M]CQC,/,038969GKH>_^KZL^4GG*6%_X3.\^"J !=[3][8>"/[A\_N5N_9>L]8; M]&J]3N\D#M>-=='T"-Z, M_V5'[']'DS'U27K$(SEL]PR0Z5CPG/3?QW NT[M #\W1@^AF^.!)E'>:J:4'&_ U*$TP MG1^-LF._@X.-^#)6X7GDRW0Z,%AIM,)@Y3EP;3>H?'(6YH[=$6B.6&=_L0-C M"U+)201GI8SM.RSP"^U%X5/;>7B=C\LIVUR'M'O,?[D;"W;M3Z;Z@PNDZKQM"!9CRD"\5H)*R(/?JQ:\/C,:0!RXPM07\M M/Z'!@#3P-GX@:G3)XWQ2BD=145SG\O24IY8I)2U=:QS"'S#8PETK=GD$A/*C ML6P\0:1<09%U C:.I$4(9K=!&E90HIQQ[IJM^!<+YQ02(VL^LBM/@4X32(Q8L]Z"6I^FDH9J8HR+R1 M[[K^(PI7JJ=% :RA%H;P%_C"$-,A&?R)3X! 45$X.<;_0%5 AAS?1K&LK:6* MNP4-$Y603P69A,58G!8K+ X:H P+KA"NFRB5);,QYC:H ?Q_Y-13RR0U^^5A MS'41'IIE>$ P0D>"7EFB.!UL6,)U$:[A-=+?E0= OQ>PZB6/(_^5\@%@M2Z? MAN)E\L,K)OV$05-MTTH!\F>J'MBI[C#G!ULHG,$^'&&]4D%Z/ M$1@!*X'7!D[T7VC@XG06OT8-O="M=-YSW:L7/G]>#>^J>WE04G M71EE8$H?1J0PU=8!IEH76^5@51O'<.>N,U[MQ,4J ]JQ[>12QE6) \9 GCQ? M,8AG#.3)LU&74MEGS]?4IECY1AVA1#Z;QK!3YN%<::Q^:=&F/:>NV>@5+_/7 M@T]KUKR8#B(;5K147'9RM.+-5S=GS,F]GB&UQ]=\+D$>\F4]>? M"4&]#R4B?!)X$KTZ$YLN5Z1F*E3G+NZ'-*_..78H4_#*M.&]$A!A,M2#O0S M!1%NX0;4M?3:Y6%X,Z*=?CX$D#/L7Q*[3A?M(Q#0KO6[S5KK8G]Q &.G*F.G M#+SKPPNC-F? *@/O9@3&^7!)EQ0"/;IM:\.6.S_B[K)RLK3ZK-)=.+7AE:ZQ M[!/J?V=X>>:=.+5A\!9!A]9S!QUVRQKHU2Y[S5KKLG\>60/&1&EEH@STZ\,+ MHU=5X*6!_F,')(R>+F;C^IVGGB-@L78SJD.T(6D_087BNHMK6]KRIUN:\'(3 MC45P'0<(JU=A**)P'[U[Z)N.%PO[*LJ>_:=M>=&?K6ZK?=GN]>NM)K^H=SN# M=GW8;[?K?=ZR!_V+40?NN5#6D&;]Z2(+LHB*^5*:34W$MI+4:S"B)[,D01DG MBK+5;9A*NX&L#=,"[M R_]:165:ZJ_ZVP*-LL:==5D=?6O=O+L7,-]."2,?>G MQ1IC[G5GVZ=\:\:*O+/NC6N,K=>L$^52IJD81F6LA:[IM 3)A@M'YD)[09\F MPP:C#%7O$M[N-2Z[%6+)3X['HK$?A]RS0PT'X_UHO"B-NOLM>A'HX#33(XU4[J7&O@::&'=14!K=PV@:2<[NG1]K&[$Z$L@IMRQF?@^%5ZXM*GCDK#!>-/;>-/=^?H^!>GO)*)O'PQ:WK,C'R>J-2\Z M)]'FTZBX!FPP &>DO[IL, "W#<"5F@IL 7 +@T-K EQ[<&$ 3C?$ED\\$O"9&U(:4AA/IZZS95!I7XV_MJ^@.B?&:-&$;9?"*M5ZS9/:YJML19:6 L#LOKP MPJC-&;#*@.RA0/9B/R"[?8BM56LW3R,YRU@+31.X5H7A*MCF74[C\1>T)#U* M?M<*9ZB"S-&BL=3"4)QAACY=O@PO-#I:.^6F]R=6K''HTW/#/9J%]V> M 6\S%FO16*PGB5%X]]+TJU43KM9JGH>/H3N5%[+HR<=1][[JM3P.DO>9\GM1 M'P:"?ZOS$;S.2^X^\EGX@OVR.W4W'T2$YDA-\Z+ILX5I8CM.]#KXVG^96_R* MR6C]>PW7,26?]!DOH0XFD M(B%.C7DB6CWOK+TVI8]+WQ.=<[:"+V;5#I%#\QP,C.<;($#99PC M,YSLNY7<'PW(7;&^?&9(BY9LV33K MM]-LKIU&]6O@A^&*%"IU@Z7??S.[FTW%U7W6 [/PLA*Y\J)@Z&/S4DBV;XV=+3_SL313>A*F]-G$[HRQT5GS@;CCV_CCZ_?07___GCJ.WS(N0[[R-;J MU"Z: W/0K)MTZFHY3&!+#SX8==""#09(MP'2"WV!=/N4K4[M\N+" *ENTJE+ MQM8>YJ*<$UMN0%]Y!#1B+BHD([-8]T?U&'[A--GO*#E=NLZ!T$5YGC-TK\=T M%,,,K17CE.)JASS+TJ41N5&7M;8,>V&7V584MA6#8Q6!I,X,;2Y(-&Y&OX5" M3BC>3Y3N,3G#HOS59D M3PS^:?.]2&EVQ%7FG+S-^2;PLROP!]B>7$W\('+^0Y\OW;H<*BK9J_4&_9/* M>S &:EWY_?ETL?ZL[8JNP&%T['QX:9R XSD!I>$7S^,$[#+(M3TXK6H&8Z"V M<@+T2XRT_7CH"M9N5"<.LS@QLL8\H5UV9 6YH\5)_L*0I6&&/FD51^7%*84L M=3K&+#"MDL[ #_JQ<;N-RG:L/.N-RN;[E/5'?WP6!PM MBYJER[M7[K-#H9G[*]D7(WMQ=< M**'/D0[Y2\2!,O"I[3R\3GC_.9Z(P+$V(T;AW7_,OVM[&A66L/5M>XU6[T>- M]!QDQTM>Y,TR!7CQ.G^$P,3WJ?!"P>#'Z<*X(BHKB\8"_A<(P2;P[''(!%# M9I]X8(U9IU5CZ,+3]U#EV2,/V0^;FYU2/_;\2I_8/S1;S9;\8=[>]%*CTG_Q MNMGHEBP* V:YN$)<_Q;++G6_77_9K63993,YM^RR(4R676.!"*<"/GP0[JS! M_O$+RH&RDT4%^D?AU^P=VMW2.WSP(N[=.Z",LDG&6R>T7#^, W$'+_/&]:UO MF[V:@+>9(M0&L5AHUU##6H/I(NQ=I,M*<8:^:V^L=-MJV$6#971174U?[F1" M^HW^1=XX]>=LTU*.]4N'A+?66-BQ*VY&[QV06?$1Y,&>9^,=FM=#NZ!7^>4[^>9OG8&C$"5H=FX)\OL(3\^!N57K=Q\82>))1#!MHX<:'R>3OYZ$%ZOIEM:0,@3/'D&_[;J<*(S M&U(P:>N ):U^H]G>4SJ=)F#S#(RE^O'Y3<$YO[#%@V & E2E=^83T,!EF7C/ MYTJL:T1U<3F.#6_/=IJ<1[BM[.9:Q\UGIU:G (H7C<&^BB:JP]A<<4/%8"(M MV#!@H1]_SAXLSC:W6#-0Z#7ZNS*Q>J#P641 $/];E1 !9#46!@KT8XPNLV'"6'J>2BH ;DK)O4:0FF7CF(-E&X&I:5N //0]5E$ M[[Y;;HQ4_]7W[4?'=4\//#NMVD5W?_T&C!W1;'22QJ>O^D=\[X0U]F Q][,S M.X;5G_3ZMEFJN!G2@PTFXKY-Q/WRN!%W]97,JAXN)-"J=9O-D^BB9,R)!FPP M<7<]^Ɛ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�.'R3WJ*OW:I^QIW-C]S-"E/S*L.]2LX.+<:U5 MW89S3^,<:T;ZPD2H'"6UHU ]"O2C@[B%-PWTSP3]$ NH,".*0J=MR8.T+ALI MCK8F!3I(M=B09'N2Q*5R,+EFH(;<<"DAN/?Y'/R>007Z0%8EU4-(_19LA#HN M2:B5!8A/4- 2.M!MO3$33\J0M?(F)#T7V^X5=_Z<<<\E0EY^]V'JWXY;1?IL M3'I;BTG)%G_""R[_B8*&&]8\&VOZ6,ZN//ZX92#*46/CR$DMCNB&D&FI(475 M#4I\B.<6*_AW,!G OLTX(Y,;DR(Q&ZCOS(8DU@!? B4:NI6:!JY*<'W&DL(8 M2^YO<_'*D[,!]CX#F-&B\4KJ:1"KA-@]G3(Z@34U[.L="J!-G8(P6#+2-D0^PH@]A*13/.ZN'T0*0RNZMK!@/HAF,F1SS8=H?K!N(& M4F3#TJ6J#AO*QSDHQRT@RLSH-(T@Q:,,0=P.BAMJJ%")"F$/RB%>8CTDF6OF ML1N*Q]2C:M/"M40U&^!O,X!'2E&HU4 >3*L)Q0W U38E>MF82NCE[T2R8C8 M3[+;CX22G_[^X:CW/LKE-:!5 NV./!#FY^\THC(;/-FD3%BSP:(2%O$-7]=, M*F$NM.?'Q%Q!&TK93,SJ!K.$G@:S2ICU^7Q.@Z6#N41FTB"$;-]%)PPZ6*PAH6 M:(^R*9S"U!LZ"/0VL&Z;@RM =*.P#6L&&V,=O3 +2[M$\!6@7B-NA*IH :('>ZK=2/7'%]CPPF M^NB3 W/@!?5\1=P-\N?ATV,T!B.N4SR<)I7VJ<]E@HUPV8Q5\<:W MC2)+]0$Q8ZN9UD-K+;635NM+=X'=J2D%'82F-]S>,;>'7(&?$$D2;)&73X[G MN\2]$GRN3^W[04<,)B\X E["4-LXJ7@V:VV5QN8-G:US,SX4U#-EE,BP1R_(%BKBRK4X;:RJ= M>EL/9$6IMX9#N^30N>L:$_4V(KY_NP9O"O78N%(M^=I&J\:2=YTWU-A16G85 M ]9+BHA178N-%F62N>G D9/L;3BQ8TY<2D7G^HZY\SD7BO[7N'KYM-"WU W8 M;AA3KPT;G[*Y8QN?8CM0TA 46H+@8\.X%SHB7'GBVJ5^&].R^>QZ1XN;N6[7 M++-?B%I%(;ML$=^>IR4;\[)9^9+7Q]*!K^Q%M8:%.[JJ5CF<551AXTWVDD#J M"ESJ*0E-4'IV.MS[\SD6R_#I&(.%ME3^)K">'JJQHHPF&SER;OLM($?88ORD M#10VBL)6&YKLGB9WL%X0U-%/R]!"7\'H+>E20J.--CDG6>8P\QE+8I[N!)N;Y(YKFX!CTVGAT-ML\KE*Z&F;YE&R_7CSUK!HJW,D,^F5/1;RIKL7&E&S".3J/DN)%U%!Y9@\SJ.DO+!^QK,^TQ/YYP!#F)YKYO@ON+2)2"2 L%GQ=$4.Z.C*+@K9;:#NIY^M+)60N""6C"H$A@1YVU M)M@SKZXP=3:"+$S-T/RR MN!!D_Z-.V+W>5T7R>V@))IW>4(0!RN0ITSPIEME'LH06'Y7P:H/,/GH%D500 MK'/5P?_7[-QQH)9[QY?8TQ? @:B$/FC]D9?5ZKPJZN:ZMG9L(70V<48@N/D MYMRX T+IPA[;1NW>=*I+QK8^U0L1+&<#,<1"A5_.G>\^E28NWM'I3 TF7V5X MTFTPAE4BTZ>4P'^S+X&=4/B\ MP$_&W.AX(7SOFV"^FF?ZZ:U1E1K[LCDJ,;B_8 4M06UP[MY?+#R8$]8\+Q1Y M1:[>X#$7YOWB\:T1:7(7".PCA].SR_J$E':MG.P^>GE#'7WPP!Q)6#_"O@9? M"E%G)*L4"-)!&GJ_9"!46:T M)X^W&I?,PO%<")V\,9GV'*:O+H$E9H#U(+%+S7O8@=%UI3[72GA 0GUK8+#^ MCN>"_*M196OMXUBY].@-5%^F/5O_=1\M_X9!HR_-O6AQ5Z_MGXIE]M&K]4N# MHQF,#WW(/;V>M8KMRP1>)HG!'T?\"W5'!$9-D,5?QO[<8W T[7MY^5?4"9$_ M@6=Z[M57B.R=4;W>*^J4KXN)X$R%' ^RDOI]P6%6?D/IWJS42G@8W-W+V71$ MQ#QQ56LMU661VL= MN%87MHQB] ^^C683&!ZU[-\G%J]7V!G+9=BD]I'SVZ( ME(2DTZKQJBXZJ7+AD_.)(N+?L/*YXOXJ4UFO\KX$H^2F*CB,)IT9F>-?_@=0 M2P,$% @ MH"N4IW>89<\#@ ;\H !4 !A8F-L+3(P,C$P,S,Q7V-A M;"YX;6SE76USVS82_GXS]Q]XZI=V[F11=IPFGKH=OV;<<6*/[;2]3QV(A"Q, M*$(%0-FZ7W\+BA(IB6\ )5!P,YG$ELC%/@^ W06P '[ZY74<.%/,.*'A::=_ MX'8<''K4)^'S:2?B7<0]0CJ__/S/?_STKV[7N;R^^>*<>8),\27A7D!YQ/#W MCY]_ M'?><;G'[KL/_0_O M_^VZ)ZZ;$?#;'(63^7/B'!^X!_V#]_WCS(/WR/N&GK%SG>$W8^# ?+]X< ]]HZ.L>MG-:63&2//(^%\[_T0JPAXPQ ' 9XYUR1$ MH4=0X#PND/['N0F] ^/ MW@B/41>J2@ 260 G)SS^\)9Z<1W5T,LI?$+^UET\UI4?=?N'W:/^P2OW.\"& MX\SY8#3 #WCHQ+J?B-D$GW8X&4\"J5+\V8CAX6D'#;R@*VO!/9H+^>X)PU/0 MBFYCT%+.UX>;%9WA'5E=#,6M@3QX7/_' 62\,<1QH)_#5'D$_BT"NP#"/ZSB>!59K-X/11X M41#7N"1CY7G\*C 4M90B\1DB)-9PH6- O16"$@WB)C=$?!"W.S!DSPA-I!9N M#P>"+SZ15+I=MY\TO^^2C_^\$R/,SCB'%K^%RPT<)3+,8'D O'1 M6>C+_Z[^BD"' (KF9^(",38##_L;"B*L JFF0!/8,FW\"PV]1ITD*\"$[C?A M%',AS0Z_"<^&0Q(0,#?\,1IPXA/$".:@&/7B3X'O7RD)Q6_P. 0[7 5CPX), M290';/Z 0S,;L' M-R>@^F6?GLC6 BJI("J78\1F-S $[=@ ;>?>@E^?%ZFNI"$O1T/!D"=^)V)T M$7%!QYC=$@1!!!$S#8+KR3,4B; ( B$Z0X$@6L%4H0B#^L/H$SA\0J]-$.0) M,8'A/.(DQ)Q?T/$ AM9R+"(;"-CJ^:@!'"F,,>9#%/TVUZ04DS'Q/9K)0!9L M_#Q\FM?-0B>B%ITH"#46469*;1!6%D@Q@>(2#S$4E_:7K"YJ;KU2U)[V/[V* M:UA0.1>;TR;RDR7##WB*PTCV@$\,0JCK*)3!H!H.18%&>M0D9BQ\OL6(XX;U M4T.8"4R-#42+MB%3M(:/RGO;A-8/6"#HF?X58B%4/P?_$(WEM"#VH;D3CRBA MJ"/-B$?U?2*-"0KN$0$3>X$F1* K,^8AH^">M^47&D-:69B\66!ZI-+&^^: MT#@N;T0#,.YHA#X<6,)9'7=*WFBQZ/Q.);6)0*/%^\/&1VKZ)BH M00LJA3)X^+33=]V^>^"Z'6?""&7PYFGGL.-$'!2ED[G%ZC@O6"Y+QLN_KJWH M2[M2RL;AWX.-O*=2$H[L(Z%^(UAU82GH=V\5=)W8(Z7A^*W24">P3&EX;Q\- M>;XZW_POAP+D!)A8+I? M# /KP*^7 )C28&$86(>&/*@6QGOU M:KQ1'F[*CX418!U^"G*Q4]P6AG;Y"9Y9WUXOF3XEP<((KY*$\DT2*78+([Q* M[&4;75+DUH9T)6W_*[X7RH=DOY?#%P/&%X M!"^0*4Z_V>8.N\9E[^\F/'UH1K(M007IMF7W"OVS,66"_"_^52W3LD2,D5TX M.(1*"F39_IB$A LYW3+%5Z\362$J6"I%&*&+RI][)(WV7B7)!)JM &D9P]UJV3(VT.K%V=?-[#=-IOD3ML[!H0[5DIP+ M19C37_*UL!4DC(#'A% ([<[QD#*<6@5[ @, $B(VNX%P+YX&D%:&QA[X M)A288:[!P8[4,-('L=!KN6LOMC\>S$="#=65U:FH-:G+Z>I:.:?=?<%MPHCD MY3-ER;8Z8=4P@26^WNH4V.I :'U:JQ83%LYGUV*B. :W.O6U+)2D#8=(5N?( MUB0F9T2LE2>[-^ZI>'Z %D]<6)T16P]Q^3R3U5FPM0@HFS&T.KVU%OK*J5^K M4UMK45 ZD]\XKW6?EKCDNO5U0%]VMHY57( =BU4Y^IN9?6%R3\8EGO]_$\91 MZ;+Q)KNS%(\"49%J:(YI39]E>FB24=T,W::T=E"M[3!I!FI#F-;L_*;RK4T^[*;>=&MW,Y=Y*@RT1N[U:7DG#3K-6FE5AH="6[$B:C-/0A&0% MF5R!\L#O-%Y\RA'2RNE5^FL@E:*,Y"&,$,/G*(X2QK)XY=20(@GFSV^*SXZ_ M&W[E\[3E;&BKT]"491LYE2=3L$PW6DW45L%7)1C[\6K/#>>1O+C@;GC/$B\8GV$!6LT_P/)6 ]4SQG1+,(T^+O8N MGD>!\!\SC_#UJ8/Z0 N$F +[R8:;U0\R3ZJ WTGQAK**9+G0$*?$Q_[Y#&)NB#.6 M72N^7$OY0#X5J2VBG,=3VT:9*[5%E,NAU591YDHU=8N-=J>ZQXS(.'I]=B:9 M%\?3Y6ES 45^+GO+)5-,ZW:I^4BK=5'F3:C875-W>I#2YL149488?6)ILVH4<^)L?H( MU&9D%25&67T8:E,;4Y'R9O41J@W[5G%BH]9YJV_$.U?DK6J=Q6HY-1JIREIG MM5I.4W$+*LE%M_JDUVTWIR:;%ZP^$G;;#6YC8XO5!\=NW:"7-)Z_78BMLI%- MZ_39KMG]FI>$>P'E$9/GYBZN'I.#[7O,X@CYT1MA/PKPW1!B9>+)G=DDB 3V M"YX_$X*1021D2WFBR25N\HOD K1+>RF=DW)J:WE M+7]2#[ZJ83H^2^;)SAB3ZZW*&?+;*,U$GM+OL07 _MD4FL8S_A*-!V!8AG-M M[R+!!8KO!8NK6X4 1<$M8DU:\(9F6T!;++I]EZ3+!M6N8ZLSF[9 US9L0N.4 M)9/>/8Y2DK/2YS.EJ?_8_$[/23JRU-44/*#GEK=4VGXXZ*9@3)P!D+VX/5VTAY\#G'.LUU9V$V^O3$-[(O.+ M_\34=_"72FH5C>(96>5RVC?1M7#6N:4QJ1NK/;4J&=OKH,W/Y3;IZM;S>6)6)]#KRVK?-2KBI2JU9[;)V0$MAAWTK3NJ*"S)>AY<,O._"7;NP M1J7ONX/3 ]>R^]M4];\8L6L:L6VYP+(26G:#!;H]0?%*1_=I%[&G^%_HCM'+ M O8/^Q>P%4\O.)CBSS04HVT%2+5*VC\V'O 8$;"<3&Y)Y6!B9<"AW+;Q#,X[OE=)L;?4EF?D_H : MN[HT*D));#LXYPE NP%;);O]L$V;#ZI9R5:/,)NPI=;GK1Y9;J-159EPJP>5 MVR"HB3>W>J2Y#?)R(SVK;[EN;)I*@W>K3WS<1H/)'6@UO@&[<"8B^4+^,X#N M_//_ 5!+ P04 " "V@*Y2R$^/$*<> #<'0( %0 &%B8VPM,C R,3 S M,S%?9&5F+GAM;.U=VW+C.))]WXC]!ZW[929V;]@>O_&ED!ZEU@.YHB/^SM]R9A./MR>/CR M\G+@C%T_P%X40F/!@8VGA[W]_87HA16B7OS/E]Z[_KNC_?[)_M'[ MQZ,/7_KOOIST#][U3SX=?7K_W_W^EWX_)^!'@J*7^^=+[^2@?W!T\.'H)/?% M.\O^93VAWO5%[HOH^./1IY,3Y_CD_?'[8]3_/!I9CC,>]4_LXQ/4=_*:XMF< MN$^3L/<7^Z^QBH#7]Y'GH7GORO4MWW8MK_>P0/H_O6O?/NB=>E[OGCX6].Y1 M@,@S<@Y2J1[8[8NW,!Z\$C^(?_VZE[/>ZXAX!Y@\';[K]X\/%]_>2[]._^J$ MV0/Y+Y\<)G_,OKHF^N4X_N[1Y\^?#^._9E\-W*(O@M"CPW_<#![L"9I:^_!6 M0P!-=0G<+T'\X0#;\>OD@- K_0;];7_QM7WZT?[1N_WCHX/7P-D#P_5ZB>DL M8A/LH7LT[L7J?PGG,_1U+W"G,X]J%7\V(6AWM4T?8/TX& MYV^/"+X%CGP0.Y-5C2@V>(9Z3&+%$\'BX<-8L>6GBS02D!A:K]C'TWDB^B$$ MN71J.L>^ YB1 S_ I.0Z\+F3_348CL%IXRD:X" X]>%+TQE!$VJD9\3^\MVW M(L>%!^OL<0]M_VRY[>7WD[<:#';7=ZD[IA9=^CIZ#1$HDPFA1M+'JC&&!0H/ MVT4#)>[>8RL8Q7T<8I8GRYI11?N'R N#Q2?T??3W^T?I]/%;^O'//Q"=DY%S M"E$01 6W$1V\P_&%"[,WJ#ZQ" J&44AG.!H5+1O;H[,<)HL//6N$O#ANDA-] MV!W>-6W.K,"U&T!;)E@GK*>C("26';8!E\E6@?C2(CXT&MPA$FN2]C418*4B MNM!?N!>6".A,=_!RJ0%E.AFW2!7X;E'(?+0(BI4'5>B:M/=HO5Z^SNA\=(9\ MF .%;%\J0IW^U%Y7!$]A,@U=/X*>,(2(+5Y7!6=HC G*E$3!Y2OT!4S YUAD M?@T3;G"+X:]^"#,TZ/=T[8<(7).$#5I20TF?A2 ET96V3)5,WZ90_RT74HUA M/0ZDG_S\1BR(A6 8@S"(BB#VX1I.Y<^JL.0PG"#2B#GK)'7:+V2\-(5J'S!8*%B^W&/A &X^D4D]#],_Y51/M*,2IP?(-) MC5@>;=N9PAJ1]E?J5"2&=:TH%7@>4#S)@!(W%OF%G($K?4>P$]GQ8N$!D6< 'ERD291Z;6L$F*?SSW>M:STD:9.G MKRY7$%O^K))8:4'+/UHC3RP^6GE2J;8#UT[I9:U9CN24V$N28;PN MI*:9,\YDM\_Z/?W>C/B8N*&\Z][T*VC M #3",ZJ[19N-\X1?*.>"7L-++Q8$G0T]T1_8WST,L_/7O9!$:Z^P66,4YADK MC;/<(W'52&&F^5AOFC91%N36\QAK_03F<& ,["=MP"ZYYX:PYI"^ZW>,=#FI M7P*S8L+"%5,_0_G.?)0E(1;#R.&[=,=8'?DRJ!_,AUJRUF 8NW9!Y1C%)MOU MM5^&\?A(>XREJ]YUA&)+=F:$S]H;@>]%5_ R&=@3_<'6*S-&&>I/Q]N%NB#+Q[#J M[\@$IZ=\ C:#^5E_O\4'DR-;SD#K[[?X*PGRK[JF!&)A B^MLL Y34L#++^ MXUGJG?.\[J-M&>2M%HXQ<^GO'D3,55!KR*#J'\=PNO_E8M ,X#O]/1T?0.Z: M709=?X\G6MM<9X\<^F/]!W&#Z+-J>H9_6T:V^(Z(S ;O]1_\TGM))"RT.D1. M] \+6C1/^7XI9B!N'_+[X8I]H$O_ZF:#X4.([5\3[ &&X/+?$:C=UG9"CI:, MV#Q8A6-K-L"4%!V=.O^*@C VQ",^=1PWZ==WE@O+J'-KYH:6=X]LSPH"=^PF MF^^'XX%KC5P/#'6>_@$YPWA$\.\X:+YA%>4B/%K''H4>+1!O1(6>%^M^CZ!G M!="GTM08S-PN=@ A?DJ&P0_+BX3*9=K714T!#@R^ZR"(D',1$?"_B3*)6X[_ MF+[@RU=$;#<0VW4H([U#U+'=VP)=);SS-WV+7N(_"99?\4GL^HTV"6Y5H!)L MFVQ7[VA#^OJD+FS\E:>EYE?PL"X*3M_=P9<0(33P ,F"Y;W50C;1ZZ@)O4J$ MJ'C+<1B01G#\%;U53YNHM601LGRQ;%X%WJID#B%JMG.$8#'D+!@4B5T2)1+4 MQ)^%89XXB!I!2D8!GDZQ+^AW*AY6H;.LNZQ^7LDQ$O$L1EHX7C6%2Z+[N74\_#B]&3.I4_D9,XF7,Q^TG+>5W/]YYEB]8T",C6@K#'=VC!UX0IM)H MY+GV< P+:1J5B>O,(TI):0"T=VM-D7AV>O5)D[15E41?M"J:,U]^3@P_.YNP[Z:E/L1<5SZXWUZBR@M(J)2M0-VRMF\1_RK1JA$*_7(#.V*H#,8!F51>4! %8(+(RJ<*@!JY,\,L*#[KN MS!QL3B>S"<\R2)_S9W6UHO!ZVZCS-%LV:>/DCT2&5R'%>8O"1?D,96071T0P M>]SAD'HRRTLKJ>(<2'):)W*2@W6FLRA,C9'NDR^1>AI"OQS!EVGWPSF!*>]X M00MZ/%%Z56<(6E"[6AI(Q?X7P.1096$>?D!V!(/.K<"U>DS*Z11'OM -+@TU MJ&27Q,+-L1E7?(-*A1 E^YL*S2U'5-7+VC9$JLBX#0?%V;Q8@"BWUZH::G; M^<^(A"[XU4TWEM6*,G%?ZVY7JSCIO.&@V(!Y;J9E _R7% G=7)N=4-&-FZQP MI=9,%WISK'2C8UYPAX)&/+62C$=%JR,EHT*Y+ _ER M/RJ6 ;6V+TDN=7[D-9=;TLR">?OIOW>%>V6-N>@-DU(Y;49C#3%>$CD=A1SY M':&'YHN!G#Z5IZ?Q5/:4*"RU4&VM3S8%,)C\PE38?58 9K]N9[."'Y&@A>],J@LDK!*\&[_O*?:4_2<"HDB+5:P;6"!/:X#SKA()=I4*"HJ/=($) 1$+] M6A&=>I5'T%RB9)I'W';B4E8?7J;*V9PJ(UPVSB-.+;%?;FQYRKY.9J=O3HIF MYY'6"8$N +.0&J][58RMXUBY;P/IS3D>L."@9G;L>O\_9P&V@./CL<6RZ]:' M]N8KUF[-&!K1X3R5S@+S/.:(N?2A51O'7A_Y.@Y"S0'.^7V>I]UR&4\MX2,\,9?OXC M7A2F/J[]T/*?:-H_&>,LHE[]BURR0UJ^%ND-<>T5+)%7FZ9U^G$^#OSV-XR= M%Y>M.GD6R7SRE!"P]+VB@?N,G%6E$B%D)Z1VC%DY;U,M2@>B:S@HCD?+C?4O3.)R-[D-%<*BWQ9>5>1]A5IG_V:W*03;UJP0BG[ M8M*Q-;)VX6/?V!DS.M;/7_O/*#T7_9IF!@;8\H-'G)PR#6^7[@&@9J'?0BA@ M)Z=?^V-,IFEF08Y>;KQE38CGYG#)$$=)0S4>Q>/USB+AG"K' MS2-)2%:Q3+U H_#:#V )1-5)CY5Z1$1L<5HE13V*&RND^W7F%V!/>13+4M2C MH.:3USYY6KW6$ NZP<.,(,L9^C\LXM*UZCV8\$@>2Y5,*7JX>"S2(YW<^"?^ M Y*$Q"FI(TW&'KVGPP:UXE0>(J#2M?\0C0+7<:WXUB[?.1V/7<\%*XI5EDK) MEWI+MQ&-.H;C_\,0EOR 1FE%#O=+*7E:XAT$),S9'WY;M3U\]/,&9LAI-.5/ M+A0\U)INUJN$;LL/M:7;/3W=4$RSI4?TU$LR9<"O&6\28.4!-97L[C3VSN(I MP;5'5>B;GU#$WFF0R!HP'4AF0DYIZ9JT-.'@@Y0'I/746,<>XD%-G.P2[]IGRB)8S& Q1UU$NQWU+4HO- MJMP20Z]_V@=O.C@SQP?]8XG-N@M_.I_9I.M92ZU- MDG(-AE[?*:X-],NE-ID5/NH[+;9AA>6R*6:%;?4.LF5QS#+<08;"FM#\E7!I MV6)S99]RPK6H[!1474GA6G+=P](]K53+$=W/D+_->@!3%$0QX3S> .".7>3< M8M^.X&FQ4X4;:U(NT5S6^IE0Z[G!R9^C;J%I*1LD5T#2S1GD&3E7F"R=A7\7 M$7L"&M$33;BQB8A4=.SL-+UQ^-R:N:'EK6EX%=$ERW401)9O"V5))81+O:?D M7A9*&PS'!5TBO4IY41G._:Y$Q4KIOG:%=M8AJ*GR'4*PTD-<<#/Z.BB[WWJ#2HZ-&U5BH^8N_N8Q M3@.M=5,+.>5RH.-VFG>#L3E<3"BVTC-X!";+Z/B:S+]2G4Z<14;= S MVM21=#9D&V/[)$H?.F6\'Z+IU"+S]/+=U)E_ [CQJ@$?T?B)Z<#ET;YG;K":5_07?$%2,9E:FDQ?*^=)64HH&9:XSB MFPF":_\.P=!WE!FZ<=V,L/A"9_WL+:B9$=:.79Y^IA912PL[U^#)!6>Z^&EN ME4RP;V[22>H#.YKQ%HV;8+."Z4.EU0J;5V(W&O'1A3I$>A&![I\TGJQ8\^'@ M8AR(F45"N@F]9=DC"]\1T$KS)M@MYV;5>Z:"QK<_*5V"X8X62L-RT_+NHI'G MVL/Q&,7C4UQG'E&[Q/DN<;Y+G.\2Y[O$^2YQODN96OW* @! @"+O_0=5&FM?(V_+=W+V#B0Z$P*)VC8<0S!,)P@\CBQ M_'57L]+O8Y3T\(HKRR4_+"]24T71L,9:4_:U6'_0,RJ=DCE UQ54GLRV\ M[%+UL/"J3F9;./.*"@N^Q)528>/XL YH*5:.:L ])889>Y5FW=6AJTL:[(K3E6;!=E7M>F1] MC;J4S+#W(%PE]H[5@G.O7#4HU0V7JVL&?#RE?Z( MVCGKD;,UW@AA4% -!E1K& GB&=X:0=N#155Q0XD2HMGL2C%JD]O9 M*>>(/+LV*HEP$A?MTO/W[Y&-GWSW3PAPXL#Q' >K5Z8+);H;54"%[9I1>#W. MY+!:XTUWD@YORX"%N?%&N]>;RY.WX1TPIQ_4,85>E4;DF1OJL1=D!_M=$U%< MV<$FX9M58, 7XF#!0%.;&H,V+,"YB- G0=Z"#>K7AR9EOA5,ZKQ$ 3,;=^)* M(3MV#R/>CU"#UWP+2-2"Y>+15PE[$*MQ!=WX'&(T8MGA'VXX.8^"$ 8RN7RU MO8B>.G,:! C^=1ZM5S$V04*\F@N?U[7);A0205@C2*J __L,W(H?IMPY^ @$ MLP+7GJ_*QZ5TN7&=1X3HO7+T)UH;Z*+@'L\M+YP_PI,!96H?+ \%IU,<\5WM M+BE82O\!?DE:H&TUH3>_0$E[@X00^RA]?9EH8?/6R.E\E*6^@4V!C0V[ LDJ MT Y@RI?B7%<>E- U(&%.3_AM54?XZ.<=P4YDAP$$6VF $O SD#4"6M9Y2-(& M>4G&\F>E1N4/"Z*G*$E8GCX1E)0Q"FZ>JA8BI=>EYPYD/*9"^+I''L@%1,KW>22SL+9 M(!3TJ:)BE6Q#SM7<@RJWL,YDGSS"3P&$4+3R1CQF$1;]MO"JRL72S1+#<4XY MT2QLB0 5NE^X@?4$P^(I(\/BL%TXC5HMIT,DZT2>/)I!Q_E*;HB8]\6\D3PB M5R_'M0/2M$1@M6/"&SE6PY*";9G"K 2A[-R,)>,K;5*'C7N*E2!8QYW&!:.A M.-;'!2L-$S)^92LJ7+BF,V$K:AVBY14T0[2-HZN8T6"7*NDST(JFX%H^!TL0 M3PQ\UU4(M5ZF4>QFW*4E1TSB$CJ8(=;773455E23\A)[C QR<\4)$H:YZZW\ MM2.],CN$:Y-6#*F^_9PO<8=+DXDFW9I9O![Y4Y6%F ME,_(=M[DQM98#]]&PY'G/F7%V/1XLD=W M"E\9CA_@TV"2>N\5XW(5TS;0III]R1S:-@Y?(VQ5;^(AA"4Y/<]"-%W; M=,N[:KA=-9Q)=6.[FAY]:EQV%2Z["I==A"0>^8W5WK.Z.U=VQNCM6=\?J[EC=':NK MB-7M>E&J#:NK+Y?5/:O;,?7?!:NK]R;6-EG=OKX$34NL[AO(Z'"RNIWG,O3@ M* TXTU<3CO*(.WY0R%%>N3Y@"AMK+BM6 KA957L>!!HY"I M;4YKP+F/UN23H^2P2>P_/2(RI9KD+D7CAU B0(JHB9W]0N!BDX&+1,G#.C$J M['IF>=1+/4P0VN">GBHIVX!"U?%611J(,D7E,E0@R(;6M3^+PF! KSIX)T[B M58I1BN,&6=2[Q^X\^_!_79@6(%:>BWB M8G1Y1_"-X&@&4[8P:!F%5!SK-(Q)S7"8!OD]1J,RDK8 M+'V.[.O&+-4\);,.=W35,;=^/J&9J.#:SXPU'&>'FEQA0H_Z (!QI@Y\#L!K MF'UO1@%M^?D-X77$S="#7;[[>!0@\DQ#A"08HJ=^ 3[/C56$WR)"0/RHFAW8Z9_FT:&Y>2!,C&II":CWNPWP+"(.S3FI<'U_"N_/Z M>$VSNIUGLSK*ZAZO9WJZ]N]*G1-?U-LBAPY-6 -Q;X>9OME:^3LAI MBDF5. O&6VW, '#K(O$-K=Q")/*7XG[0QSQY[4DI6OG;3DQ MR\O6#3&]DZJU"285KAWF%]P:8BI:)[RW$%,^OB#O&=V 4YP(94#DV]#& LD> M>%C-#,=7,"]:'GU)C=N@I!4EAQPF5\O1W?R^6.G4ZI/UV@8+=0-D'SSAY\,X MSB#S1-OTEU5%TX]_GI_R*)?_=LL*G7X748A^NZT#_QZ2!-4WA)^(-9NXT('$ M#BVL$&">SI+5!7Q:+^IW\\V*G*]8(4!N[_YX3&_.]9U!_1HP*3W1','A)<(J>Y8>@"EV>S>)C:T![\2H6+G&=XCJ;4U5$:U&XQ*F; M/P<)\Q?8Q)U)%9=4BND.QSJ-*HUET''U!B] S/E2WDA-!4__QH+C4L/\I09,+N\'7]:6WN2&>5D*UVJ0/T1LX2^A^ZKFESB MHK/,(!_>;@R_7GS(K++Q<>OIY_0_(VC\;_\/4$L#!!0 ( +: KE*0_JLR M*U< &Y-!0 5 86)C;"TR,#(Q,#,S,5]L86(N>&UL[7U[<^2XD>?_%W'? M 3<;L3$3)_738WMFU]ZHUF-.ONHNG:0>[][$A8-BH21Z4$299*E5_O2'%Y_% M!YXDJ)X-[[14*F8F\Y>9 !*)Q+__Q_,6@2>8I!&.__3-VU=OO@$P#O$ZBA_^ M],T^/0W2,(J^ 6D6Q.L X1C^Z9L#3+_YCS__]__V[__C]!2<7UY] HLPBY[@ M>92&"*?[!'Y[^_$[\)\?;I9@&<6_W@&>O@KQ]C4X/GK[Y_O3M[^[> M_O['-^]^_/[-JW=OOO_CVS_^[G^^>?/CFS<5 C_SUP*5__L1?/_JS:NWKW[_ M]OO*%Z^#\-?@ 8*K\\H7X?L_O/WC]]^OWW__N_>_>P_?_'!_'ZS7F_LWWX?O MOX=OUE5)\>Z01 ^/&?@V_(Z)2-XWCB%"\ NHSB(PRA X#9_TQ-P%8>OP (A M<$,?2\$-3&'R!->O!%5$]/8CRI5',(I3]NN?OJEH[_D^0:]P\O#ZW9LW[U_G MW_Y&?/WYZ/M?WK-OO_WAAQ]>L[\67TVCMB\2LF]?_^?'Y6WX"+?!*8&*6$%( M&:31CRG[<(E#AI&$7*#S&_2WT_QKI_2CT[?O3M^_??6^I M'/_21BT[[(@_I-%VAXA67AN+^@EF=J5M$K0M\#5,(KR^B"TKN9VL&^%OLR"Q MK/4NPK9?X([$-VA7]&.2UH7&68 L"WU$TJ+0&K:1';8(^R5C&9B$<$R"CUYC5$64H_H=324_K1Z9NW(O+^2PO= M;L&9*'2T%]^D%'L&!2X^'X(JE.%S!N,U%%&_H(W#H_=*\Q=+8?CJ 3^]7L.( MOQ/YH?DFY*._7<19E!W.R!0D"= 58?+\O^&ASAW1P0PG^8?LE?[T3<_#K^MB MTN_3$97\1&=/,#[]?"M+[&_HOF$>"4SQ/F'#K;1&L])]_\S9 ,$',$: AYA,$W;9*:H:_2;!VUYM"K9X4$NO[5O' M&29SX,5]2IB%F:Q5-![2LX8:$3M6P-7^9T89_)+3_G_3 ]^N9=RI" = Y^N0 M._*2LCC7G]&#N4K#OJ\7JRM*?GJ<6Y6,NQ3ABT*1DBYM&.."\%E37I)"U MQL9#>MJK$;%OCP5Y0.E/;Y#MBL:=NO!&J4A-GS8CY&64A@'Z+Q@DE^235#58 M'CUNYN8-<@Y#*.<$*"O >$UOOD.08 E=>:C^9L!5T+Q]0^>+=@-3KQ&PH>T* M0??FSIGY:?!MT+2:_)'&O(2AP^SE$+!I^$6:C2;858V^\;"9IFO$'!J[T#%A MQ#85_#'T=BCPH):\4WO3N*4U;F45OT^2VF"E:-O=SVNN[3OHV;=PP:DVA/IC MY8.X8!E]^8@!,E&_O;3F#7R(:.(DSCX%6VES;W_6)*E9I^4LIUFR 93/] ;> MBP(>TI!O&D?ZRIXV_5T77"'S;<\3[X+GJS5A'&TBOC/^:;^]AXF:2W82,;&4 M#J+.G)3P W6&@'/TQ5V'H,+2VO,6%F2*B#W'N(P0U/&%ZG,F>B[I.+-XRL(S M&V_1.N[3BD\:1NK*M;A1S&=T-W"'DRR*'VZS()//#/73,-HV;J7I;O=83&P+ M?H S],6^!V#"LJKS%1)DB(8]A[B*B7D$O- SR (ABII#=-$PT7X[36<.46%' M5W=!CHDO#C$ $Y95G:^0($,T[$YHDC.RP'_ B6(A4>-1TT&W(.5T9I. G(TO MMMZ.P-'\IJ$>S[1]/,N14;0],[[=!@A]V*=1#%/%^4WC41/%UD@Y,V/&!>1L M?#'C=@3P@'H\TS;24K0],[[8PN2!S(A^2O"7[/$,;W=!K!B5.TB8*+J5I#/S MSKD!S@X(?K[8>3]$6%)OGL*!S)"PZ C/=TD0IQ%-[_#--T4O:'G>2.=']-S9 M_S,H>8F=1V^,OQL6+*,N'R% !MJW.(%YA AI!?SZDT8#:H62N]D+9>);4&_5 M/N[7C5^:1CI*MIE7"7&RPPG+Q]-T#CS#^SA+#F=XK;B3.T#*;$G?0]IALJ7" M]80ENR# 9'W$>0/*W!='D,,1*RK5<\R:V9@*0X&6'%3VW&FQ7I,72<4_2[+^ M>*OF1*T$3&!H(>C,8023D_P'>OX>@E7LC9?TP8.EM.8E%*@-A1H(;T=$!@G+SS.1;0&DS^*:V/ 2@W=B9ZE=#JK=N MZVR46277"7Z*XE!QPM1%PX+2&S3=FWXQ.F;_74"U.4&K\GP%I=T=.!PK M&3BL^\0U3K, _=]HI[Z$:*=@0?4UBNZ]@;,#A)]7BX1>@-H\H45M?H+1[@72 M,%BI_JKKSVA6F%=H.*CL9_HDY#TQY%8MXRY-^*)1I*9,&^9(6V.A MZT<<*Y8]'C^GI\0F'?NFR3@ QL*;LL=.K>,^K?BD8:2N7!OF>@O#?4+Y3C4]J%C9;(0X8 M=;Y<$M$_E[6%[CY&LO38>TM-BC8@#2^7D :<_O8&V*QIWZL(;I2(U?=J, MHQ?/X2-Y7:AR(*_]63-'K]*R;ZDY%Y"S\>1 7B\*>$A#OFDOGF?MR$GG_SM'&X@(;2^@4\PWL-% MO/Z)=B2YW#-'_T10E/&7[I%5;5*^:5#TQ4S"7T+/B)@JNP&07=='0/&[D>? M#+L+C2/[;E62EYJO6WNN^\FL_BQ('\ETAOYS\8]]]!0@(DZZR,Z")#F0N,[]C@3AO2T$EDXAY (=8_@)Y@II'#DZ!C$OAZZ#B93@AM90^;L_' H M*9BPBMI\A@0UT"@Y <)*J^&1N:=\CN\CA.BJ.Q(CR1ZN M0>"KKT@ A>55YR\HPDMR-A4O22=RD57V")/:;%7%-=J>UM?^,37[KL!X@+"V M8O'#!WJ0P,,Z\D_KJ*KP^FIERH6Y]H+V&^Y2:"?6VJC8:KN8YHNCG"0M1;Y8.MCCJD'F"-#[U*6KR#4S;_D,EV^ MZ3K!.YADAVNBFHRLS^G*?$>W+\@R0\4A^NGHX]%'U[YCY-Q88@GFK$Y #"=#D\LLMS:"4P,,Z2IP#4.@(HWQ(@ADH>(*)[+'J_@)IAD=;=*K>+'91"@*,IC>[N_3:!T% M2013XCXX9)^2T>DO.(JSG\G7]^1=U48"(T8FD<> L8NQHQ '1#&;C"$,J6>RGK-(I_=5MH#SG6XKI2*<0=5Z'Q4K:(U6OXY* MGIYL,$H@U.Y)ELO97:/1XBV3%[;GI8S7P8$6:!'OY6LA7DM7$55I=B5/U+S: M?-!B_,5]'RBM_QLX5WPK%7SWT/$*)2W$W6Q(45Y@(PR\5?H^SQ;)]FQ#<3DYFB'#V#PZ\2]!UT7&PTY_'#4Y2PPSHZG -.PJ%R MAH!R!#G+R6=@Q]DBLWRBWN#H31[:3QJZ3A9.9^=FAW,&"%F! M8*QC.KRHP.M4NMR!'0G=>0U,BYOX<'YGM6.)@OAA"0-B./E0I5EO-DS,H/1I MB+B#.K2<)4"49^%&GFSSRF.'E=7H/4ZH"1%C5YELR13Y2+S6!&TY^Z;]QSTY MY_9VJ/%B@BO;TF!\@6 \79F61J)7+V :,AHUE>W2RL]>ZCY&?RRV@,*L3)>ND@"J>>BE1W7^@H*J>+2OTGW( M9QGGL:RG2=P?B?'.)Z3=P8DGN'<"W\Q?T^@M*=F9@7MLU@/&;-&$71GNZ)O8 MVVW$CQ?3QLCYXB54M-Y>,B9;H9UD72SF"V:\P7:5G1^6+H,65E"?Q\B@8U!8 M&VTY4!S==6/CQ)F;,V9CGBJ[[3I%YLD>G=K!,7='Q48Z'.;58;#*I8CJ5S8< M/6L6GZJTW P7..9'*M,?08S!+DC $V5V O8QBDCDP7;^[']FYQ6E*:L(S<]'E->!2G+ A 2.QAFT1-$GN2[.NT'#V'KFZV@ MFIGP6SLGN>=AO6:7< 7H.HC65_%9L(O(-+[RTBH^*D/-H'QTD+J#FMZ")W'@ M:'T:Q2#D;/WP" 7\L+HF_<<*'<%$^=%>2()C[6+@M"6"/N$R2H^F20?5GE3MI&1+HH,[><\:ZOI#SWT MK"#32=^UM^29ZX*S=RXS#&6[!PVH= ZPM?D79PE*GJ!@.K6[7;$M"R,/RTE8 M1(>3',F/^*Z-IS[4P*?/;:I*\Q2+'N>X&D!A''=8E=MV1CY1HV,1C K=D;RC MLI'IJ8NT8=;G)T36O?@T#@(26]'B%B M\J,?MT21<*O9&*&3A,D%,:TD+5_]P@Z]%$RDD@9C!L8A:+"DOL8PHX+U'3V8 MJ;:A5'_29"^C2LE!FJ^T%,;!$S/I4#WN5XQ?:D;*&I:QXC3)*A9,?FM:+_F( MWC>ZWH?9*KF%R5,4PL5S)#56=C^KKMHN6DZNHJ5HZW010K&G8; 2-U'Q/\NDR\!Q$LI2@OM5^W M>+$O*?B 7S@G>;/O6-+D73]JCF@N:8E)/U3,X&;* ? MZY@>[>,!U7BFZ6JH*-1\.7C1YY0BHQ9IP2^HJEZH;KX=P\+'",$TPS&\#@[L')OBV-#Y MO&;8ZJ#G9)0H>-&&2(R9#T/%$")81E,^:K\:)4K5YYS,AP^GPJ,NN:<:2'A_ M\8/Z0-)XT* 6O$K(P>2"D_=K&&G7.NY5BE<:1G7E3F2\1:)J&<7PBORH=)R_ M[6D+^;B"FM/4)^4"&!O?\I_'6+3E0!M:\D_OQ[E0*94[.H#%8I=63>_QLR;' M=NJT7"P%&0=/SMAWZAT/Z<0W':.:>B>LS!427!(]MUT!J=W+Y/_ MK>^"9PUK5R-O#)8*._L^PT^0>'7SB G*Q[ZEKMX9(EKW4$ % !UWEA1"@%P* MVC-RJM[T%\\[FDK0&IQZB%CH<=XDZK('/12\/!FYAM%IZSK?KC!OD4!-$'(V M$PYO?$$D!-%83Q=/&B_W!"5W*^K-8+9^Y.5T4^O'Z^F:3OS2<&-%+6B//COC M>QN+>'U.!B*$=W3IHV/-_81,QN<>P@ZWIN@V]KIDZ(G=2\&%E;3G-33-+3BZ MQ5WA-9'7W$*$Z)0P7G\,DE]A9"I XOK[->?GA)Q( M87F5^0M&GK/B;)AW%(PF\HV?8$QF9XB(LEAOHSBBTS):6ZWA((.D]($9(&W? M501#YBQ!C:4?'B,+&U;4H><0H3HZU('JW";RHG.X2V 8L0UGJH$M3K+HGWS_ M6<&#>LF87);12=;%/28E,^X^%79^.(\,6EA!?1XC@UI 85XC!K[D'X* WEAR-T0]&7?;*>=7*<;9K*OOEIHR5.]2R\^K@%99?D[%NY."/V M+2+4OP/4QG*3Q[%OIMZ"2INQ-]7E(0)'!B]@H!Q&MOE/.,;UUQ3.I[/I($%, M'XU!XJYNJ?HV8MR^RX< /]Q"'CBLK$/O01(.5.66^Y#@-^'5TM1H.O6@-* , M4#*\5:R3LB%&/W",8OA F\#.P)4D$6O>]S:@/T_1:;OWK<>/S*M^[;=(:#6P M2H>$J&#DH_2-A @7>U%K[.#+',#*V.]D.+%J07?'RS[F%CQ8^1&CE,*3L\@T M3E#2"D<.FX?0:7E>MA3%>R+5JE@C?8 ;G,#B,EN87CR360=.UE$<) =6TTJO M$J3E1ICM'5S%9(8)4XT&)([$,&UBXD0L^RO=3S KKA#(U[OW3#SAY_3Z9C]\ M?0RK.^JMXA#&%VQAJ)9&H8*6]85<5%#*"KBPE=NH80IJ\O(B>%"7&.0B3Q+\ MB)0B]GZ ,=RHW4C22<+4)(Y(.FFS\!2E-.U.0/,T1G2#<^3?'1KS%(BZ7]%[ MV_-UO6 S]A099GI)X<:#!E.O*J%QAD=^B^EVE\!'>F+\J1@I\W0Q\0LR408D MP$78DWZD[4#A7CUZ!0HJ\9@N*YS?YG,-$]:[\4.01B&M/HO0GBR8='+#TB3U MT9!D87^H:',>XA2\(RD(LBR)[O<9;?@%,DQ=JKCY45QLX8?OJ**.-54_$X2% M)Q8W6Q&FO),I8&QYB21G/%VVN54CQGYI'2/[/L?(>NPWTE[BQ"=&\8")35WX MGHFQ%R3LJ5^0=%">Q0G[:?)-+'J,OJ8@3_7>;?B#*#@Q_;_"Z.&1#G!/, D> MX*<][0FQVARU\-:9F*G3U@=-E9=]+\HE. VX"+79F(?-X[61QZ9:GQO*J XP M$-P!9P]6FY8V]-/-VV1UI#R?4R3L'N67/__3PU+#0:W,%R? 3K%SY5U<5TV#_[%3HS_(9]-,]UV+_-9;'^^S[-6+>^.[Q8 MKR.Z71:@ZR!:7\5GP2[* G0#0Q2D:;2)0K:;MMKD-\4>SL0?X'JU8QMM,G[I MB+%F7T?;@CAIQUD1DN8Q@T),L"-R@B@&(9?T!"0-60'>%#' MOI[.K! [!7G4VT_(/.'H^F>M^Y#E"%IH7M?'P%$_.SJ?.;ZUVKOK=]1 ;6LU M.*S;48V3"W"&MSL5O3AD@8)#,;2/HWC'\\(M^.+"4EKQ4/6K7NOJ-*7;, M_IK0@DE"5E!TT%+OR]W^O+[FV^BY*&,37,2ZS0^;[\4"R^C(1[VC(Y6SZT\G MZN%=N>M5W=A;'K9RZZPK,\_OF_7(QKOUWW[9KQWK=J1K5%?SE';=L7)6M_$! M0OH8]!*V;_LE.T#YG48Q$!S]< 0YP+"2_KP&![7B JX*7":[DP1F9.(%UWEA M@\;E)!T43)H;ME%TX"5AN-_N$3WP!XK"CF_/X28*H^P[/SQE !\LIS4_L1!. MD;,H,9CZBA.65Q6I+.V4T3$1"ZF))E$'TR;*@2;G&0\_G& 8F+8<4;NNO 7A M*#?$D#/"P=OS3-ZJJNC1O2Y?FWL(D M@NGBK6YN1X*(YHYN'U$GN[.<(5B\!;LB_Y!2GC[LK4KAA*55YRTFM:;-.2#F M74C<"XX:,@/C)%:_Q[ZSX;$=1,RLHY6H4X]]Y['']N.$I57G+29M'OO.FL\T/%9I.MSE?C(Z/_$JE2Y5I6F]#M-MI:5!&:6M! AQZ:LTWH4;*78-F;[Y"E*H&(MW8A%&J=NQ<@[B;&-O*S,$ZBH,9<:#W\9KV0F'8\W)_ ML".OX;672N N.7;VJ'QV&,N.J?P+0@90".&'2W/C=.73O=0=!6N?O'I&8["I M>P\J?WYP2X_3?GBXS($J)O!]0(2C!<@P3EGR]0;^8Q^E40;);/(I"B%_NQL8 MXH>846&!3"4>N)?%I.3)K6P.8@VUKU,F#FM!F,OCU\4!H]D?'AO+EVYK(M!5 M3[3>8=!3L%>*#*HR@T)H(*3. V5%;CXK,M]3\/.0(-/@0HBV!*[!A&3[33J?1>OAI1S7UD%29.]OIS M <"W:R'"=[1A0L"E $DN!NV<(.3PH0I "W&LK?3^X^(J5HGW).A>!P=*F][/ MRAGG(36B]P2$:$^]I!!&?-O,<$WXVK1M?3E&-G\F*-AQWOS:8>$3J!263/N% MM!5/$<]XZR863+#7DTPAUG(V>C5%D#ZNDNL@R<0OBY#/@>D\VO\J)L(\$CN&ES@I[KU*T(!)?8HWIWOBNP$3'& A.75@*&1G=P&4ES8AYNNXD-\''QW%R>?#@6.869D MH4BYLPMWUG#]X4#\@KA"8?^+,(N>V(BF=2FQ!G6C&T$4N3DXUD(-=,,,M'JC M-XG+0<']1S\,U@!Z;*[T^<&,RM0*0SD7 'PX "H"S2F5UXJ74DS7Z)A(N(DR MU6N3JD^9=/K(J;C);M6N0_+#H5K4C;L5XH]JA6%SLE-<>51+)-/D?1Q&"-92 MI'?8X3#EAK^E?1Q+\GS50YU3 ^O:(+0*W$LTIO:=FD)$T+B'C?YQ)@/O.=PE M,(RD,ROMS^EC7J7CH,5XA3K=9=PEU/6S \L@TCW9W=:;!G^M2. ^3?FD=72L M\+&'YBU.LNB?8N_V*LZ(%B*:]&2Y$Z5!=H"2083KI>R@FTV%'[7_J. HTG1^ MF+XD=%A-D7[#A%H06FU R0PL!A!RXD7U=&(C UD55MRTJ^)7ZK3U(53EY=[W MFGGOI)(T/_7)&[5- )NJ?VYP"Q\N9W2,.]\.H#&K&<#%4G>CNP/*' M9CF=4H*^@X+AV=DCBN,5BOKA< /(- \O=^C+3Q3RK9'\/M!&9>3HJQU^%+#C M5GJU!= *9/9>2]I%\LD<4(R"Y[]JIV6!0PK:L]S<% #%Y%;(-SRP0,(?F-/ M#[-'F(B=:BZ4SCRPFXC!#*"+J"$B/W!$8OA >X(*AV',_/"0842PM)+\TWYC MHD6Y%!4HPBFFF4T=UUH5LT!1K:V3WE>AJ@^6/!<'J7A6MY+2JJ!*%IZ7#-&D M7*6>XBU;64R6XC]52EA,K904'"-D$KD+8 MQ>B55X76ZF@)64B\XA%L8*V^W%56%F?C1JQ#,/7<;8 M>;9A5F\G 5S^K@7S"I23AT4A7+&N43KJH$76I@-VLG'09HC/.S/*)#]>X&N4 M' :U-V8.:'5& ,JX9;G*)L!>RP [VX,WC2LOI([7O%!5#%@&5XW@"(B A;E4 M1 2%C)78/FA!(P7V/(MT Y]@K-:N0H*8S1C0(.XPT9EP#KZ&[2[(>H-UJ_:\ MAZ?/_0JX;H;@&FOIJ'$*5(6:U27)& -'8^KN^6RH[P2EJB+]AZIW">G=*,5R MN\V,U2=HFC[MI&HUT=;!Q=G60T?&U%>_&\2V/V':J]T9X"B3,&6H'J=-"?.1 M/5/^S)**9ZI0'>.\E:7!$!.,A%_2$G"V+?7M/F6GGK^CU<:\^OO^T'KDP ]W MU0!(?IICU$YX>_7L5/,'5V++:7NG6(>[BY/RL4Y/Y!'L_"@TN<'LXQ'%T)XD0:Z@3LQ.5AMECA^N(/)]AS> M*[EP-PU]!+MHNIC;%KS8;1&$V2EQURU8$W9^N.$@2%A6<=X!4G>[?4+_E($, R@$H-^J7J#KB6?)(]PQ;W-R)>Y(:+;.VORX[;9]XGJ= MB*D+$W(1K_D'D/R1?6*^3!KF8'LR/L31]7(JJKCQ+IJV$A@\LP.5SF:0V#R[5"#!$.:'%**0G_T-NM 3=; N/DB!UNWE7KN,OJ M[K8= 3\<7 -PK8V \38 IDW\C^RO%YL-#+/5)K_DZX8LM58QE9C^/RT)> H0 MG>;?P#1+HI LQ.@?2*2I?U#YIHIC.V&O;R0.Q+$_,>!"THE <=5=0N0$H>AV M16;X+)+0^E/V RRE\2-FN#0Z/ *:+]# 4,VVR-PBEQ!0$<$JYE&,_:?"')1B M\;_1*4CSLPL9^W,2W8P4>\UNL#X^N">:+U0AY&I3"7QC2Z9OLN-*:G]F51R! MC+R/BQ.9*YX6[*_+-%&EY,(J8>Q_F;S"D*%V]R'J4[G ;H MIP3O=^0)\CMQJ2R*]W MCD;B6&GR.:Y<$YFYHIQVC'S'[/(V"Y*L6N+6%GE/ MP#U\B.*8VBK-;;$G7T XUK5;6\%8"_>OR4:M!N(RWN:O -@[L >K;P'*US!J M<39?O7,/OXC7PY$!DD\E8H*S08M>/EWT&<]+ON-U2\Z(*@SA=)] G8IGNL!/X7H\Q% <968.N-GK;%VU/&X3'(VKV!T;.@PZ+LEG0 MT0:X;B3PL([\TSJJ*7PEIW G-OYA3R8V,$W/81HFT4XXXX<@C5)61UOXY!U\ MSCX@Q?)P'>KZ:*ESL^]#C)NH B_X^>%$!E!C?+M[F5\VQ-B+B]IWHGY"FJ'9!M"9S?W9%#\_^FI46&;/21]:0M57\ MB\O]F#"@(@T0XK 5%[\9263=%:M$QG1=6P:$+:,UQO#"Q#C;$UG)W(U)HS7 M])(QV$#H)FM_D.'F*K@-=DX?-<,O 1)6T)K'@*!N+*8<8SIOS- 9122(&;58 MZ"=NNYM"YWT>WL5Y>1"QLC['B-6=HI0#B%;P5J/KP#1;^#BL9ZQ5,IZ N.^> M1B_,LP]>&4OM5.^URZX_$B0@]U;*3T,0:=;EFTQAHIH M9WS8 ))S\F[HD,$**RAOC"%!E&FD0A@F"%POH^ ^0ORN*+$K4OFH] R1"]8: M-FQS-JZKLR2)_>$GEP\( =D Q)/Q%8G\\ %']G19:)42 M&'(RJ"0PXFRWD* $?[4!56& D$:4&)3R@.(.&=_&9$NV@^TB-4K!,97A$:,U M&4GX+)?X.OOP0U4PO=)C9=H&=:R*O!R4(U.[MW_X-W&3M!\VKHTT M-M7RW%!%QX#F=X+3@9!7S7UH1+3I!KX;^ 3C/:27(ISAF,6/OT;9X]D^S? 6 M)CHCG#1)D]N9I%A8OJN)\>3W1^1< 64+#4VJZ&)-%8\QV P(I#7(R--T M9JL.!Q7!>1:FV#MRJ*EP+E"IQ)7I!HCJ[@)";!U7_4AC?)"E:++/*,/!\E9C M90L*(;'@K7[JV]B@""S64^\8(T/1A>(J)JSW-C:J%)V;,X.1Y>J4;-^Y%4)9F2^O8.- MCI+G!:ERB)IN"!(M9AH=" [\OWK]D"0I&C3+D>+P=?4]4H,1ZRES'I"A*EJK MS5&GBT/^SX1N]SF%J\U%FD7;(%.[A[;YI#XF=4KVW>4S;S\+$J'YG&_ M7OS2,BH53*])'%9PPX9I'VQJF6_?O!=VR3IC?X[WZ3Y J^0JWB3P'WL2XJXR MN$TU!@,U>NK:5:%O1^=K'+*U(POZM4UX8N/-)D@'UE9YS^4#K,-R+B&(J(BO MIG4&+;BQCMKG &UM!K[Z^>K\].T/X)K,O^$V"LT;SH_Z+GEH$*:WHFG4PO08 M6P]&OT_P2V4FD."8_!CR#KC&TT]UVB87>JOQ!HME>AD/&2WNJ$] M,<,[6N^H5]FDR\*@%$:/I8,Z)R$(G7$PUBQ'))B#MG9?9:NI198ET?T^8X6F M&:9E@UL<@VJEC1^QP=2&L"7@9FHOJ&$J='UPW'B,6\^B8CU,%C]BQX($N345 M*WJ"MS#<)ZSF^>*97A0)U[R^8+O;YVWTK?3Z<\'=A@79DL9M,+K&&1F(Z!Y; M-:RD()<3;'AY1B$I?>C%QBWK]ML:TNQ:QLNSU99 6!40E!*69GK9--/VZ.E% ME&QI*F9A4C5,U8:E#'%Q&ZW\;5FG@6YK;)#3[WR0;/'EUEYWDT]B.CL\V6TQ MYK:QV%B3AFIKL8NRM=@G[UN+Z344<]]&;(+F85X,A9=1'&5P24;UHR90-L9$ M!?(V0JHT.[?NZ6E_)A/46\=*177/$.&6T9-+ )@(+1WC)A]'>S2TV.(D$_?K M73S3TYU0W\G-^!@5PFKS=>OV^6;R&E0% 4(2T'8WJ!^!P8K)8)L0S=D\1,P8 MB!.M)C)Y\*AD)!K-'T0CEUK_!QLS!!T^5C(NRGS=!H\Y-4*Q8B7MF3E-5.9L M$6W9MJ/V)GEOJ$:+$X\"1GG O=HY8I$D]*ITMMGZX7!T"'[Q)4CX7HY>]#!F M:L-P#(5P&%>(*57/_=?ZG53E Q\.;0T" !.2F!<5TY,C(/8-KC406<'TQ1A7 M2X@:PZ[AZ?X^B<+79P(06]A%.'^'V'B8R-BI-2K,*>IBTD]IVPO8TXGS! MCC$FBSO.&>P(:Q^*UQ4 Q(K:]!RL^O4\\/3J>L6V9LP+U<=Z@V)C"0+!#W"& M(.?(7@C\PID:._O=%WSWB/=I$*_OOA SYW/-%;OEGET<0FNHHR>HX?PZI#7M M2YV5D^! !W@Q'\:,-TOR1#EW;P*$ >C84.,S [@:4"KHKDIT"]:6 LU4;RH" M#V$/_.T'C6LZDZ3$;S,<_LJC9;H(29B,LH.- MG31];N[RE,/<'<2=_78;) >ZJ<;8BY$I!3\1V_'F')]%*U%(8,OB,7^+4$E9 MU\TDE\K_S;4;F&9)%!*;9F_PF2P(4Q;^W(<59=;N+$I1%*J%,*0%F0OS()4 E35K%BLXF;%ISH^QJN+[0[A X2W,'F*0M@QO40L!K$3 M335<67/I,UH6RXJH'6>B[BH'C.8C&F1 M-VG[J,S.:1@ZAQN8) 3NO&/]:I^E61"OH_C!CQ!D@C^VH/@98BT"0L>] TP$ MEDLNA)A^>G,91,G/ =K#2@7F1QC01F;K%9E$AON$;L"QYHF?8WR?DKA&9;Z* M=_N,1JTX)$^Q.*9WXL()?X-2>P?R..A*]D@SANQR8RHP8!+3L%):%FTX5S28 MS>B/:;2&B4<]2IV:'AX#TI=H9B*&5S(.)52[GZ$"#G4L)(2O49( M>%]GBR:9RPL5!:?%ER:<[G%A M[KD IP&7H&;;*<"E"'(6;A*H7;Q?FSL70Z@=QQYE-B1ZK]F8#QV1LC?>-DC; MC\YY"[J9S8JZT.N9%[6JTG.DNN=&.6XSF!T)4=W,CPKB8XR4@IE/&O.UI'?XN+:PVC,'\[$)&B(DZCR7"M0S ) M&ZWUM!6Q7*ZT1'@Z6G!9<@E,WEYGI24U3II-_7Q=;0V^NN?-S/7;BMCA[$-C M:/<-1NQUAO:RRXA5(W32C=QNOQ%_#*ZE9&@T6W-5)42"=$:[P%TGHJ:%3<_D M#\Y*DS*J".DC[>+BWH(A*#B*&8H?T4 6.*RH1<]!0KWXL'7%1$<[#8/4AT,[ M =660$[%T#<.AV+9]_Z.D.Z'XX]A9WA$X%ZP3:%>(7PX=$XV)FD"U:X^ MO;90P[1LVXG+UE$=,)UXU$Y*&KS!6&"OY=0X0 UXI5Y?*DO[NODQB?) JOH\ MO(>(P0YA%U$7B:+\U&N&P36A]!BDL)XD],.%AM'"T@KT%IE\U[8X&%,YESS3 MJ?92IY>*/9Z337B6[OJJ6$N"+'WKKF+=UNS-K9>V.JWX95>69\T3=ETQU.MB M2QNNCQBD1$&8CG. M<-&,>UL&SZQCWA-,,W8'7/!\EL!U1 \-P8B=S1&7),K$!662NJT.I5DXZ6%) MV(FNE;D (",?A4P$D!0R@) +X44_2W6@L::V7^L8XL> !% 2*U/"ZG:_VR'B M$ZJ6UTM#T]1Z:#JQK8(?L[!4O7#@[1M%&DU<_#;;W?P)W67A;Q M2>+<6IXGH^NY8-I24F<&IZ-)3H?L.N<3QPRF_ M6O:N=K&L'YZG@B#64.4,T"IF4#WN]>$ *-.)KA7KC#=$)(V[QF3(.<"M)/^; ME_4@*.-E357. "T9+^,N-DV1"4]EPZ201J?4NX.$2?5P*TD7I=V7T3/]*54?GOJH&/1\ M[*1JWYX*7BP]F'/S8\22P C+:\U?/% 3BD4%BJD<9 F#E!V'OMKN$OS$C\"K M>T@O&7U(>L@ZB+DY,U#EYH>/R,"$%?3F,22H#PUKL[S5CO4^CA\8GQO:+&&U M^9Q"OC^@..&3(Z8YZY A[F0:6# &B'(&"65]BC>G>_(+W]3P85:HA"165JKW MJ%5#6 D98PMNJI M!O:A_'LUU/-6-*__N7BKJ8;/SB304N=,@ PU!PFKI;LZ M_OZ=EZ5OQ?D*<,HD&Y>V"NK'@DXFU3AA_7NG&GY*<&K'TP0E!U QR@X]C"[L MH%RN8')WJN,EXTH5[?F-C8P+,79CGQT)R>1NCX(,KL_A+H$AOX.!_(R@N%=] ML<5)%OV3?=ZI*A4OL\?3X(" )1D,K>,';ATQ?*"2%"O.- 5!*2!85R3TPX6M MFPUV!0TV4=0+R(\[Q2';<8'@911'&60E %=D\<]K /BRRJ!$<)BJC8*R M(2YNRP0Y=\"K)TK^Q9K4ST)!:;Q;2P7E-#X?;)%]6-WL9'5KX\/A8_!WG)RA M(%5N[Z5$UF!O19Z-@\TOQORT"\_[ V 2 ":"']ZJ@S8V4/>,D$554#N=]$,- MU&FJ#WM44RI&K[V5,FDG +>Q&MM]3VHX^],/2Q=\.2_NUOS,@);SYB;$ZJ6. M7<5>44AGY:P;_-%+*U9]29#2+3P:).VF#HRSI3=207H9E/O#H:/,4;XX6 8%Q0)ZH=N*08.3LH7 M;/T8<]6 PUKZFP5(J(F/;RYV1;.H(4S3&YA"@O#C(EZ?PR>(L.8) DF")O?= M2#"P[V)7US?_&FQW_W;NAX>IX8:UU#<+C(2'7;&D.V4)325IG*>!#*+1LG+%7I485RL0.2I8861!&"3)@9;T!0-M[CSQK?,%Y_B1"R7QM"[WZ\Q_A7\!2@?4_F:_285%&OZ"AV VFJ>DWO_[R, MTC! _T76";:"E#0[-[8MR=Y^&*.I?/]#EJHQ2,8P):V_ . EHURU%"[OYE=( MQ0L[J%R "N9UQ/@$G[.[+Q ]P8\XSAYM+1:D.(UE+DW.3D+$NSF&B$[TM:-# MNZ[GC;1!3* " 2X1X")Y'0UHN+K[@MT%@8+!6!8A&#IQ^?=S=/DFQ-J>7M/L M+.$T\&LJ!_%K[+\W$_9*9=7:+$8U ZG2>BIEY-)?''J3]!I0.N0Y2< M0.KDK)W #S'\CDH]:SL%^5$V[WVW"J:5JZL M-G_!Q"1^AC%K52;C('U/:Q;6ME)S4O?,.0&\ 7^GO,"38.9#P7,_(GA85_V7 M=]D^6TH/"&>'CS![Q)5[CDS.E?93M''NL(^#V_.DG#/@K"O7,WE[E%0*WM9C MI,-*G@>4R"J*,MZ8)EG%$\EO32\D'PVJX/A3".G!&MGCH^8\U.$UY>F@.+?@ M>^+!R3-KN&-;NIXKQ@I.W?H'",4I-0NG3J7'![WU1FNXH'-SNIME.]?W4^^FT/6U'UZZ6.9Z;=7=7 MFR[E^*?N=N.>YI*]ZR3:LA=4/QI_]*A) ^4:*1?=K D#CTRZ2^UX0">>J1@U MM6MIVB&5G+HA[ZR46*X\H)?H* @XV*ZAD_\TB^@Y@H\P2,D4;OI^Z^U:QJW* M\$*CPAX9U?&RI(R=?/P\>L1 =:[BI=_F>!PT6Q7BB5[K1CE>?/P8/$?;_5;- M,!L/Z:FP1L2^<0KRTQMCNX9QIQ*\T2:J*7)4HXQB#:.L/Z2IQBH1!T;)R4OH ME\S^@;9$@U^]@U3^%E45@7= M!T3V$)Z ,$@? 8EJ61+=[UGU_#980_+5^K:A'Z'5R#JP#53F: EY:]*Z\+#G-#6(Y\DYV[(6C M;OF &%4JQ<*"O>A(Y\-&OB*N6$/!_<R52OLX32R0>)2$I!P4<".R@(0$<9?ZY2Q@GY#'<1@!G&G978@$W3, M9[)COB2JO=]Q:73)%2P&7L_)9/<!\P2H&M8?"!W.<->K\!%,_F- 5OYDY#PGSJ=O^G4JMK1?I3J2 M*VP%2[#V=&!IQ:O3(XXUZ"\V'1Z2,P+GO8B,X"HBMT)=5BD=V4?%%AQ5JJ/, MR,HQ8PW3,(EV_K3OED"MTV&.]>@O0AT.(QBQH<7"KL1$*0JYM6M_?F*V+S^T MIJT( (0$@(D EKVO+7L=97 ?(<+Y$B=7,;\>CW!:/"20U76=[9,$*F1RI>EI M7W8H1=_1[92"-]C@A)CF*?HDPW)((5EM3=&)Z!%&-+9?4I& M1IIHH+MO89CLX3JWZ@BF"J:F159_&J' QLE%+8PY&549=T!&'1!P_@"5 O@Q M\],!&AMH>D:@H@:>@C'? Q9X5G@#P=S&;;XCCL[U^XB'A^:9O1YJOAEA2G?U M"[:@X#L,H)-0N]K!A QD\<,2!@2)7%"-Z#I$2=_W^BG;-\2"'T"481$V/;FO M6!(RK*9 O^%!3608+U ZUC3>D\^6SO"6-C=E,\+;QR#A=Z$ODH2>"A%EF_J> M9<+%)!NBR]7ET!"B($VC341&/\Q26)[,9"Q8 K:G^_FB7N3(Q**J*@=@@HA+ MR:NB3!X'[H)GF$\--1R\]7&#*^./R3FXD!4_P21F,Y<$;J,LHY6KQ;+##Z?L M@P5+Z,M#"(1_,/K%FL#:W-]Y[J1J08(PV-$FX<2[\0:L6W,I,WBO9MABC(#@ M-%%06N+X@>XIT/T&C:#4^KB^1[20&\6D$.%[2LLDB''=>W)C=!\R6$)E'J*0 MKW0)?;:1!=@NUS2&?YRK666/,'&40QRB;3/GU,_+_OT.=_1GFCX\SBEB*LH< M,HJ2V/>F%67T/C><^Q*,C+]>FE%N\^@,QV3ZF)(8O=J4"XEB;;?B2[L[S'=4 MI?>35,EJ;C&IL7&RZU2*P :YGO4QR#" 3! ?]J(T@<<&FM?:W;S[@N\>\3XE MH>[N"U'[X6*[0_@ (5N#7A/T'LDR])H8BF+S4G7"FD:JRLB)F1(A0":D !D3 M T A!TC9#+RPD]4- M+8+&\6V&PU_/@EU$)NC,!M,;F,+D":XO<7*YIZ?#K])T3Y-R*LL;#>+Z\UYE M9LZ:0Q#C9H-1"H*G($)L'LPVH05C/]8V^LAC8Z7/#N7"H2EWP-@#P9\'[13D M$K!=>2X#N!I$7&[^>/2.Q8A%):F.6-(S1Q62FI,)>19.9HL"ER3'A;I@.5MD M$'HW6]0 &FMJ>R:@UMI%M2!Z<7M];3Y)&/NM4.V%:J&CG PR$Y6<^[II:U9L MU58W3BM[I1\.Y5?$P8/%ER#))U650G4^-*I,'APP-VBD95L8.V:T@TF$U[=9 MD&1'4Q!A6Q7.)^ #?(CBF&XB?>#-@?R8BKBS,^P\2D+)8VU>,J7-"9A3&V_9I>Q=?,VWY*<*K6QM$%^^G,KD48A!&1T5!'/W =Q?"!'A;L]+&"WEGF MEC5F@&YE/YV+M8@SCOD(QB\E2/=9E<4@W0G72[(@5T&Z(FD9J>W$:#]GYWS% M=Q%W>6%]O7?!9]V#BSTOH[H8C6CZ?/SL00OSZ?SQ2!B7$^[8S[6ODTAM4W4TD;S(;/6)Z"J'FO,\%4R+=1%@;+^&-*J4L;I)K@XC_I48 MIM-$;"X^:+=QW\)LJI16&BW4VA3+H57;$]/^Q',PV,XK\>O 4%7"K&VDOR*C M5 BWJ68&^84%W5QZ_^*NHF036KF2I!-$7XDM@5G%7SV;M1F"-1#_NNS3?B N M7N+EQN*6E+TWT5A9M@GM75'6"2+RW';97%FNS9BLA?K79J7VXW+K[IU^9'ZI MB:#FGM_PI.V%;/OYDC*7%LF+'1W/QJNO=C]Q[!RZD@E\)9;J=$?2KR4$D_.. M:&KQ'"G5)S<>-.@\4B7DH!DU X+2]R-4M"L<]^K#*^6BIE[!+Y1XSTESS]:^ MI4[B-3T>]2G8PG.\#2*I8Y!N^4^Q.NB6Y^5[HU,KLK+6'$+G)5J,O35C)4K1 MGE*L-0:5%OS"Y1T[:MW -".C/!G^6<'^YSC*TIO;S_+]>R0)Z5M%+V'[ :%D M)U!D#,&WA&7ZG1\Q0@XSK*1"K_%!Q]"P0\4S$!]6!E$R<\!VH]3]F957A\CB+S\HYTQYW>\4=Z ,@>, M^]><#9=WA7$3Y9(F\YO93YA>/ZK,:_6N%S-\]!Z5]74,41;:1X]2?(D1RJ\[ MQI&O,N_OV1"B92R_6;T?6PM?VYA23V3.9$Q1%MI'[U)\B>G&E*]TX\.S447+ M7'ZS>S_V5KZV4:5RXG8?&W[/&HN,.86D(*A_&;NTVT< ML:X)IL.'%XA-DXWOZ:?0-=^==/,I?(3K/8*K37$U'4R>HA!VX(+8@!G16V]O M8(@?XNB?!!;VYFH19:8AU(X!!"'$AD(-+"X68] K@\FX_+BGHCAF% MM/2Y4MY\WL@D!K\PF0>NAAYMR'1JH7@4X%^D-2(/#-%)3+R*0[R%MQD)U'1@ M60I!51L@])+1MX@>LO:C#&<&"FX@9^=';)!!"BNHSF-4T @TS19Z'AM]6X) M X2L ^.J?\$\'::[+X&$^KS&9MAM)COG#VF?JD6\/H=/$.$=%>OBF8Z04.NT M_S YHS/E0^2=G/QG3$$0KT&%K1^>I (@UM#D#,!"#9P6=9R 8#E5*X"?8$S6 MW8A(M5AOHSA*LX2X_!/4=C))@OK(23&P[VB"+?.S.F,_7$T-2*RESUF ANIX M+8[PFMKE;B$B-!^(8!^#Y%>8D9^UO6V8EL&J>H"V@W1-@&#*/*S@Z(=S24.& M5=7G.SQY_H(S8]Y4L)O:D>PD>Y91#*_(A%YX&>\->"9;>C7@Q!V/"^X#Y$U*?>OGDO/(I^\K=S MN(%)4G^C\CVK_3"747 ?H2@[G*$@3:--!->?"+A[\G2<54Y%RKB>,];J*#L2 MQ8XYK''(:A280-_\.1>S[LPI%51X>5 1]02@7-@3$!;BGH"X$!C@4N)7TT8# MU]:('4/]PBSO"2;WN!A(\EJ?BKD8%?%X_>HB!A?.5@N[U7AB%6,QR([I7CT,BQYPS'61*$V5^C[/%LGV9X"Y-"0I6( M,D!('_%>PBYZ"A5P)O )QD/5L&.YMAQ06$EO?H)2=ZZ<$Z"L0,ZK]**QQ^HH M#1X>$FHP(D?$;$2Y.K:?CD%\[*%K?ZBL<^,)*<;/KTI3*="PBA)]!@@98^/$ M<^A5'*M-92A4+;OL(* /12M!^TYRAA%AC,5&;O5P!]N7K_S.#V]D]/!&[2$_ MO*@?0"RE5R_!$@[#[HHA;E)%9)+:R^IT<1'366LE:W1'?DK)>$@7)^I[[\JD M#;*R:JQ^\[O.]+NF.6!#+&8&?9Z9KZZUZ-9_G3NHLE5P(,,PXR[OL%ID-5.<:FR<),YS$4Y 6!6">2KB8H @E\.'1+@FXMA MY3-"MZW:]P2<'4$K9 "%$.9)ZRE>%S7J9>LONFA[44OU1VF25>85Y+?FG()\ M1!;K^Y@@L@N2[$"OP).=>'<_JVZ*7;1<#/LE%W;CW[318A /*0$?@PJ[MQ\7?F#2HH$]="09O!5^(,Z?EA+C;/ JA@\/(M5\C/W4/?O@?I?0<)]%=)28A%F4_YZ%5:^RKL9VC@> M25'I09:%-R0?W,I_/!)3?1EBW$Z M=#\OI%$#Y(YRG<*9;R0PEIN:?XP0)&QB*)H(WI%OIX\8K1=;NGR6GIT/TM&< M#0[0=3)'+WB"G>@8F>5<0<#8^C!;ET4.JVCRM8X-+?&7._PQ6M]!,H&[P8< M98>".COBK6A,\@0UK4J6@1/S(LQ!AL$V6I]FE#](N 5*TOYN7AO;$T98:RE M:"WKRZES/E^(GB-HQ0K5"6O'.#5&CH)>;HZY;0I!9F">VB: C1#P>4BKSAV' MQS/S;, M',86H-,$V;H;ZD78N;Y[X:TYQ#G>^6OK0BXW+_B\(R-$G(D0059,,'J2RR[T M/JX9]-O).1G)!:LBV">"F0\C]0 H6$);'@)0]?)<^[G6S;W7I>2H+G0^GM[8 M$'[$XTZU?+7T"31'+4Q%AHA6&D3QPS5,-CC9TDL,5OBBZ:H097-]%6_*5 MU>:6?)IN>&$MN[B87H>@>L3#-F>37ILV)7%15Q)'-9']^L+<;R[W=M1)Q,%SPE#NY!A M0C\_8*8=?6A#XC2%Y'_KN^#915W8-/5@Q2UX'P[B"KK;1PBSGQ*\WY%W5FY9 M(4=/WZQEZ-N/@^6%??2N1<$8,,X@9^U7-PLE7+&.?N> (;()GVO_*W[\7Q%, MZ!'!PY)>IZ&:'I&E: 6_'@Y.O;!@QTZ(?EK\[)W7R:#9[G>#.IT'>RH5=[M M+CO1O6F%(J[BW3Y+6>!XI][@II>,!>R.R3HHGV!!\YUG/M:#2YM'=2G*8PR. MO85SXJ/8NZFNC*E.I'6OK.VFH8]'%TW[#E&?UOMU\>8@.EA68[XB@?I F&9N MU_;"ZA.Y/BIVP7 U19N;8W3/Q(:TYB\> ^YAJ5\#.QF[Q/'#'4RVR[+ON.() M]"$RFI5)_62=E(CQH\*(\ 3$([;57NP^5(E)XH45%.@Q-M68Q(&A#$\9,$O9 M)OF^O QJO@>X:[S'5#/!,L?3DEN]C&+R612@XB[LLX#?8;#4.0%NSLM&+DN/ MM]M=@O8<!(DD.M$I ^O"E'!V36W"ZZ3IHW"#HUWT#>.8;4IAA%1WZC(]P M&.8F)2=00*5X ,GR_+0V,V<;#NM5? /I%4=$N ]!&J6?8WR?PN2)[LRS-"MM M"$&&0[*.HR.@?G6*-=X6)B*69'$ZGZVN:W(AP2H&A9B R0FJ@O+$.*B+ZFF5 MC&U;;)OP6L7YI=G=\81X1)-S7=E3OV7.H*"GC9"5:I!CP@YV+.MWVGD6 7I1 M:B_4Z5*:UXBTEN4TH)FX%L<\,#759U"_XTX8+T)XNW!.YQ+W1_;F62AP;G]N M9@=]4+YX6W,Y?V@+D)9V[.B! R(*ZQX?I]$:\NM %#?L!JAH[@GU4G6R75=R M!&&5I0][=7)(87G=^8M*LQ^G@*3&SWR7;H070?WO,/D.7:5&[;V=*L;W;JH8 MW[NM8GSOV02@!Y>!*L;W[JH8K6+07\7X?G+/,)]L+(WVLZWR]V+RM1QEW]MB MTF;I[6ZX"^-TLR186M\U]\X0G28.I6QPM(-)]%3RD7+3NLQI'8MBW:*\/^]( M +LG8XP%LF.#O+L,IE!X4#Y-);Z57C\7C%)S47\;IM"@3CM>SDQTVY*NW< Y?!M7>8]'R'I82[&F25<9 \EMS_*-7E1<'1WZ"^"$)=H]1 M&$AWE1H@H'=Y>B=!^[94Y3#]G?;#4& I#7FI=F'UY3FE*ALK)65RY@X?FN\H M7_XU0$!3[UT$7[RY#T*!I33DI=IS<^=<&L:NTQXIS>T]A>&K!_Q$M+N/L^3 M35[\TK1X\?'?%I]ES+OZ;76EED_;-]S;PSJ&AQ.PV*=9$I!5Z[36VZ)6?*R MZ54HC'#Q^?;N9K&\6HQG<&<+%8.CW];7UMG"OL']',2$_!-,3L!9$ =K3PRN MHE9\K(#I59B75"T^+<[5K,U5$F>I4^@Q2,IVOF#IKORB.W&P]*V$0A;!PCNVAA>>8D8% XDF396,K4(T!G9J?*^+*_D\D 504P&4!7!A/O9\& MIKLOV(73%Z3=(R]8C>SBGIQ TH5:P[-K>IX9K%I^3"4@?HQ]]E["6*,>28GX M2%!39B/[\.]FZ,,UP'6]N-3U[, U\&0JA,>^+)N?TJ<]#MCV4W7A G78:.F'<(ARZS.^D6U,&9R6$(Z-_&.M_]$''J? M)-!6[\SZ=L>RGC;W8=RA__F$L_^"V1G>$I6'<$V;XJXV^26V2O=@:[.P'*N& M6;K80*7@QC@#!TC/'@F^)[QY+=ZPDTF4M\?CDH(U# U/LA#,%/F!0,;^2^0@ M48NVBQ&2\'[3JPTHA/$T!)Q'*2OYN DR\Y7D('WW)E#E-Z+GKP5;0,0;*#KW MS>U;+4##YX\U/T>T];P]EP/<],+OQ-,O_K$G,XR/,'ND)R"?8)K1^=3J2TSL M]C':74.B@3@+'I3<6X&H/LK23!P<&/"20 ME:;[X='J2&-M9<\&5>&PG"O@;$')%Y1(EYQ]&(N[%MG1D[.,+J<]4K* \!HY M#?1[/[Q4&VW=-%"AZ;DA:Y &(C)XZL1E*L61)S<8N >]QM"W+)AO7MT.OX9K MMVA]EE ;YP';7+WZP9+\1#[,/R+_N2>4__S_ 5!+ P04 " "V@*Y2>3*! MTJ0T "/_ , %0 &%B8VPM,C R,3 S,S%?<')E+GAM;.U]6W/CN';N>ZKR M'WPZ+TF=T]V^=/=,3^U)2K[U\3YVR['=,]EYF:))2$*&(K1YL:W]ZP] 4@0E M\8(%@B %,K4S;&\%-L;OCH+0\AS+)1[Z]=T:!>_^X]__^9_^\K_>OS^ZO+[Y?C2Q0_R" M+G%@NR2(?/2OCW?_=O1?YP^W1[?8^_/9"M#1);&C)?+"H_='BS!<_?+QX^OK MZP=GAKV N%%(>P\^V&3Y\>C]^PWI"Q]9[ ]'EU:(CN+_^^7H]/CTY/WQY_??S[Y^=/_/C[^Y?@X1^"W9%A'N?_[Y>CSA^,/)Q^^ MG'S.??'>LO^TYNCHYC+W173VT\G/GS\[9Y\_G7TZ0\=?GY\MQYD]'W^VSSZC M8R?/*5FM?3Q?A$?_:O];S"(=K^_3 F@5'#RA _@MR/J1478K;+^X&/#I'7A#_^NN[''IOS[[[@?CSCZ?'QV_[KV?QMT^^?OWZ,?YK]M4 %WV1DCWY^%]WMX_V BVM]W2JZ"JP M60+R/%1>=O&H6QM*:]PT923:F% 6R6P)-O>0%F$Y_@)LIV>?L6 MF?W/R/)#Y+MK.5[WFK? ZB.R(Y].Z-6;O;"\.?IN+9$HG\5M6V"23AI;6(_K MY3-Q1;G;:=0B=B>GST\X=,&X\78M,,=.6_=^0;6P[]'R&?FBS.VW:X&Y"SKZ M"579+H@CC-IVF]9DY,1QJ#@+[@D59^Y_XQ6$Q2H*;3/\2$]B-/7IP?*"$\4+ MSO(>C;:99G,Z]9_(JR?%;[YYVZRF_U!-!YU(,;M-H#5VZ6V!^/2XB)6C>$(O M2.2%_AJ^D&M(M3:$QP55#:F&L;*\-8SC[9:M,7CUQM6(>^1CXL#8+&K?'K-+ MY,_I0?C-)Z_A0@K6$A+M+8"EY;KG44"W2A 5\!VT]98O,;T\G)!M\2<^$ T M=YJV* FH\F@EYA8KM*1N+&4TVKNB)#UDER(F=B+@&BBCT>IB@&E9^^U:8^[) M>KMQ*!QXAA/[BPRGI43:6PBT-]]R;SP'O?T_!-QB>XU;8_,!S7% ^_)"R,VI MN&T;BG:R%:YQ0+7ZOR'+O_(<9B(55KI+V[=X;4Z.1""G)8U;9#,!)>GOFGXF M+*4J"+3.+IO#!LSFFK? ZH1VY,2=N9:P06JG49NV)\H)V-X4MVEC9Y,7Y$^> MF?RPA0_UG4;;;.4-NA/?WB)I^?:&'/UQSYJ[;:-/O_%Q93'9\=Y>8#=3D&<^ M61;RDO9&BN COH/\7]^='!^?''\X/GYWM*);AEE0?GUW^NXH"B@S9,78MESV M-S1#5&HYM\FX2]F,>:3J38#B;_89CITUSO'X/$P\2H421^;KB,S.V9)A*C%..U,4:;$*.9%3S'\QX%[^>6M4KBC) ;!IM/=@.. MTH__>(R> _3WB#)V]4+_$T#BC^IIU$=)-1_!+;:>L4LE- HFGA/+HP5QZ7X* MKOX>T2T$&4D]+1TC:C:&KKA^0*&%/>1<6;['I-S$I@=HQ+*IG4LTPS8&K2D1 M:CI&1>_D.!&\]Q9V;KP+:X7I[3QW^$%&)4)-QZAR'?YFN9%0#&1YVV[VA)2D MJJ"B"W<<+F,AZ;$3@&D!R+.IO(%.02D9S3)74KQJY_,[\6SQ?)D: CIXGX8+ MY#<>0!45':.X3'55YE99HB?K+<\+ @VEEI2.\6R\SW0+/F,OUABS_<=TNP!3 MV9(JD@EW:[F):]A1-1;[VC7[)$/X 5$]+D)4MGQC(7+747RI@XT#2%#+CEK% MB'GS6V31.U&S^1$@UIF$DSD::PAI'@L@M;&JM9XSW8LQ^AV'BXLH"*ELR@3N M6F(<8O2TZ+ZV[4=T\Y*UY4I.2BD)C?QGYT63$101Z>EY(S'()KUHFDD6A!'< M6VOKV67G2*S7I',CJ8T"B'8C_1J*\3TJ?;#&-!Q3#4TM:S$(4 A;:&D+?=S) MJ33[;;7=9S>@JM4(4,(,H=K#ELQ4;!,2./Z5K M]Z\$>^%O].N1#Y-5#3O2@<4W0IQ7[ I5\]IOHV>V0LN;8R;KD]6"PJLWVXW8 M742&>S%Z.D9V[Q-Z'0G7]ZZ5U%2DE-/0-P(937.[ MH6;9*\%P46L=7/_PJ#K@,JN"C? +T]UDN*^BHE.GY?W3329W0:F@H^4&; 4+ M9H>F_S"!\6*YL64ZO+!\?TUE(=S%($90^VZ6%T:=Z.))U_),Z^4V\Y!/9UG1 M['N2A-[(^7I$Z'460"(U;%(^13SM\MC(@)N:1;V'S-Z.XP#]/ " RB06 4M9 MGGOX9<2M_L#E:7=#V(<"<%7I61RL3R-892HU!VD47$47)9Z2=ZH<'Q):;K_P MJ0>FZ.++,1J"$*\P'Q!18P=/V1N":!)#3,S@Q9$;@KP20ZX G9_52ZM#1:>A M=9M#.@JW&J<(SXL;@G8J!E452NIE_R%J%'E$U,OT/B$B:XT1=U'SQ#JSY3\X M$* 8S5(S#@5P*/@!;!("L2P<0+/5,QB 32*@>/;>8+:TV)(L"YSC@)FML$D! MMA\KF<%EN&D?!I=8G"S'SNQK/ R[HEAICI39*IXBQ:3*RG;R:3 '@>!MM#Y9 M(L/.<+^),'; !!J.WV $G=C::YA(Q7$=C+HLAFMM.EZ&7 M^F8-&KBHGDX,V M&-58#+0ZO'Y2?VP8J+7D 3/;MMD$L,K\>@[@8 X$,(!"!E##'6#P);==52/# MR7!7#0PGD0HJ'#FS56$8EHQ\#[&?8%";%M9XI[R\H&%O1Q<+<'M4>@M,590'C0/ MBG"YL0(ZFHNE)1S0)CNE/O3L*2F3+]'6&%L%7L5=-?'U:.XD9\F_XXL7+@"FN$ M:WF^N',=-OMK,)TE/I-;$B3VQ27E:D$;X!?$_Z*R,';COGNL[\J/3<,I_SO" M\P7M:_)"QSA/7VR9SBZQ&S'6FRC&8-(ZM)H2IO:X.;<";"L8;1GA/HU51IN# MT]8QXHWI\![Y,2?I6H,,K)1$%_R#5V$)@@I)I2$/5V\K=AZ=(P_-8/7M2TGHXY_A=4W5O,2_&=&5D(9IT>A6 2E_(WC]]S1H$$!BVQH67-4B5E$]F6 M,)G.)FC]EA.1*N(ITW4A(Z4%B&DM MGBTGI0N;:^4[14V.:]Y83]%\>G%AV:[L>NTYDR5[+NH?\:\0[BO):"D)20\U MWW)9W\X2>YBM5R94)+9U+2DM-EL4'S*4B3O+_Q/E%@;(4EM!1<]#/0&R?)O5 M_KE$+\@E<=$#B8'4$-(RECA99BW#_$[+3F21S'E0043/ZHDCT3<:VVX&3E8/ M@F4.T_\Y5&V#K2D)\AK'+35E^VVU>IANL8=B75G*GY1KK7%'WZ'D;6/PAMXT ME-*=[[!++P_$0_?6.C8IBK-1W5Y/Z76;R0,X!(.?;<13<0S_#V:B55NXAC8V:J M3JWL(;4BD4-DIG]<[$@A%0==AI".EY_[C%"),L+Q,?.Q==@**M4O.4QFRFGP M,MJY#7!\S'R.OOX%Z4UVP1!L*LRA,SE/K/(,!JO7!#J?T, M0JW2#SN4>M @Q K\[FT6>>YEJJB8"I$/IVBSN//A0200-]-FG><^[3WQ>*3= M*D45@51M%#+^FH#GH3F+[#](^,KCZ#A@ZB28 8 )Q$&V4?-Y&[FGPY-OK4;/ M]63FEL053YS_ MB=*G 9](2?'/!V2[5A#@&;;C;3*=\7= TC\@9QI+,?%42/4=ZY@K$:[CC?!L MQ=M\R>ZS,>\/B"ZL@.[D-+:&:HB8L$>;R=R+J8"+:[7/B[:=F]3[N8Q\*C82 M9A)I$O\QG>"K-^3;.("50Y"AWN&H8]S;&G05\89$$V6$B"B)\MTNTB[1!ID"04]VF>AD@)D 5D2YBF#GIF+8P$7R.PU_C1R0%U.\^3A09N:AP809J16\'"_#O=B5!Q>I M.ULY3&:[785A*M"<3,^S!F-4HQWS;#ZS_:7">)5=B3A0X^%7>NO=/OA.S0>I MU'I JDTQE)!:Q5O6Z MWO$7Y6G]J\21%5I^>& X53Q#\I/R$BR'"Y.8J6 M6DDT ,^D&I>=7 P)3UP9$=01J<23.H:,=TN!=3SV?LC@ED1=9N"H5P(/$)SR M2-H,)_6J3*(%7GF]R<^55)7WH/K:DL*\"U6O\@8NK&!Q[9+7UA[H*^_@0+($ M"@:@Y]$5FW8\]>_I;2O]96(GQS-%Y8:BX\WQLXM89;(PB/]$E^4)**)=N@^I M<+*:[AY8KL]T]B-(NYL^)W;N&^_JS5Y03M U\;-*(;>(*B_39Q?/A1\2T<"$ MIN=XJD9PC=^0T]ZB*":O)80IW8"PK"I-Y5^HHK_=D.\0OE$P67.+!= M$D2^U"M%S?O2A0C[?W;TOU@N$U42LCZO??)"Z8* MZ?F:J@UT=@M."- !#*"J)PR7V @Y<5T>9I>C7*#I;-O'1^8RTR%"3??:DAU+.8U^276I]T\EJ'2'IY M3:RF=RA<,+V,<;6$JB_B-#L9X:X5I]'0]HEU,B:ZGNB%)%S?NY874LV (1X7 M"&\TN JJ_=J!"N5.)?4.1YV9V)3*G4*JFAYDV[GRQ?5H,WY21R%E&S)*"-5N M1IF\=4!AIIL-FH(E0JV;45VF%Y/T\9!F@]HC)F5;WZ<[L6T2,9M#@A6KU&[; M?H2\9LPJJJ>5!9I[:Z;>;&4U9S!675;)@*\BJFV760X;C [(1?FD^A:5$ M.Y(C&0>@8Z"&4$>2?T<\2[[.*4Q5RU/@:77UQ%FR5>U:?% 51'2,82.(2\LC MBX^DEI2V,C+GNR%>D&&44=#ZN'SL8]UQR^;?')%9:&#:6LI-Y#J>SII9([%.GHV=M%6W-D3$;Q-R,CR=OK79,&DT@Q:1S'?JE\W M3(7WZL[G)E=3(0M@:EA#HH!.?V+_JH9)FDW74#+\&FP44KR]>4ORIJ=1*P+;_A5B,^ V3)=UPR4 M7;)YNO,HM]7([1J;# ?<[/=VM(F6&\4.^OEVH"ZP(09A7B' [#-4PO1> MB>B6[X#7"FCK$ 38)4RL_(037[@J)ZE3;Q8?.*&*. A2SC MO5 (#J39=PWE)U7IDCPY-OLVH1K)\H JCJCIIY4:ZR8D)(]CJ_[0ZN5;N\V\ M%Y5!G+PVCMF'48/PV;SW A 4S*O@F'X%: G;E A6I32$MS#SBRIIM< MU" +R5SAKTT/Y&GX9L=59:X3Q])LE;]!EME6+?"R3#E>16R@DA2(I$C^),?4 M;%N*(D1+LVOY*]WJY*7):[,BU9I#J4YKVEP7C56>5' M9Y_?'NCA7.S7 59^S/:W#C!@/IH5>>3HFGTA5%9Z,Z_2R-09Y;6:S;8.J01< M0]G;S;2<&NY=[F ?5!1AYJAKN$)I*%K.\?INA?2_T]E^.=3*HN0B!#HM.E[) MH(Y4R!I8:E(="UIK207WYY:7IB'P(NULU\=VA6S2,D.CY?+Z[3(YCXHZ[%Q< MJ06.5*\$_K*F\F<4.I9&YU: @]BFE74&%$<5%'HBCXHXU+"USZ. JAE!<(D" MV\>K=&T6,/-$!WSN NO*RE ?!=H0!9K,2C%7X#WBN1<_5N6%:20T>X:-@FWG MRO )BCXA6CT1@M6\ZBC:4,6 E @4I:BET,H> U+E4BJH="Z@!(9(X)-CKJ3Y MCL+-,_8L%>X>^7$Z+/2V5TVE)]*EC$L=#SRD_6[ZE!(E%42T/%*QT[V,["BG MT;GDJ!T>$9H)8I8DZ^!^(W0M6%G:H.A^SF/#6['6PQEUU+FU4@;6;[E^V ,P52YO\D'QJ M2*Z,MZ!LJJ'2$P%5QJ6>4H/%:3B<.RFQ!:.KJ:AB,4R2'S 1';> MS!4_965B!>5.=979S@7.'GM:"G9O]]E0P B1TR%7OA'BO&+7I9NEG"<9&0,D MW+F\D0." *?49)&3I17>,"OY+;&\X(DDF8>I'0NER8<(;"^6I-X;@07C7H?= MI#@CM*%8@U#58ATJYH=.P5\)]L+?Z"^4*2F#,YATYQ).%@PB-[_FBKK].D#Q M+3=7!0@HW<0)]D2@"3"LSW.4<;%7C*F +SZ&U"@A)>=4]ZSIN;RX2-VF;)7E M2LF]2C*=RSB109+VYM%,+DE, ZO$O)= 3F5; H*[G>+9ZI4N. M%__-*GE(>?G!M+58Y+EG8Y:O;?R 7)98'-N>8R:?\TQ*&>0;]M2Y-%,$U6Y9 M:="2,%>D[;S3*"C'"E]W[%QX;;C2\I1WW!7+[+X@7KS2?L?AXB(*0K)$OI2D M$J>IY['R2FYD1)$PR!BK:>#1>4,%4D>B)N"EG4 ML#.+^FUHLA(FJ>=94&Z6<=WXYI'_2.I)4#&*G4/N(&TCB%:/5$TZSF58>WTUX@)W*IK)O0=>A@-PKQ"WI$=N3G7L]" M3F)"7JZB3>*^DE3%-GK7H6MPOG<988>N'5?[HV-!3CR1#:$!=C'F>&K-\92> MIZ&H77)@JI,''.JIC9F[/S,XM M9.9"UH.Y1NB2Y%4IT29$JR?RK9K7+A-:U2;LCFFZAY2F.PB1LYLH*"5KJHGT M1,B4,*DG4 B'Z):J\WO9G),E\<.T6N#5&XNI1?)*5;-^]!H/*GA5H54"R(^) MS8>4V"PUQ4.Q-S1&MYD$,=?<4)]B*'5N0LGVY"059ENO$7^/J_T,.A5'BTP_ M8TIE-RF5S6;-7*U_/_-*2G[5D>F)O"IE4Z^[C*) U@@](O\%VXCGN>63Z29N MO#MCP_X#LLG*'.W]0'2:8O%J^D[YS MLU8A]A5UW0>\\H_*M@^12&]:4"E>Z[[/GHYB]I[S]5[N:3R55#ZA.+@'A(J" MWJ2"3I]>R=."1('E.4^OE&C2S73S7L"-9],/J8+/S%UW:/F,?)%A29.6&L,] ML];0(]ER[Z-G%]O3&3U:6:00G&<14EJT,]K?=VN)+LG2PAY((=MIJ9/;R1L& MK?KM=GV0=;D=%Y1MN5@:J11Y@$['(@>]2OQKH 0%'O,@-F,^ V7DBW

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

  •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ǩ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end